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Primary human hepatocytes are a scarce resource with variable function, which 
diminishes with time in culture. As a consequence their use in tissue modelling and 
therapy is restricted. Human embryonic stem cells (hESCs) could provide a stable 
source of human tissue due to their properties of self-renewal and their ability to give 
rise to all three germ layers. hESCs have the potential to provide an unlimited supply 
of hepatic endoderm (HE) which could offer efficient tools for drug discovery, 
disease modelling and therapeutic applications. In order to create a suitable 
environment to enhance HE formation, hESC culture needed to be standardised. As 
such, a media trail was carried out to define serum free media capable of maintaining 
hESC in a pluripotent undifferentiated state. We also ensured hESC cultured in the 
various media could be directly differentiated to HE in a reproducible and efficient 
manner.   The project then focused on the effect of post-translational modifications 
(PTMs), specifically SUMOylation, in hepatocyte differentiation and its subsequent 
manipulation to enhance HE viability. SUMOylation is a PTM known to modify a 
large number of proteins that play a role in various cellular processes including: cell 
cycle regulation, gene transcription, differentiation and cellular localisation.  
 
We hypothesised that SUMO modification may not only regulate hESC self renewal, 
but also maybe required for efficient hESC differentiation. We therefore interrogated 
the role of SUMOylation in hESC differentiation to hepatic endoderm (HE). hESC 
were differentiated and the cellular lysates were analysed by Western blotting for key 
proteins which modulate the conjugation and de conjugation of SUMO. We 
demonstrate that peak levels of SUMOylation were detectable in hESC populations 
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and during cellular differentiation to definitive endoderm (DE), day 5. Following 
commitment to DE we observed a decrease in the level of SUMO modified proteins 
during cellular specialisation to a hepatic fate, corresponding with an increase in 
SENP 1, a SUMO deconjugation enzyme.  We also detected reduced levels of 
hepatocyte nuclear factor 4 α (HNF4α), a critical regulator of hepatic status and 
metabolic function, as SUMOylation decreased. As a result, we investigated if 
HNF4α was SUMOylated and if this process was involved in modulating HNF4α’s 
critical role in HE.  
 
HNF4α is an important transcription factor involved in liver organogenesis during 
development and is a key regulator for efficient adult liver metabolic functions. We 
observed a decreasing pattern of HNF4α expression at day 17 of our differentiation 
protocol in conjunction with a decrease in SUMO modified proteins. In order to 
further investigate and validate a role of SUMOylation on HNF4α stability 
Immunoprecipitation (IP) was employed. HNF4α protein was pulled down and 
probed for SUMO 2. Results show an increase in the levels of SUMO2 modification 
as the levels of HNF4α decrease. Through deletion and mutation analysis we 
demonstrated that SUMO modification of HNF4α was restricted to the C-terminus 
on lysine 365. Protein degradation via the proteasome was responsible for the 
decrease in HNF4α, demonstrated by the use of a proteasome 26S inhibitor MG132. 
Additionally, a group at the University of Dundee has shown that polySUMOylation 
of promyelocytic leukaemia protein (PML) leads to its subsequent ubiquitination via 
RNF4, an ubiquitin E3 ligase, driving its degradation. Using an in vitro 
ubiquitination assay, we show that polySUMOylated HNF4α is preferentially 
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ubiquitinated in the presence of RNF4. Overall polySUMOylation of HNF4α may 
reduce its stability by driving its degradation, hence regulating protein activity. 
 
In conclusion, polySUMOylation of HNF4α is associated with its stability. HNF4α is 
subsequently important for HE differentiation both driving the formation of the 
hepatocytes and in maintaining a mature phenotype, in agreement with a number of 
different laboratories. Creating the ideal environment for sustaining mature 
functional hepatocytes, primary and those derived from hESCs and iPSCs, is 
essential for further use in applications such as drug screening, disease modelling and 
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The focus of this thesis was directed towards studying human liver biology. This was 
done by creating a standardised model for investigating the mechanisms regulating 
human embryonic stem cell differentiation into hepatocytes. In addition, the roles of 
post translational modification, specifically SUMOylation, were investigated within 
hepatic differentiation, focusing on the effect on hepatocyte nuclear factor 4 α 
(HNF4 α) regulation, a vital transcription factor for hepatic development, 
differentiation and metabolism.  
 
1.1 HUMAN EMBRYONIC STEM CELLS 
1.1.1 CHARACTERISTICS OF HUMAN EMBRYONIC STEM CELLS 
Human embryonic stem cells (hESCs) are isolated from the inner cells mass of 
blastocyst stage embryos (Thomson et al., 1998). hESCs possess two unique 
properties; self renewal, capable of dividing indefinitely in culture, and pluripotency, 
the ability to differentiate to cell types from all three germ layers; the endoderm, 
mesoderm and ectoderm, Figure 1.1 (Cai et al., 2006, Hoffman et al., 2005, Vazin et 
al., 2010). hESCs are defined by the expression of pluripotent transcription factors; 
Octamer 3/4, Nanog and SOX2 in addition to their cell surface antigen pattern; 
defined by the presence of stage specific embryonic antigens (SSEA) 3, 4, Tra 1-60 
and 1-81(Pera et al., 2000, Hoffman et al., 2005). Pluripotency is measured using a 
combination of spontaneous (Fletcher et al., 2008) and directed differentiation to cell 
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types, including cardiomyocytes (Melkoumian et al., 2010), hepatocytes (Hay et al., 
2008), neuronal derivatives (Lee et al., 2007) and muscle (Xiao et al., 2008).   
 
1.1.2 HUMAN EMBRYONIC STEM CELL CULTURE DEFINITION 
In order to realise the full potential of hESCs, it is important to maintain cells in 
defined and optimised conditions. Creating a standardized culture system for hESC 
maintenance will provide an ideal resource for the study of human biology, in vitro 
modelling and cell based therapies. To date, the most common method of 
maintaining hESCs is on mouse embryonic fibroblasts (MEFs), which are capable of 
secreting the required growth factors to sustain replication and provide extra-cellular 
matrix attachment support imperative for undifferentiated regeneration (Ilic, 2006, 
Vazin et al., 2010). However, limitations of MEFs include xeno-contamination, lack 
of definition and variability between batches of cells (Barbara S Mallon et al., 2006). 
As a result, human feeders have been developed as a successful replacement for 
animal feeders in an effort to create a xeno-free hESC culture environment (Amit et 
al., 2003). Once again, the use of human feeders suffer from variability, limited 
sourcing and an impure hESC population altering the accuracy of results following 
an investigation (Barbara S Mallon et al., 2006). Therefore, other culture conditions 
have been explored. 
 
Feeder free conditions are important if hESCs are to be employed for use in clinical 
or therapeutic applications. As a result, research was focused towards generating a 
fully defined system whereby ideally, the media are supplemented with recombinant 
 23
growth factors and the extra cellular matrix support is synthetically produced. A 
number of groups have  
 
Figure 1.1 – Properties of Human Embryonic Stem Cells. 
hESCs are isolated from the inner cell mass of the blastocyst stage embryo and posses two unique properties that make them 
ideal tools in research, clinical and therapeutic applications. hESCs are capable of indefinite self renewal, defined by unlimited 
cell division in culture and pluripotency, allowing the cells to form somatic cells from all three germ layers; endoderm defined 
by alpha feto protein (AFP) positive cells, mesoderm defined by α-smooth muscle actin (α-SMA) and ectoderm depicted by β-
tubulin expressing cells. 
 
 
significantly contributed to developing the ideal culture system. Xu and colleagues 
were the first to establish feeder free hESC culture using MEF conditioned media 
(CM) to maintain healthy self-renewal (Xu et al., 2001) on Matrigel™, a matrix 
secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells (Ludwig et al., 
2006). Subsequently, hESCs have been successfully maintained on recombinant 
vitronectin (Braam et al., 2008) and laminin (Rodin et al., 2010) resulting in 
improved culture definition. In conjunction, CM has been adequately replaced by a 
variety of defined and serum free media (Chin et al., 2007), (Chin et al., 2010, 
Hannoun et al., 2010). Additional research has been employed to create a 
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standardized completely defined hESC culture system capable of self-renewal whilst 
maintaining pluripotency. Clinical grade hESCs have been developed by culturing 
the cells in a fully xeno-defined medium, RegES (Rajala et al., 2010). The hESCs 
exhibited the correct morphology and gene expression associated with embryonic 
stem cells in addition to their ability to spontaneously differentiate into all three germ 
layers and be directly differentiated into neural cells and cardiomyocytes (Rajala et 
al., 2010). The xeno-free defined media formulation can in turn be optimised for the 
culture, expansion and differentiation of other cell types. 
 
1.1.3 THE EFFECT OF THE MICROENVIRONMENT ON HESCS 
A number of differences have been noted between various cells lines relating to their 
default differentiation lineage and culture properties (Tavakoli et al., 2009). 
Therefore, it can be concluded that the derivation technique and the culture 
environment play a significant role in priming hESC properties, in conjunction with 
their varying genotypes (Frost et al., 2011, Reijo Pera et al., 2009). Studies have 
shown that the environmental conditions affect cellular epigenetics, which in turn 
alter the behaviour of the respective hESC line (Frost et al., 2011). Despite the origin 
of the stem cells, variations between the methylation patterns on genes were noted 
affecting the integrity of the imprinted gene expression (Frost et al., 2011). In 
addition, significant differences in epigenetic and genetic stability, transcriptional 
profiling and pluripotency marker expression have been documented when 
comparing various hESC lines (Allegrucci et al., 2007).  
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hESCs have a comparable gene expression pattern with epiblast cells, unlike mouse 
embryonic stem cells which are more comparable to the inner cell mass (Tesar et al., 
2007, Brink et al., 2008). The differences in the state and expression patterns of 
hESCs and cells directly isolated and analysed from the inner cell mass may be 
attributed to culture conditions (Brink et al., 2008).  In an effort to ‘push back’ the 
state of hESC to a state comparable to the inner cell mass, Hanna and colleagues 
induced the expression of Oct4, Klf4 and 2 in hESCs, and supplemented the media 
with leukaemia inhibitory factor (LIF) and glycogen synthase kinase 3 and mitogen 
activated protein kinase pathway inhibitors. This resulted in generating a more 
immature state of hESCs, which was now comparable to mouse ESCs (Hanna et al., 
2010).  
 
Studies have also demonstrated the ability to maintain the undifferentiated and 
pluripotent state of mouse embryonic stem cells with the use of two factors; 
leukaemia inhibitory factor (LIF) and  bone morphogenic protein (BMP) (Ying et al., 
2003). LIF maintains stem cell self-renewal by activating the STAT3 transcription 
factor (Ying et al., 2003). However, the cells begin to differentiate towards the neural 
lineage in the presence of serum, thus BMP was utilised to block differentiation by 
promoting the expression of the inhibitor of differentiation (Id) genes (Ying et al., 
2003). Further investigation has defined fibroblast growth factor 4 (FGF4) as an 
essential component for driving differentiation towards the neural and mesodermal 
lineage in the absence of LIF (Kunath et al., 2007). Interestingly, FGF4 does not 
block the BMP pathway and therefore promotes differentiation, but is required to 
redirect the subsequent effects of BMP signalling (Kunath et al., 2007). Therefore 
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supporting previous studies depicting the secondary action of BMP over FGF (Stern, 
2005). Culturing embryonic stem cells in optimum environmental conditions allows 
for the intricate control of the self-renewal and pluripotent abilities of the cells, 
which has yet to be achieved in hESCs. 
 
1.2 HEPATIC ENDODERM 
1.2.1 HUMAN LIVER DEVELOPMENT 
Liver development is an intricate process regulated by growth factors, transcription 
factors, cytokines and cellular interactions, Figure 1.2. Hepatic formation during 
embryogenesis has been classified into three stages: induction, specification and 
maturation. A distinct set of growth factors coordinated with transcriptional 
activators are responsible for the regulation of each stage.  Hepatic induction is 
defined by the formation of the definitive endoderm originating from the primitive 
streak at the 8-12 somite stage in humans, Figure 1.2. Subsequently, the foregut is 
generated by the invagination of the endoderm. The ventral foregut is accurately 
positioned from the developing cardiac mesoderm, permitting signal responses 
required for inducing its development towards hepatic fate, Figure 1.2.  Hepatic 
specification occurs once the primary liver bud forms, growing outward from the 
ventral foregut at the 13-20 somite stage. Angiogenesis and vasculogenesis, mediated 
by oxygen sensing factors, occur simultaneously during liver bud formation, leading 
to the vascular anatomy necessary for hepatic function. Liver maturation is 
completed after birth, whereby hepatocyte proliferation decreases and mature 






Figure 1.2 – Human Liver Development. 
Liver development occurs throughout development whereby the primitive streak post embryo formation differentiates to form 
all three germ layers; the ectoderm, endoderm and mesoderm. The endoderm is then primed by hepatocyte nuclear factor 3 
(HNF3) and GATA4/6 down the foregut lineage followed by liver specification induced by bone morphogenic proteins (BMPs) 
and fibroblast growth factors (FGFs). Hepatocyte nuclear factor 6 (HNF6) and one cut 2 (OC-2) transcription factors are 
responsible for hepatocyte commitment followed by hepatic maturation activated by hepatocyte growth factor (HGF) and 
Oncostatin M (OSM), which continues post natal.  
 
1.2.1.1 Hepatic Induction 
Fibroblast growth factors (FGF) 1 and 2, secreted by the cardiogenic mesoderm, and 
bone morphogenetic protein (BMP), produced by the septum transversum 
mesenchyme induce the initial phase of hepatic development, Figure 1.2 (Rossi et al., 
2001). FGF signalling activates the RAS/MAP kinase pathway (MAPK) leading to 
enhanced hepatic gene expression and nascent hepatocyte stability. The FGF 
signalling pathway is capable of initiating down stream effects either through the 
 28
default MAPK pathway or through the phosphatidylinositol 3-kinase pathway, active 
in the foregut endoderm (Calmont et al., 2006). As liver development progresses, 
morphogenetic changes result in the distancing between the hepatic endoderm and 
the cardiac mesoderm (Jung et al., 1999). Consequently, the concentration of FGF 
decreases inhibiting the differentiation into an anterior fate such as the lungs. FGF 
concentration gradients induce varied responses vital for synchronizing 
developmental events (Serls et al., 2005). BMP 2 and 4 operate in accordance with 
FGF signalling to encourage hepatic competence and specification of the primitive 
endoderm via GATA4, a GATA zinc finger transcription factor, activation (Huang et 
al., 2008).  
 
1.2.1.2 Hepatic Specification 
The Wnt/β-Catenin pathway is also involved in hepatic induction and is responsible 
for stimulating a combination of differentiation and proliferation of pre-hepatic 
endodermal cells. This is carried out via the activation of the Frizzled receptor in 
response to the Wnt ligand (McLin et al., 2007).  Hepatoblast proliferation is vital for 
liver development and hepatocyte repopulation during injury, which is stimulated by 
Wnt9a, secreted by sinusoidal and stellate cells in the liver (Matsumoto et al., 2008). 
Additionally, Wnt9a has been demonstrated to increase glycogen synthase 
production and enhance glycogen accumulation in the chick (Matsumoto et al., 
2008). Wnt3a has been shown to promote liver lobe periphery proliferation and 
regulate liver morphology (Suksaweang et al., 2004). A zebrafish Wnt2b homologue 
is a key regulator in liver specification as well as a possible factor affecting 
hepatoblast proliferation (Ober et al., 2006). Wnt3a has also been documented to be 
 29
expressed during hepatoblast differentiation into hepatocytes. Its subsequent addition 
to a cell culture model resulted in a homogenous population of stem cell derived HE 
(Hay et al., 2008). β-Catenin exhibits its effects by interacting with FGF 10 
stimulating hepatoblast proliferation (Jung et al., 1999). 
 
The transforming growth factor α (TGF α) pathway is involved in differentiating 
hepatoblasts towards the biliary lineage (Shiojiri, 1997), which is assumed to be 
achieved by the formation of a TGF α signalling gradient, however, the exact 
mechanism is unknown. Hepatocyte nuclear factor 6 (HNF6) and One-cut 2 (OC2) 
transcription factors have been demonstrated to regulate Follistatin and β-2-
Macroglobulin, TGF α antagonists. Studies in HNF6 knockout mice revealed an 
increase in the activation of the TGF α pathway, in addition to limited segregation 
observed between the biliary and hepatic cell lineages (Clotman et al., 2005). 
Therefore, HNF6 is required for repressing the expression of the tgf α receptor II 
gene (Clotman et al., 2005). Furthermore, Smad2 and 3, modulators of TGF α 
ligands, knockout mice display liver hyperplasia; which is rescued by addition of 
hepatocyte growth factor (HGF). It could be hypothesized that HGF regulates hepatic 
cellular organization and further contributes to hepatic specification. In terms of in 
vitro modelling, it is reasonable to suggest that inhibitors of the TGF α pathway may 
commit hESCs towards the hepatic lineage. On the other hand, modelling the system 
in 3D and the generation of a TGF α signalling gradient may lead to the specification 




1.2.1.3 Hepatic Maturation 
HGF and Oncostatin M (OSM) are soluble molecules that promote hepatocyte 
maturation. HGF is secreted by an array of tissues present in the liver including the 
septum transversum mesenchyme, endothelial cells and hepatoblasts. HGF is 
responsible for binding to the c-Met receptor resulting in the activation of the 
SEK1/MKK4 and c-Jun signalling pathways (Kamiya et al., 2001). Activating the 
above signalling cascades results in the up-regulation of glucose-6-phosphate, 
tyrosine amino transferase, carbamoyl-phosphate synthase and albumin expression, 
all of which are associated with mature liver (Kamiya et al., 2001). OSM, is an IL-6 
related cytokine, is produced by hematopoietic cells present in mid-fetal livers and 
exerts its effect by activating the signal transducer and activator of transcription 
(STAT3) and Ras Pathways via the OSM receptor (Wong et al., 2003). A number of 
hepatic gene promoters are directly regulated by STAT3 via binding sites in the 5’ 
regulatory regions (Runge et al., 1998). Like HGF, OSM induces the expression of 
various liver markers (Kamiya et al., 2001). At birth OSM is down regulated whilst 
HGF is unregulated (Kagoshima et al., 1992). The liver undergoes a functional 
switch at birth accelerating liver maturation resulting in the preparation of the organ 
to respond to environmental changes; including a significant increase in the levels of 
glycogen and changes in oxygen tension (Kinoshita et al., 2002).  
 
Developing a complete understanding of the signalling pathways involved in liver 
development will provide significant insight behind the underlying regulatory 
mechanisms. This in turn was translated into various successful differentiation 
protocols utilized for generating HE from hESCs.   
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1.2.2 SOURCES OF HEPATIC ENDODERM 
Hepatocytes are in limited supply and existing sources suffer from various 
disadvantages, which limits both the ability to study human liver function and the 
applications utilising functional HE. Primary human hepatocytes isolated from 
human liver are the gold standard for use in research investigations and clinical 
applications. However, they are a scare resource due to a lack of donor livers and 
suffer from diminished function and viability in long-term culture (Kim et al., 2007), 
insufficient for high throughput drug screening and bio-artificial liver devices (BAL). 
Liver grafts from matching donors have proved successful in diseased liver cases, but 
due to limited supply, it cannot be regarded as a stable form of treatment. Porcine 
and other animal isolated hepatocytes have been utilized in preliminary disease 
modelling studies and drug testing however, they are an inaccurate substitute for 
human hepatocytes, as they do not accurately mimic mechanisms found in human 
hepatocytes (Behnia et al., 2000). Xeno-contamination and hyper-acute rejection 
prohibit the employment of animal hepatocytes in therapeutic applications (Butler, 
1998). In addition, risk of zoonoses transmission and incompatible liver function 
render xeno-derived hepatocytes as an unsuitable component for BAL devices (Le 
Tissier et al., 1997). Hepatoblastoma cell lines such as C3As, an immortalized 
subclone of the hepatoma derived HepG2 cell line (Mavri-Damelin et al., 2008), 
have been utilized in BAL devices but exhibit reduced function when compared to 
primary hepatocytes and cannot be used in therapy due to their cancerous 
nature(Tilles et al., 2002). Additionally, there are also concerns about tumorigenic 
transmission into patients. In conclusion, existing sources of hepatocytes limit the 
 32
potential of the use of hepatic endoderm (HE) as unique and effective tools for 
research and applications in the clinic.  
 
Human embryonic stem cell derived HE may offer a possible solution. hESCs ability 
to infinitely self-renew and differentiate into any cell type may in turn provide an 
inexhaustible supply of mature functional HE (Hay et al., 2010). hESCs and their 
derivatives are ideal tools for disease modelling and genetic modification of their cell 
surface antigen expression may result in reduced immuno-rejection when utilized in 
therapy (Agarwal et al., 2008, Basma et al., 2009, Shirahashi et al., 2004). 
Standardised culture systems for hESC maintenance permit scalable production of 
HE required for high throughput drug screens and employment in BAL devices 
(Sharma et al., 2010). hESC directed differentiation into HE has been thoroughly 
examined and documented. Most techniques mimic the developmental mechanisms 
activated during embryogenesis. 
 
1.2.3 APPLICATION OF HUMAN HEPATIC ENDODERM 
Mature functional hepatocytes are in high demand for both industrial and clinical 
purposes. Hepatic endoderm may provide a possible long-term solution for liver 
disease due to the limited availability of donor livers and the lack of successful drugs 
on the market. To date, hepatocytes have been utilized for drug discovery 
investigations reducing the requirement for animal studies and increasing the safety 
of human clinical trials (Hay et al., 2010). Extra corporeal devices are currently in 
the design phase and suitable supplies of hepatocytes are being sourced (Fiegel et al., 
2008). Extra corporeal devices mimic the functional liver, which in turn alleviates 
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the pressure on the diseased liver providing sufficient time for self-recovery (Fiegel 
et al., 2008). Hepatocytes could be used for cellular therapy (Alison et al., 2007, 
Asahina et al., 2006), on the condition they are in abundant supply and maintain the 
functions and properties displayed in their native environment.  
 
1.2.4 DIRECTED DIFFERENTIATION OF HESCS INTO HEPATIC ENDODERM 
A vast amount of research was focused on developing effective methods for deriving 
functional hepatic endoderm from hESCs. The resulting HE is characterised using 
specific criteria including hepatic specific gene expression, serum protein production, 
cytochrome p450 activity, urease function and glycogen storage (Snykers et al., 
2009). However, the exact combination of techniques employed varies between 
laboratory groups. 
 
There are a large number of protocols for HE formation ranging from embryoid body 
(EB) derivation in fetal bovine serum (FBS) (Rambhatla et al., 2003), to 
differentiating hESCs utilizing 2-D systems using collagen, gelatin or Matrigel™ as 
the basement membrane. Agarwal and colleagues cultured hESCs on collagen in the 
presence of FBS, knockout serum replacement (KOSR) and bovine serum albumin 
(BSA) supplemented with Activin A (AA), fibroblast growth factor (FGF-2), 
hepatocyte growth factor (HGF), Oncostatin M (OSM) and dexamethasone. The 
resulting HE expressed a number of hepatocyte specific markers including albumin, 
alpha-fetoprotein (AFP), CYP3A4, CYP7A1 and was capable of glycogen storage 
and albumin secretion (Agarwal et al., 2008). Schwartz and colleagues generated HE 
solely in the presence of FGF-2 and HGF on collagen, the resulting hepatocyte like 
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cells expressed GATA4 and HNF1 α and 3β; were capable of albumin and urea 
production and exhibited Cytochrome P450 activity after treatment with 
Phenobarbital (Schwarts, 2005). HE has also been formed on collagen in the 
presence of FBS supplemented with insulin, dexamethasone, transferrin and 
selenious acid, where expression of albumin, transthyretin and albumin serum 
protein production was observed (Shirahashi et al., 2004). hESCs cultured on gelatin 
in the presence of HGF and nerve growth factor (NGF) generated HE expressing 
various hepatocyte specific genes, but showed no further function (Kuai et al., 2003). 
Hay and colleagues demonstrated that treatment with either Activin A/Wnt3a or 
sodium butyrate followed by treatment with dimethylsulfoxide (DMSO) generated 
immature hepatocytes. The hepatocytes could then be matured with HGF, insulin, 
OSM and hydrocortisone to give HE that expressed the majority of hepatocyte 
specific genes, were capable of glycogen storage, produced significant levels of 
hepatic serum proteins and had inducible cytochrome P450 activity (Hay et al., 2008, 
Fletcher et al., 2008, Hay et al., 2007, Hay et al., 2008). 
 
Basma and colleagues established an efficient protocol for the purification of a 
hepatocyte population from a heterogeneous endodermal population. The hESCs 
derived EBs were plated onto Matrigel™ and treated with Activin A and FGF 2. The 
cells were then placed into defined media supplemented with HGF followed by 
dexamethasone. The resulting HE was further enriched by FACS sorting for ASGPR 
positive cells, a specific feature of mature hepatocytes. The pure population of HE 
expressed hepatic gene function comparable to adult hepatocytes (Basma et al., 
2009). Cai and colleagues developed a physiological protocol that mimicked the in 
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vivo situation. This involves priming hESCs with Activin A to direct them towards 
definitive endoderm, followed by BMP and FGF generating hepatic endoderm. The 
resulting HE was matured using HGF, OSM and dexamethasone. The HE expressed 
a range of mature hepatic genes; however there was no expression of AFP. The HE 
produced significant albumin and interestingly was susceptible to infection by the 
hepatitis virus (Cai et al., 2007). 
 
It has been debated that transferring culturing conditions into 3-D environments may 
enhance HE function; as this potentially mimics in vivo development more 
accurately. It has been proposed that culturing hepatocytes between double layers of 
ECM in 3-D structures will establish polarity and enhance hepatic function and 
viability mimicking the in vivo situation. One group has successfully differentiated 
hESCs into HE in a 3-D environment. Baharvand et al., cultured hESCs in self-
renewing conditions and by using the hanging drop method, formed EBs. These EBs 
were then seeded onto collagen coated 3-D scaffold in culture medium supplemented 
with FGF-2, HGF, OSM, insulin, dexamethasone, transferrin and selenium. The 
resulting HE, differentiated from the EB’s, expressed a number of hepatic specific 
genes and produced significant levels of both urea and albumin (Baharvand et al., 
2006). Du and colleagues successfully constructed an ECM free synthetic culture by 
sandwiching a hepatocyte monolayer between two membrane like structures. The top 
support system consisted of a glycine - arginine- aspartic acid - serine (GRGDS) 
modified polyethylene terephthalate (PET) membrane. The bottom substratum 
consisted of a galactosylated PET membrane. This resulted in hepatic polarity 
including biliary excretion and enhanced function when compared to 2-D collagen 
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coated cultures using HE derived from hESCs (Du et al., 2008). Ng and colleagues 
successfully combined methylated and galactosylated collagen nanofibres that 
optimized the interactions required for the maintenance of functional hepatocytes. 
This enhanced interactions between the nanofibres and the asialoglycoprotein 
receptor (ASGPR), hence promoting hepatic function (Ng et al., 2005, Lu et al., 
2003, Yin et al., 2003). An unbiased synthetic approach was additionally employed 
to isolate polyurethane and polyacrylates polymers capable of culturing and 
differentiating hESCs derived HE in 3D (Hay et al., 2010). Polymer 134 was 
demonstrated to successfully maintain differentiating hESC, where improved hepatic 
endoderm viability, hepatic gene expression and hepatic function, specifically 
enhancing drug inducible metabolism, were noted (Hay et al., 2010). The polymer 
was then coated onto the matrix of the bioartificial liver and supported long-term 
maintenance and function of the hepatocytes (Hay et al., 2010). These results signify 
the importance of ECM interactions for maintaining hepatic function. 2-D culture 
systems have been successfully employed to differentiate hESCs into functional HE; 
however, high fidelity hepatocyte function and improved cellular viability will 
inevitably be attained in a 3D system. 
 
1.3 LIVER ENRICHED TRANSCRIPTION FACTORS 
1.3.1 THE IMPORTANCE OF UNDERSTANDING LIVER TRANSCRIPTIONAL 
MECHANISMS 
Growth factors and extracellular matrices are components important for the 
regulation of liver development and differentiation (Duncan, 2003, Zaret, 2000). 
Another important part of hepatic regulation is the array of liver enriched 
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transcription factors (Cereghini, 1996). The function of these transcription factors 
range from regulating hepatic commitment to inhibiting the differentiation into other 
lineages such as biliary or pancreatic (Lee et al., 2005, Watt et al., 2007). Therefore, 
it is essential to understand the liver regulatory transcriptional machinery in order to 
provide high fidelity and stable human liver models. The next section reviews 
important transcription factors required for liver specification, commitment and 
maturation, with a focus on HNF4 α. 
 
1.3.2 LIVER ENRICHED TRANSCRIPTION FACTORS 
Forkhead Box (FOX) A, GATA4 and CCAAT-enhancer binding protein (C/EBP) α 
transcription factors are vital for hepatic specification during liver development, 
specifically through the activation of the albumin gene (Bossard et al., 1998). FOXA 
and GATA4 relax the chromatin around the promoter region of the albumin gene 
allowing access and binding of other factors onto the DNA resulting in the 
subsequent activation of albumin expression (Cirillo et al., 2002). This type of 
facilitative interaction is termed ‘competence’ as it primes a cell of an unspecified 
fate down a particular lineage by initiating its ability to respond to a specific set of 
signals. 
 
The forkhead protein, FOXA1, also known as hepatocyte nuclear factor HNF3 α, is a 
transcriptional activator of a large number of hepatocyte specific genes. FOXA1 
binds to cis regulatory elements within the promoter regions of the albumin, α feto 
protein (AFP), transthyretin, tyrosine aminotransferase and PEPCK genes, triggering 
their expression (Navas et al., 2000). HNF1α has also been demonstrated to be 
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important for stimulating liver formation (Lokmane et al., 2008). Interestingly, 
HNF1 α null mouse models display a lack of endoderm competence and are thus 
unable to initiate hepatic specification. 
 
GATA4 is a member of the GATA zinc finger transcription factors, which is 
involved in the regulation of the heart tube and foregut formation during 
embryogenesis, more specifically linked to myocardial differentiation (Charron et al., 
2001). The GATA transcription factors recognize a consensus sequence AGATAG 
located in the promoter regions of a number of genes such as the insulin growth 
factor I gene (Dame et al., 2004). It has been demonstrated that GATA4 is essential 
for hepatic specification as deficient mouse ES cells failed to differentiate into 
definitive endoderm (Watt et al., 2007). As a result, GATA4 is essential for the 
differentiation of extra embryonic endoderm in developing embryos. In addition, 
GATA4 plays a vital role in pancreatic and hepatic formation in conjunction with 
GATA 6, FOXA1 and C/EBP. 
 
C/EBP α is a member of the bZIP transcription factors that recognize the consensus 
CCAAT as either a homo- or heterodimers with other members of the family (Hattori 
et al., 2007). C/EBP α is a regulator of gluconeogenesis capable of activating 
phosphoenolpyruvate carboxykinase, a key enzyme responsible for converting 
oxaloacetate into phosphoenolpyruvate and carbon dioxide. Unlike FOXA1, HNF1 α 
and GATA transcription factors, C/EBP proteins modulate hepatocyte metabolism. 
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The hepatocyte nuclear factor family of transcription factors are thought to constitute 
the majority of liver enriched transcription factors responsible for normal liver 
development. HNF1 α and β, HNF3 α and β, HNF4 α and HNF6 are key components 
required for liver development. Each factor has a unique expression pattern, which 
has helped to differentiate between their individual roles (Cereghini, 1996, Costa et 
al., 2003, Kyrmizi et al., , Lemaigre et al., 2004). HNF1 α is exclusively expressed in 
fetal and hepatocytes suggesting a role in specification (Lemaigre et al., 2004, Odom 
et al., 2004). HNF4 α on the other hand is expressed in both fetal and adult 
hepatocytes (Lemaigre et al., 2004, Sladek et al., 1990). Therefore HNF4 α can be 
implicated in both the differentiation and maintenance of the hepatic phenotype. 
HNF6 is expressed in both fetal and adult hepatocytes and in biliary epithelial cells; 
however, its expression is ablated on biliary maturation (Lemaigre et al., 2004, 
Bezerra, 1998). HNF6 is central to regulation of gluconeogenic, glycolytic, bile acid 
synthesis pathways and is essential for hepatocyte proliferation (Jacquemin et al., 
2003, Costa et al., 2003). HNF3 α and β is expressed in both fetal and adult biliary 
epithelial cells (BEC) and fetal hepatocytes; but expression is obliterated during 
maturation (Kaestner, 2000, Lemaigre et al., 2004). HNF4 α, HNF6, HNF1 α and β 
work synergistically and cooperatively to coordinate events throughout hepatocyte 
differentiation. HNF4 α and 6 co-regulate glucose-6-phosphate expression whilst 
HNF1 and 4 α control glucose, lipid and amino acid metabolism (Costa et al., 2003, 
Lokmane et al., 2008). HNF1 α is essential for the regulation of bile acid production 
and fatty acid oxidation within the liver (Coffinier et al., 2002). In conclusion, the 
HNF family are intricately involved in regulating hepatic development, 
differentiation and function. However, HNF4 α seems to play a key role in all the 
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above processes. As a result, we focused on understanding the properties and 
characteristics of HNF4 α. 
 
1.3.3 HEPATOCYTE NUCLEAR FACTOR 4 α 
1.3.3.1 THE PROPERTIES AND STRUCTURE OF HEPATOCYTE NUCLEAR FACTOR 4 α 
Hepatocyte nuclear factor 4 α (HNF4 α) is a highly conserved member of the nuclear 
receptor superfamily of transcription factors (Hong et al., 2003) and is expressed in 
the liver, pancreas, kidney, colon and intestine (Sladek et al., 1990). HNF4 α is a 
constitutively active orphan receptor that binds DNA strictly as homodimer to the 
direct response-1 (DR1) elements with the AGGTCAGGGG(T/A)CA consensus 
sequence (Sladek et al., 2000). HNF4 α has also been demonstrated to bind to DR2 
sequences but with a much lower affinity when compared to DR1 sequences. In 
addition, HNF4 α has been demonstrated to coordinate with other transcriptions 
factors such as C/EBP α, p300 and HNF6 to activate the expression of a number of 
liver specific genes (Viollet et al., 1997). Studies have shown that HNF4 α directly 
regulates a variety of hepatic specific genes involved in glucose, amino acid and lipid 
metabolism, cell structure, liver differentiation and immune function (Wisely et al., 
2002).   
 
HNF4 α is comprised of five functional regions each attributing towards a specific 
function carried out by the protein, Figure 1.3 (Hadzopoulou-Cladaras et al., 1997). 
Two activation domains are present at the amino and carboxyl terminals on HNF4 α 
and are responsible for promoting transcriptional activation of target genes, Figure 
1.3 A (Hadzopoulou-Cladaras et al., 1997). HNF4 α directly binds to DNA via the 
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DNA binding domain and contains a ligand binding domain that has recently been 
shown to bind linoleic acid in a reversible manner (Dhe-Paganon et al., 2002, Wisely 
et al., 2002). The repressor domain provides another method of functional regulation 
responsible for inhibiting gene transcription, Figure 1.3 A. The deletion of the 
repressor domain actively results in the up regulation of transcriptional activation 
(Ihara et al., 2005). The DNA binding domain is created from two zinc fingers with 
four cysteine residues each linked by a hinge region, Figure 1.3 B. The ligand 
binding domain consists of 12 alpha helices arranged in a manner exposing a 
hydrophobic pocket demonstrated to bind fatty acids with high affinity in bacterial 
expressed HNF4 α (Dhe-Paganon et al., 2002, Wisely et al., 2002). Mammalian 
expressed HNF4 α only binds to linoleic acid however, no difference in 
transactivation function was noted (Yuan et al., 2009). HNF4 α can adopt two 
conformational states; an open form where the α 12 helix is extended and parallel to 
α helix 10 and a closed form where the α 12 helix is folded upwards (Dhe-Paganon et 
al., 2002). However, both the conformations allows fatty acid ligand binding, 
whereby the carboxylic acid group of the fatty acid binds with the guanadinium 
group of arginine 226 and the aliphatic chain is arranged along tunnel of hydrophobic 





























Figure 1.3 – Structure and 3D Schematic of Hepatocyte Nuclear Factor 4 α.  
A. HNF4 α has 5 functional groups, including the activation domain (AD), the ligand binding domain (LBD), the DNA binding 
domain (DNA BD) and the repression domain (RD).  (Bogan et al., 2000, Sladek et al., 1990) B.  The 3D schematic of the 
HNF4 α homo-dimer zinc finger heterodimer binding to double stranded DNA. (Dhe-Paganon et al., 2002) 
 
 
1.3.3.2 HEPATOCYTE NUCLEAR FACTOR 4 α Isoforms 
HNF4 α has six known splice variants, whose relative expression is regulated in a 
tissue specific manner. The HNF4 α gene contains two promoters P1 and P2, 
responsible for expressing six distinct splice variants, which differ in their activation 
(AD1 and AD2) and repressor domains, Figure 1.4 (Briancon et al., 2006). 
Differential expression of the P1 and P2 driven variants have been documented in the 
mouse fetal and adult liver, whereby P1 driven transcripts are most likely found in 
the adult liver whilst P2 variants are predominant in the fetal liver, Figure 1.4 
B 
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(Tanaka et al., 2006, Sladek et al., 1990)s. Variants 1 to 3 are expressed from the P1 
promoter, whilst variants 4 to 6 are driven by the P2 promoter, Figure 1.4 (Sladek et 
al., 2000). HNF4 α v2 is predominately expressed in the adult liver, whilst HNF4 α 
v4 and v5 are prevalently expressed in the adult pancreas within beta cells (Ihara et 
al., 2005). It has been speculated that the individual HNF4 α isoforms have specific 
functions, suggested by their varied spatial and temporal expression. HNF4 α v5 
lacks a complete activation domain-1, which could account for the reduced 
transcriptional activation potential when compared to variant 1 (Ihara et al., 2005). 
Studies have also shown that the activation domains present on the carboxyl and 
amino terminals of HNF4 α interact to enhance transcription (Hadzopoulou-Cladaras 
et al., 1997). This could also be attributed to the limited transcriptional function of 
HNF4 α v5. In addition, the deletion of the activation region 2 on HNF4 α variant 1 
resulted in the absolute inhibition of transcriptional activity (Hadzopoulou-Cladaras 
et al., 1997).  
 
Additionally, transcriptional regulation of the HNF4 α variants has been shown to be 
influenced by specific activators. HNF4 α v1 transcriptional activation is 
significantly enhanced in the presence of co activators glucocorticoid receptor 
interacting protein 1 (GRIP-1) and cAMP response element binding protein (CBP) 
(Torres-Padilla et al., 2002). On the other hand, HNF4 α v4 lacks the complete 
activation domain and has limited transcriptional activity, as observed with variant 5 
(Torres-Padilla et al., 2002). However, HNF4 α v4 is also capable of interacting with 
GRIP-1 and p300 via the second activation domain but cannot do so synergistically 
required for enhanced transcriptional activity as observed with HNF4 α v1 (Torres-
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Padilla et al., 2002). Therefore, there seem to be distinct roles for the individual 
variants demonstrated by their varied functional abilities and interaction capabilities 























Figure 1.4 - Splicing Differences between the Various HNF4 α Variants.  
HNF4 α has six different splice variants generated from two promoters, P1 and P2. All variants contain the ligand and DNA 
binding domains and differ in their activation and repression domains. Variants 1, 2 and 3 rely on promoter one for expression, 
used in the adult liver whilst variants 4, 5 and 6 rely on promoter two, used in the fetal liver. (Sladek et al., 1990) 
 
Differentiation expression of the P1 and P2 driven HNF4 α variants has been 
detected in tumorigenic tissues. A significant up regulation of P1 driven variants is 
present in intestinal metaplasia and gastric cancer, specifically in the intestinal type 
(Tanaka et al., 2006). The intestinal form of the cancer is defined by the 
transdifferentiation of the gastric epithelial cells into an intestinal cell type (Tanaka 
et al., 2006). Conversely, enhancing the expression of P1 driven isoforms resulted in 
reduced hepatocellular and renal cell carcinoma proliferation (Lazarevich et al., 
2004, Lucas et al., 2005, Chiba et al., 2005). Throughout mouse development, a 
switch between P2 and P1 driven HNF4 α variants is required for liver maturation 
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and has been documented to be involved in various cancers. However, the expression 
of the HNF4 α splice variants within the human liver is yet to be elucidated.  
 
1.3.3.3 THE IMPORTANCE OF HEPATOCYTE NUCLEAR FACTOR 4 α  
HNF4 α is a vital factor associated with both liver development and adult liver 
metabolism. HNF4 α gene knock out during embryogenesis results in embryo 
lethality due to visceral endoderm defects (Chen et al., 1994) This can be 
circumvented using conditional knock outs; however this still results in the formation 
of embryonic livers containing large red lesions, with discontinuous parenchyma 
(Parviz et al., 2003). In addition, glycogen accumulation decreased and E-cadherin 
expression was reduced, resulting in limited cellular interactions, in HNF4 α mutant 
livers (Parviz et al., 2003). Forced expression, using a recombinant retrovirus, of 
HNF4 α within fibroblasts induced morphological changes associated with 
hepatocytes, such as forming polygonal shaped cells and increased expression of E-
cadherin found to be localised on the cell membranes. The results indicate the 
significant role of HNF4 α in regulating hepatic architecture and organisation (Parviz 
et al., 2003). Additionally, driving the expression of HNF4 α in a dedifferentiated 
hepatoma cell line (H5) resulted in re-establishing cellular junctions and polarity, 
inducing the expression of silenced hepatic genes such as HNF1 and activating 
hepatic functions such as serum protein production (Spath et al., 1997, Spath et al., 
1998). 
 
A large number of genes involved in normal liver functions such as glucose 
regulation, lipid synthesis, fatty acid production, xenobiotic and drug metabolism 
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contain HNF4 α binding sequences within their promoter regions or have been 
indirectly associated  (Sladek et al., 2000).  As such, HNF4 α is an essential regulator 
of adult liver functional activities. Duncan and colleagues have demonstrated that 
HNF4 α regulates the expression of genes required for glucose entry and glycolysis, 
whereby pathway activation is inhibited in livers with mutations in the glucokinase 
gene (Stoffel et al., 1997).  HNF4 α is required for the expression of the cytochrome 
p450 genes and Phase II enzymes necessary for drug metabolism (Gonzalez, 2008) in 
addition to coordinating the majority the genes associated with the apolipoprotien 
and lipid pathways within the liver (Hayhurst et al., 2001). Overall, HNF4 α is a 
unique transcriptional activator responsible for effective liver development and the 
efficient maintenance of liver specific metabolic activities. In can be assumed that 
HNF4 α plays a key role in differentiating hESCs down the hepatic lineage. 
 
 1.3.3.4 REGULATION OF HEPATOCYTE NUCLEAR FACTOR 4 α  
The mechanisms behind regulating the transcription and function of HNF4 α remain 
obscure. However, covalent modifications of HNF4 α have been documented. HNF4 
α is phosphorylated, acetylated and methylated whereby each modification results in 
a change in function including DNA binding, gene transactivation, cellular 
localisation and protein dimerization  (Viollet et al., 1997, Sladek et al., 2000). HNF4 
α contains a conserved protein kinase A (PKA) consensus site located within the A 
box of the DNA binding domain. Phosphorylation of the serine residues via PKA 
resulted in decreased ability to bind DNA and reduced transcription, in vitro and 
vivo. (Viollet et al., 1997) 
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Sun and colleagues established that the phosphorylation of HNF4 α via protein 
kinase C on the conserved serine residue residing between the two zinc fingers 
reduced DNA binding, transactivation, protein stability and altered nuclear 
localisation. Mutating the serine residue resulted in the diminution of the above 
functions. Treating a hepatocellular carcinoma cell lines (HepG2) with phorobol 12-
myristate 13-acetate, a PKC activator, increased the levels of cytoplasmic HNF4 α in 
addition to decreased levels of endogenous HNF4 α due to 26S proteasome mediated 
degradation. Phosphorylation of other nuclear receptors demonstrated similar results 
indicating a possible global mechanism for the regulation of nuclear receptor 
function. (Sun et al., 2007) 
 
Post-translational modifications (PTM) of HNF4 α appear to play a significant role in 
regulating protein function. SUMOylation is a type of PTM that regulates the 
activities of proteins involved in a large number of cellular metabolic functions. 
Therefore, SUMOylation may affect the function of HNF4 α, specifically within 
hESC differentiating into hepatic endoderm.  
 
1.4 POST TRANSLATIONAL MODIFICATIONS 
Post translational modifications (PTMs) occur once a protein has been translated via 
the ribosomes and have been found to be involved in most or all cellular activities 
(Walsh et al., 2005). PTMs affect cellular processes ranging from protein 
degradation to regulating cell division to inducing differentiation, as such play a vital 
role in maintaining normal cellular metabolic activities (Walsh et al., 2005). 
Phosphorylation is the most common PTM and is usually involved in the regulation 
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of the activation or inhibition of down stream signalling pathways such as the 
phosphoinositide 3 kinase pathway, vital for cell proliferation, differentiation and 
intracellular trafficking (Karpova et al., 2006, Opazo et al., 2003). Methylation is 
another form of a PTM, whereby a methyl ion is covalently attached to the target 
protein or molecule (Imhof, 2006). DNA is commonly methylated; a reaction 
catalysed by DNA methyltransferase, and usually results in the repression of gene 
expression (Macgillivray et al., 1972). Proteins have also been documented to be 
methylated. Histones are the most investigated methylated proteins, resulting in the 
epigenetic regulation of gene expression (Nakayama et al., 2001).  SUMOylation is 
another PTM demonstrated to affect various protein functions involved in cellular 




Post translational modifications involve the addition of a chemical group following 
protein translation (Walsh et al., 2005).  PTMs are essential to a variety of cellular 
processes and provide another level of protein regulation, which is usually reversible. 
There are a large number of PTMs that take place in the cell such as: phosphorylation 
(Burnett et al., 1954), methylation (Grewal et al., 2004), acetylation (Glozak et al., 
2005) and glycosylation (Spiro, 2002); regulating various biological activities such 
as transcriptional regulation (Waby et al., 2008) and protein degradation (Orford et 
al,  1997). 
 
1.4.1.1 SUMO- THE SMALL UBIQUITIN LIKE MODIFIER 
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SUMOylation, another type of PTM, has a diverse range of effects within the living 
cell (Johnson,  2004). SUMO proteins are highly conserved in a large number of 
species and have been shown to be important in many eukaryotic cell processes 
(Hayashi et al,  2002) including; cell cycle regulation, transcription, cellular 
localisation, degradation and chromatin organisation (Müller et al,  2001, Seeler and 
Dejean,  2003, Verger et al,  2003). Despite the name, SUMO only shares ~18% 
homology with ubiquitin (Müller et al,  2001) and is approximately 11kDa in size, 
comparable to the 8kDa ubiquitin molecule (Müller et al,  2001). SUMO has been 
found to bind to the lysine residue on the following consensus sequence; ψKxE 
(where ψ corresponds to a large hydrophobic amino acid, K is a lysine residue, x is 
any amino acid and E is a glutamic acid residue) on the target protein (Rodriguez et 
al., 2001). Three homologues exist in mammals, SUMO -1, -2 and -3. SUMO -2 and 
-3 share 95% homology with each other, but only share 50% identity with SUMO-1 
(Johnson,  2004). SUMO -2 and -3 have the ability to form poly SUMO chains, 
covalently binding to themselves via the lysine residue at the N terminus consensus 
motif ψKxE. SUMO-1 lacks this consensus site and as a consequence is unable to 
form poly chains (Kroetz,  2005) and acts as a poly SUMO chain terminator (Ulrich,  
2009).  
 
1.4.1.2 THE MECHANISM OF THE SUMO PATHWAY 
1.4.1.2.1 Pathway Overview 
The SUMO conjugation pathway has a lot in common with the ubiquitination 
pathway. Both processes involve the use of three enzymes; E1- activating enzyme, 
E2 – conjugating enzyme and E3 – ligase (Takahashi et al,  2001). SUMO is bound 
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to its target protein via an isopeptide bond formed between an є- amino group on the 
lysine residue on the target protein and the C terminal carboxyl group on the SUMO 
protein (Desterro et al,  1997). The pro-form of SUMO needs to be cleaved prior to 
protein conjugation (Desterro et al., 1999). This is carried out by isopeptidases, also 
known as the SENP SUMO deconjugating enzymes (Mukhopadhyay and Dasso,  
2007). The SUMO activating enzyme (E1), SAE1/2, commences the reaction process 
by interacting with SUMO (activated by SENP enzymes), to form a high energy 
thioester bond. The SUMO conjugating enzyme (E2) then binds SUMO via its 
cysteine residue in its active site. This intermediate provides a highly reactive 
species, important in the final conjugation, usually facilitated by an E3 ligase 
(Kroetz,  2005). SUMO E3 ligases act to either activate Ubc9 or bring Ubc9 and the 
target protein within close proximity of each other, thus enhancing SUMOylation 
(Ulrich,  2009). They can be regarded as E3 enzymes as they are able to bind to the 
E2 and the substrate and facilitate the formation of the bond formed between SUMO 
and the target protein. It has also been shown that a large number of proteins (~ 40%) 
can be SUMOylated without the presence of the consensus sequence (ψKxE), 
demonstrating differences in substrate specificity (Ulrich,  2009). 
 
1.4.1.2.2 The Enzymes Involved 
1.4.1.2.2.1 E1 
Unlike the ubiquitin (Ub) E1, the SUMO E1 exists as a heterodimer; with each 
monomer corresponding to a particular region of the Ub E1. The SAE subunit Aos1 
(SAE1) shares similarity with the N terminus of the Ub E1, whilst Uba2 (SAE2), the 
second component of the SAE complex, is similar to the C terminus of the Ub E1 
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(Johnson et al,  1997). The monomers are never found individually and hence it is 
assumed that they are unable to function independently (Azuma et al,  2001). The 
SAE complex is responsible for preparing SUMO for transfer to the SUMO 
conjugating enzyme, Ubc9 (Walden et al,  2003). 
 
1.4.1.2.2.2 E2 
Ubc9 is the only known SUMO conjugating enzyme, unlike the ubiquitination 
pathway where each E2 has a specific set of target proteins (Hayashi et al,  2002).  
Ubc9 contains an active site with a cysteine residue which is responsible for binding 
the SUMO molecule directly to the ψKxE sequence found on the target protein 
(Sternsdorf et al, 1999)(Rodriguez et al., 2001).  Investigations have confirmed the 
presence of a conserved N terminal region known to interact with SUMO is required 
for the efficient transfer of SUMO from the E1 enzyme to E2 (Tatham et al., 2003). 
Interestingly, mutations within the binding region did not affect Ubc9’s ability to 
recognise and bind SUMO to the target protein (Tatham et al., 2003).  
 
1.4.1.2.2.3 E3 
In contrast to SUMO E2s, a larger number of SUMO E3 ligases have been 
discovered and have been categorized into three types; the protein inhibitor of 
activated STAT - signal transducer and activator of transcription (PIAS) family 
(Hochstrasser,  2001), the nuclear pore proteins Ran binding protein 2 and 
nucleoporin 358 (RanBP2/Nup358)  (Pichler et al,  2002) and the polycomb group 
protein Pc2 (Kagey et al,  2003). E3 ligases are usually substrate specific with little 
redundancy found within the system. 
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The largest group of E3 ligases are the PIAS proteins with four genes in mammals; 
PIAS1, PIAS3, PIASx and PIASγ (Liu et al,  1998). The PIAS E3s have a conserved 
region consisting of a SAP domain responsible for binding AT rich DNA sequences 
and an SP-RING domain which binds to Ubc9 and promotes SUMOylation (Schmidt 
and Müller,  2002). They also contain SUMO interaction motifs (SIMs) that are able 
to directly bind SUMO (Rytinki et al,  2009). It has been found that the different 
PIAS proteins SUMOylate distinct sets of substrates, with occasional overlap 
(Schmidt and Müller,  2002). The second group of E3 SUMO ligases consists of the 
nuclear pore protein RanBP2 (Nup358) with only one known substrate, RanGAP1, a 
GTPase activating protein important in nuclear transport of proteins (Nishimoto,  
1999, Saitoh et al,  1997). We have also shown that Ran GAP can be SUMO 
modified in vitro. The final family SUMO E3 ligase identified so far is the PC2 
protein part of  the polycomb group (Kagey et al,  2003). Pc2 has been shown to 
SUMOylate the transcriptional co-repressor CtBP, localising it to the nucleus (Lin et 
al,  2003), and to co-localise with PcG bodies (Kagey et al,  2003).  
 
1.4.1.3 REGULATION OF THE SUMO PATHWAY 
SUMO modification is a dynamic process involving both conjugation and 
deconjugation enzymes. The deconjugation enzymes function by cleaving the 
isopeptide bond between SUMO and the modified protein (Melchior et al,  2003). 
There are seven isoforms of these isopeptidases; including SENP1, SENP2, SENP3, 
SENP6 and SENP7 (Mukhopadhyay and Dasso,  2007). The SENPs contain a Ulp 
domain at their C terminus responsible for cleaving the isopeptide bond and distinct 
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N terminal domains that regulate their cellular localisation; suggesting each SENP 
has a distinct set of substrates (Mukhopadhyay and Dasso,  2007). In addition to their 
deconjugation role, the SENPs also play an essential role in maintaining the levels of 
free SUMO within the cell (Ulrich,  2009). Other forms of SUMO regulation include 
the E3 ligases and the presence of the consensus motif on target proteins. It has 
previously been stated that 40% of proteins modified by SUMO do not have the 
typical consensus sequence; as such, this could also be regarded as another form of 
regulation. 
 
1.4.1.4 THE ROLE OF SUMO CONJUGATION WITHIN THE CELL 
Over the last decade a number of groups have investigated how the SUMO pathway 
is regulated in response to different stimuli. In response to heat shock, 
erythroleukemia cells induce transcription of heat shock factor 1 (HSF1). After its 
translation, HSF1 is phosphorylated prior to its SUMOylation, which enhances its 
DNA binding  (Hong et al,  2001). It is also widely recognised that SUMO alters 
protein activity by modulating other PTMs, such as phosphorylation and 
ubiquitination. For example, SUMOylation of IκBα, an important factor in the 
inflammatory response, prevents its ubiquitination, and therefore inhibits its 
degradation and subsequent NF-κB activation and nuclear translocation (Desterro et 
al,  1998) (Hay et al., 1999). SUMO can also regulate protein activity by modulating 
its interactions with other macromolecules or proteins. Various models have been 
proposed such as; the addition of SUMO by altering protein configuration, creating a 
new interaction motif affecting its function (Johnson,  2004). An interesting example 
of interaction motifs is arsenic induced RNF4 mediated degradation of 
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promyelocytic leukaemia (PML) bodies. In the presence of arsenic, PML is poly 
SUMOylated, and following the recruitment of RNF4, an E3 Ub ligase, PML is 
ubiquitinated and degraded (Tatham et al,  2008). 
 
1.4.1.5 THE IMPORTANCE OF SUMOYLATION IN DEVELOPMENT AND CELL 
BIOLOGY 
Various studies have shown that disruption of the SUMO pathway causes abnormal 
cellular differentiation. Moreover, disruption of the SUMO pathway during 
embryogenesis may lead to embryo lethality (Nacerddine et al,  2005, Nowak and 
Hammerschmidt,  2006), demonstrating the requirement for SUMOylation during 
development. Due to the lethal nature of Ubc9 knock outs during development in a 
variety of species such as mouse (Nacerddine et al, 2005), zebrafish (Nowak et al, 
2006) and yeast (Johnson, 2004), other experimental strategies are necessary to 
determine the precise role of SUMOylation. In vitro, there has been a focus on the 
role of SUMOylation in a number of cell types; human embryonic stem cells 
(hESCs) and representatives of all three germ layers, Figure 1.5. These models, 






Figure 1.5- Importance of SUMOylation in Cell Biology 
SUMO modification affects a number of cellular processes. (A) In human embryonic stem cells (hESCs), SUMO binds to Oct4 
in the nucleus (blue), enhancing its stability and transcriptional activity, which is an important regulatory mechanism in hESC 
self-renewal and pluripotency. SUMO modification also plays an important role in somatic cell biology. (B) In cardiomyocytes; 
SUMOylation regulates the properties of the Kv1.5 potassium voltage channel located at the plasma membrane. These channels 
play an essential role in cardiomyocyte membrane potential. The inhibition of SUMO modification to the Kv1.5 channel results 
in the opening of membrane channels, exporting potassium ions, which results in cellular hyperpolarisation. (C) SUMO 
conjugation in hepatocytes regulates the transcriptional activity of C/EBP influencing albumin (ALB) expression within the 
nucleus (blue). SUMO modification of C/EBP inhibits its ability to form a complex with BRG1/SW1/SNF essential for high-
level albumin expression. SW1/SNF is a chromatin-remodelling complex and BRG is a core subunit of the complex. (D) 
SUMOylation has also been shown to regulate the activity of the GluR6 receptor in neural cells by endocytosis. Kinate induced 




1.4.1.5.1 Human Embryonic Stem Cells 
SUMO modification has been shown to have an important role in both hESC self 
renewal and pluripotency (Wei et al,  2007).  Oct4 is a POU transcription factor 
associated with the undifferentiated and pluripotent status of embryonic stem cells 
(Hay et al,  2004, Niwa et al,  1998). It is known to be SUMO modified, which 
results in its increased stability, DNA binding and transcriptional activity, Figure 1.5 
A (Wei et al,  2007). Sex determining region Y box 2 (SOX2) is another important 
transcription factor required for embryonic stem cell self-renewal in an 
undifferentiated state (Zeng et al, 2006). It was recently shown by Hoof and 
colleagues that SOX2 is SUMO modified as a result of phosphorylation. It has been 
suggested that SUMO modification of SOX2 affects its transcriptional activity (Hoof 
et al, 2009, Hietakangas et al, 2006) but further investigation is required. The role of 
SUMOylation has also been determined in cell types representative of the three germ 
layers; endoderm, mesoderm and ectoderm.  
 
1.4.1.5.2 Mesoderm 
During development the mesoderm differentiates into muscle, cartilage, bone, blood 
and connective tissue (Biggers and Borland,  1976). The heart significantly relies on 
the coordination of various ion channels for regular function. One such voltage-gated 
channel is the potassium channel Kv1.5 found in atrial myocytes, which modulate 
membrane potential of smooth muscle cells (Lagrutta et al, 2006). Benson and 
colleagues have shown that Kv1.5 has two conserved consensus SUMOylation 
motifs, which play an important role in hyperpolarisation, Figure 1.5 A (efflux of 
potassium ions) (Benson et al,  2007). At the initial stages of development, the poly 
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comb 2 protein (Pc2), part of the polycomb repressor complex 1(PRC1), is 
SUMOylated. This allows efficient complex formation and its recruitment to 
methylated histone 3 for controlled gene silencing. On mesoderm formation, SENP2 
is recruited to PRC1, deSUMOylates the Pc2 protein and allows the expression of 
GATA4 and 6 transcription factors essential for normal cardiac formation (Kang et 
al, 2010). Interestingly, in adult cardiomyocytes, SUMO modification of GATA4 
results in increased transcriptional activity, and promotes cardiogenic gene activity  
(Wang et al,  2004).  
 
1.4.1.5.3 Endoderm 
The endoderm layer is formed during embryogenesis and is the precursor of liver, 
pancreas and lung amongst others (Tam et al,  2003). SUMOylation plays an 
important role in hepatocyte biology regulating C/EBP, a crucial factor in hepatic 
differentiation (Pedersen et al,  2001, Sato et al,  2006). SUMOylation of C/EBP 
prevents its association with BRG1, a core subunit in the SW1/SNF chromatin 
remodelling unit, leading to the inhibition of albumin expression, Figure 1.5 C (Sato 
et al,  2006). In line with this, it has been shown that there is a decrease in levels of 
SUMOylation as rat hepatocytes mature (Sato et al,  2006), suggesting an inhibitory 
effect of SUMOylation in hepatocyte terminal differentiation. The mitochondria are 
an essential component of hepatocytes, the main cell type in the liver, and are 
required for efficient liver function. Mitochondrial levels in the cell are dynamic and 
continuously undergo fusion and fission (Twig et al,  2008, Frazier et al,  2006).  It 
has been shown that an increase in SUMO-1 expression results in an increase in 
mitochondrial fragmentation by stabilising the GTPase dynamin-related protein 1 
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(DRP1) (Harder et al,  2004). Further investigation of this pathway has revealed that 
SENP 5, a SUMO deconjugating enzyme, is required for normal mitochondrial 
morphology and levels of reactive oxidative species within the cell, partly by SUMO 
deconjugation of DRP1 (Zunino et al, 2007). In the pancreas, SUMO modification of 
islet cell auto antigen 512 (ICA512) has been shown to disrupt its binding to STAT5 
and inhibit insulin and granule related gene transcription (Mziaut et al,  2006). 
 
1.4.1.5.4 Ectoderm 
Ectodermal differentiation results in the formation of the skin and nervous system 
(Pelton et al,  1998). SUMOylation also plays an important role in the nervous 
system. GluR6 is a highly expressed kinate receptor found in the brain, and is 
concentrated in the hippocampus (Nasu-Nishimura et al,  2010). The receptor is 
known to regulate neuronal excitability and as such is involved in learning, memory 
and synaptic plasticity (Barberis et al,  2008). It has been shown that the 
internalisation of the receptor upon kinate stimulation is regulated by SUMOylation. 
GluR6 is internalised via kinate or N-methyl-D-aspartate (NMDA) induced 
endocytosis. Only kinate induced internalisation requires GluR6 SUMOylation, 
Figure 1.5 C.  The mutation of the SUMO consensus motif in GluR6 results in a 
large reduction in kinate induced GluR6 internalisation and disrupts regular synaptic 
function (Martin et al,  2007).  Another factor important for both brain development 
and neuronal differentiation is MEF2A. MEF2A and its associated family members 
have been shown to be involved in the proliferation, differentiation and apoptosis of 
cells found in the developing brain (McKinsey et al,  2002). SUMOylation of 
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MEF2A decreases its transcriptional activity, suppressing Nur77 function; and 
promotes dendritic claw differentiation (Shalizi et al,  2006).  
 
SUMOylation is an important PTM known to play roles embryonic stem cell and 
somatic cell biology. Given its importance in cell biology, it is critical that we 
understand SUMOylation in order to generate stable and high fidelity models that 
predict human drug toxicity. These models will not only be useful tools for 
toxicology, but will also provide a system whereby we can investigate the role(s) of 
SUMO modification in response to numerous stimuli. This will undoubtedly provide 
information on novel mechanisms of action with the possibility of developing new 
medicines and clinical intervention strategies. 
 
1.5 THE OBJECTIVES OF THE THESIS 
The thesis initially focuses on establishing a better-defined model for culturing 
human embryonic stem cells and their subsequent differentiation into hepatocytes. 
The culture system was used as a platform for studying the underlying biology of 
human hepatocyte differentiation from hESCs. We then focused on a key liver 
enriched transcription factor, hepatocyte nuclear factor 4 α (HNF4 α), and its post 
translational modification by SUMO. The final investigation was carried out to 
elucidate the relationship between HNF4 α and SUMOylation in vitro, using 
























MATERIALS AND METHODS 
 
2.1 MATERIALS AND SOLUTIONS 
 
2.1.1 REAGENT SOLUTIONS 
 
All reagents are supplied by Life Technologies, unless stated otherwise. 
 
TABLE 2.1.  Solutions used in a variety of techniques. 
 
SUMO Lysis Buffer: 2% SDS 
50 mM Tris pH 8 
1 mM EDTA 
10 mM Iodoacetimide 
Protein Loading Dye: NuPAGE® LDS Sample Buffer (x4) 
SDS-PAGE Running Buffer: NuPAGE® MES SDS Running Buffer 
(x20) 
Western Transfer Buffer: NuPAGE® Transfer Buffer (x20) 
1 x PBS: 0.01 M Phosphate Buffer 
0.0027 M Potassium chloride  
0.137 M Sodium chloride 
 
PBS Tween: 1 x PBS 
0.05% (v/v) Tween-20 
 
Coomassie Stain: 10% (v/v) Methanol (Sigma Aldrich) 
20% (v/v) Acetic Acid (Sigma Aldrich) 
200 mg/L Coomassie R-250 
 
Destain Solution: 20% (v/v) Methanol (Sigma Aldrich) 
10% (v/v) Glacial Acetic Acid (Sigma 
Aldrich) 
Deionised Water 
LB media: 1% (w/v) Yeast Extract (Sigma Aldrich) 
1% (w/v) Bacto-tryptone  
(Sigma Aldrich) 
86 mM NaCl (Sigma Aldrich) 
Native Lysis Buffer: 10% Glycerol (Sigma Aldrich) 
5 M NaCl 
10 mM Tris pH 7.8 
5 mM DTT 
Low Salt Buffer: 10 mM HEPES pH 7.9 (Sigma Aldrich) 
10 mM KCL 
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1.5 mM  MgCl2 
0.5 mM DTT 
CB100: 10% Glycerol (Sigma Aldrich) 
25 mM HEPES pH 7.9 
0.2 mM EDTA 
100 mM KCL 
5 mM DTT 
0.5 mM PMSF 
20 mM Imidazole 
CB1000: 10% Glycerol (Sigma Aldrich) 
25 mM HEPES pH 7.9 
0.2 mM EDTA 
1000 mM KCL 
5 mM DTT 
0.5 mM PMSF 
20 mM Imidazole 
Dialysis Buffer: 20% Glycerol (Sigma Aldrich) 
50 mM Tris pH 7.5 
5 mM MgCl2 
5 mM DTT 
Elution Buffer: 20% Glycerol (Sigma Aldrich) 
25 mM HEPES pH 7.9 
0.2 mM EDTA 
100 mM KCL 
5 mM DTT 
0.5 mM PMSF 
200 mM Imidazole 
NP40 Lysis Buffer: 50 mM Tris pH 8 
150 mM NaCl 
5 mM EDTA 



















2.1.2 CELL CULTURE MEDIA  
 
TABLE 2.2.  Cell culture media used for the respective cell lines. 
 












4 ng/ml basic fibroblast 





















































Leibovitz L-15 Medium 
B27 
100 ng/ml Activin A 
50 ng/ml Wnt3A 
 
20% Knock out Serum 
Replacement 
0.5% L-Glutamine 
1% Non-Essential Amino 
Acids 
0.1 mM β-Mercaptoethanol 
1% DMSO 
 
8.3 % Tryptose phosphate 
broth  
8.3% FBS 
10 µM hydrocortisone 21-
hemisuccinate 
1 µM Insulin (bovine 
pancreas) 
1% L-Glutamine 
0.2% Ascorbic Acid 
10 ng/ml Hepatocyte 
Growth Factor 
20 ng/ml Oncostatin M 
1:3 Life Technologies 
Peprotech 




























10% (v/v) Foetal bovine 
serum  (FBS) 
200 mM L-Glutamine  
10 mM MEM NEAA 
100 mM MEM Sodium 
Pyruvate  
1% Penicillin-Streptomycin   





Medium Eagle (MEM) 
10% FBS 
0.1mM NEAA 
1mM Sodium Pyruvate 






TABLE  2.3.  Antibodies used for immunofluorescence (IF) and Western blotting 
(WB) 
 





Alpha Feto Protein (AFP) 
Albumin 
Beta Actin 









































































































University of Dundee* 
Abcam 
Santa Cruz Biotech. 
Santa Cruz Biotech. 
DAKO 
Santa Cruz Biotech. 
Santa Cruz Biotech. 
R & D 
DAKO 
University of Dundee* 
University of Dundee* 
University of Dundee* 
University of Dundee* 





R & D 
R & D 
R & D 
R & D 





















2.1.4 OLIGONUCLEOTIDES  
 
The custom made primers were generated by MWG Eurofins Operon, Germany. 
 
TABLE 2.4.  Oligonucleotides 
 


































50 oC 35 
TO 
For - GGCAGCGAAGAAGACAAATC- 
Rev -TCGAACAGAATCCAACTCCC 




























For - CACTACGACCCAGGCTTCAT 
Rev - CTCCGCAGCTTCTTGCTTAG 
60 oC 30 
pLVX  For - TAGTGAACGGATCTCGACGG 
Rev - TTGGCGCCTACCGGTGGATG 




For - GTGACTCTGGTAACTAGAGATCCC 
 
Rev - ACTACTTGAAGCACTCAAGGCAAG 
55 oC 30 

















Rev-  TCAGACAGCGGCCGCAAGCGTAGTCTGGGACGTCGTATGGGT 
           AAA CTG TTG AAT GAC CCC CCG TTT 
SUMO-2 
For- TAGGATCCATGGCCGACGAAAAGCCCAAG 







For - AGAACGCGTGGTATGTCGGGGATCGCCCTCAGC 







For - CTTATGCGCGGCCGCGTGAAACAGACTTTGAATTT 
Rev - ACGCGTGAAGGGCCCTGGGTTGGACTCCACGTCTC 
95°C N/A 
HNF4 α 
WT For - CTTCGGCATGGCCAGGATTGCCAACCTGTTGCAGG 






Top - CACCGGAAGGAGGCTTGTTTAAACTCGAAAGTTTAAACAAGC   
CTC CTT CC 
Bottom - AAAAGGAAGGAGGCTTGTTTAAACTTTCGAGTTTAAACAAGC 
CTCCTTCC 
95°C N/A 

































2.1.5 E. COLI HOST STRAINS 
 











His6 tagged protein expression 
Point Mutagenesis DNA expression 
Stratagene, Europe 






2.1.6 DNA PLASMID VECTORS 
 




Fusion Tag Promoter(s) Source 
 












































2.2 MAMMALIAN CELL CULTURE AND DIFFERENTIATION 
 
All cell culture reagents were GIBCO® products supplied by Life Technologies 
(UK) unless stated otherwise. Greiner (UK) supplied the plasticware utilised 
throughout the cell culture. 
 
2.2.1 HUMAN EMBRYONIC STEM CELL CULTURE 
 
Gradual Transition of hESCs to MT 
H1 and H9 cells were cultured on Matrigel™ (BD Biosciences, UK) coated 
plasticware in conditioned media (CM, R & D Systems, UK) before being 
transferred into mTeSR-1® (MT, Life Tech., UK) (Table 2.2). The cells were split at 
a 1:3 ratio and allowed to settle overnight. They were then transferred into 80:20 
ratio of CM to MT followed by 60:40, 40:60, 20:80 and finally 100% MT (Hannoun 
et al., 2010). 
 
Culturing hESCs   
Human ESCs were cultured for over 30 passages on Matrigel™ coated 6 well plates 
and were fed 4 ml of MT or CM + 4 ng/ml bFGF (Table 2.2). The media in the plates 
was aspirated off and 4 ml of fresh media was added. The cells were incubated at 
37°C in 5% (v/v) CO2, 95% (v/v) air, for optimal growth.  
 
Passaging hESCs  
hESCs were split at a ratio of 1:3 and were passaged using collagenase. The existing 
media was aspirated off, and the cells were washed once with PBS. 1ml of 
collagenase was added and the cells incubated at 37°C for about 3 minutes until the 
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edges of the colonies rounded up. The enzyme was aspirated off and the cells were 
washed once with PBS. 4 ml of fresh media was added to the cells and they were 
subsequently scraped off and triturated 1-2 times before transferring 1 ml into a new 
plate containing 2ml of fresh media for a 1:3 split.  
 
Freezing and thawing hESCs 
The freezing mix used consisted of knock-out serum replacement and 8% dimethyl 
sulfoxide (DMSO). At 90-100% confluency, hESCs were scraped off, placed into a 
15ml tube, and centrifuged at 1000 rpm for 5 minutes. The supernatant was aspirated 
and the cells were resuspended in 0.5 ml of the freezing mix and transferred to a 
cryotube. The cells were stored at -80°C overnight and then transferred to liquid 
nitrogen.  
 
The cells were routinely thawed by placing the cryotube in a water bath at 37°C. The 
cells were then taken up in 1 ml of CM and were resuspended in 6 ml of CM. 
Subsequently, the cells were spun at 1000 rpm for 5 minutes and resuspended in 4ml 
of fresh CM containing bFGF or MT and placed into a Matrigel™ coated well.  
 
2.2.2 EMBROID BODY FORMATION 
Embroid bodies (EB’s) can be generated when hESCs are at about 90-100% 
confluent. The media was aspirated off and the cells were washed once with PBS. 4 
ml of EB media was added (Table 2.2). The cells were scraped off using a cell 
scraper. The full 4 ml containing hESCs were placed in low cluster plates to promote 
cell aggregation. The EB’s were fed with fresh EB media every other day for 7 days 
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until the EB’s were very defined and vacuolated. The EB’s were then transferred to 
0.5% gelatin coated chamber slides (BD Biosciences, UK). The plated down EB’s 
were allowed to differentiate spontaneously for 14 days and fed every other day with 
EB media. After 14 days the differentiated cells were fixed in 4% Paraformaldehyde 
(PFA) (Sigma Aldrich, UK) and were stained using antibodies for the three germ 
layers (Table 2.3), (Fletcher et al., 2008). 
 
2.2.3 HEPATIC DIFFERENTIATION OF HESCS 
hESCs were cultured and propagated on Matrigel™ coated plates with mouse 
embryonic fibroblast (MEF)-CM supplemented with bFGF or MT. Hepatic 
differentiation was initiated when hESCs reached a confluency level of 
approximately 30% by replacing the culture media with priming medium RPMI 
1640-B27 supplemented with 100 ng/ml Activin A  and 50 ng/ml Wnt3a (Table 2.2). 
The cells were cultured in priming medium for 3 days (the medium was replaced 
every 24 hours), and final priming medium with Activin A and Wnt3a was made up 
fresh each day. After 72 hours in priming medium, the medium was changed to 
differentiation medium SR-DMSO for 5 days (the medium was replaced every 48 
hours). The cells were subsequently cultured in maturation and maintenance medium 
L-15 (Table 2.2), supplemented with 10 ng/ml hHGF and 20 ng/ml OSM for 9 days 
(the medium was replaced every 48 hours). Maturation and maintenance medium 
with hHGF and OSM was made up fresh each day. The cells gradually exhibit 
morphological changes from a spiky/triangular shape to a characteristic liver 
morphology displaying a polygonal appearance signifying hepatic endoderm (HE) 
formation (Hay et al., 2008). 
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2.2.4 THE C3A CELL LINE CULTURE 
C3A cells were cultured on plastic in the presence of MEM media (Table 2.2). The 
cells were passaged once a week using Trypsin/EDTA at a ratio of 1:30. The C3A 
cells were maintained at 37°C in 5% (v/v) CO2, 95% (v/v) air for optimal growth.  
The cells were cultured in T25 flasks followed by bulking up in T75 flasks. Most 
experiments were carried out in 6 well plates. 
 
2.2.5 293FT CELL LINE CULTURE 
293FT cells were maintained in DMEM media with supplements at 37°C in 5% (v/v) 
CO2, 95% (v/v) air in T75 flasks (Table 2.2). 293FT cells were passaged using 
trypsin/EDTA solution and incubated for 1-5 minutes at room temperature until cells 
detached. Once the cells had detached, 8 ml complete medium containing 
Geneticin® was added and the cell suspension was transferred into a 15 ml sterile, 
conical tube. The cells were subsequently seeded at a ratio of 1:5 by diluting in pre-
warmed complete medium containing 500µg/ml Geneticin®, and this was 
continuously added to the complete media throughout culture.  
 
2.2.6 CULTURE OF FRESHLY ISOLATED PRIMARY HUMAN HEPATOCYTES 
Freshly isolated primary human hepatocytes, purchased from Life Technologies 
(HMFS01), were maintained in Williams E media (A1217601) and the supplement 
pack (CM4000) on Matrigel™ (BD Biosciences, UK) coated 12-well plates. The 
PHHs were seeded at 105 viable cells/cm2 and incubated at 37°C in 5% (v/v) CO2, 
95% (v/v) air. 
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2.3 CHARACTERISATION OF HESCS, HESC DERIVED HE AND C3A 
CELLS 
2.3.1 IMMUNOCYTOCHEMISTRY 
hESCs and hESC derived HE were washed twice with PBS, 5 minutes each wash. 
The HE was fixed with 4% PFA for 20 minutes at room temperature (the cells can 
then be stored in PBS at 4°C and stained at a later date). The cells were washed twice 
with PBS, 5 minutes each wash and incubated for 2 minutes at room temperature 
with 100% ethanol for nuclear staining. The cells were then washed twice with PBS, 
5 minutes each wash. PBS/T (0.1% Tween)/10% Serum was used to block the cells 
for 1 hour at room temperature. The serum was removed and the respective primary 
antibody diluted in 1% serum (made up in PBS/T) was added and incubated for 2 
hours at room temperature, or overnight at 4°C with agitation (For primary antibody 
details, see Table 2.3). The cells were washed 3 times with PBS at room temperature, 
5 minutes each wash. The secondary antibody Alexa Flour 488 (1:400) (Table 2.3) 
diluted in PBS was added to the cells and incubated at room temperature for 1 hour 
in the dark with agitation. The cells were then washed 3 times with PBS, 5 minutes 
for each wash and in the dark. Each well was subsequently mounted with 50 µl 
MOWIOL 4-88 and DAPI (1:1000). The well was covered with a cover slip and 
stored at 4°C in the dark. 
 
2.3.2 FLUORESCENCE ACTIVATED CELL SORTING  
Fluorescence activated cell sorting (FACS) was used to confirm the cell surface 
marker expression of hESCs cultured in CM and MT. hESCs were treated with 
 73
trypsin/EDTA for 5 minutes and were lifted as single cells. Single hESCs were 
harvested and resuspended in FACS-PBS (PBS supplemented with 0.1% BSA and 
0.1% sodium azide), counted, and resuspended at 1 x 10 7cells/ml for use. Aliquots 
of 1 x 10 6 cells were incubated for 40 min at 4°C with the primary antibody to 
SSEA-4 (DHSB, Iowa; 1:200 dilution), SSEA-1 (DHSB, Iowa; 1:200 dilution), TRA 
1–60, TRA-1–81 (Chemicon, Temecula, CA, both 1:200 dilution). Cells were then 
washed twice, removing any unbound antibody, and were then resuspended in 100 
ml of FACS-PBS. Binding of primary antibody was detected using the optimum 
concentration (determined by titration) of an appropriate isotype specific 
fluorochrome labeled secondary antibody: anti-mouse IgM-PE and anti rat IgM-PE 
(Jackson Labs, West Grove, PA) and anti-mouse IgG3-FITC. The cells were 
incubated with the secondary antibody for 40 minutes at 4°C, and were washed twice 
and resuspended in a final volume of 250 ml. Unstained cells and cells only labeled 
with secondary antibody were used as controls. Dead and apoptotic cells along with 
debris were not included in the analysis. This was carried out by using an electronic 
live gate on forward scatter and side scatter parameters. Data for 5000–100,000 
“live” events were acquired for each sample using a FACS Caliber cytometer 
equipped with a 488-nm laser and analyzed using CellQuest software (Becton 
Dickinson, San Jose, CA) (Fletcher et al., 2008). 
 
2.3.3 KARYOTYPING HESCS  
Chromosomal Preparations 
A confluent flask of the hES cell line of interest was split and approximately 24-
48hrs later Colcemid (100l per 10ml of culture medium 100 ng/ml) was added. 
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After a 1.5-2.5 hour incubation the cells were harvested. The culture media was 
initially transferred into a 15 ml conical bottom centrifuge tube. The cells were 
washed with 3 ml of PBS and the solution was added into the tube containing the 
initial media. 1 ml of trypsin solution was added to the flask and incubated at 37°C 
until the cells lift as single cells. The culture medium in the centrifuge tube was used 
to wash the cells in trypsin off the flask and the resulting cell suspension was 
collected in the centrifuge tube and centrifuged at 1300 rpm for 5 minutes. The 
supernatant was decanted into a waste beaker and the cell pellet was resuspended in 
10ml of 0.56% KCl (hypotonic solution) using a vortex mixer. The resuspended cells 
were incubated at room temperature for 10 minutes and then centrifuged at 1300 rpm 
for 5 minutes. The cell pellet was resuspended in 10 ml of fixative (3:1 Methanol: 
Acetic Acid) by adding the fixative slowly down the side of the tube and then 
centrifuged at 1300 rpm for 5 minutes. 7 ml of fresh fixative was added whilst 
mixing on the vortex mixer and this step was repeated once more with a final 
centrifugation at 1300 rpm for 5 minutes. The cells were resuspended in a small 
volume of fresh fixative, and the resulting suspension should be just cloudy. A pre-
soaked slide was polished (slides were stored in Ethanol + 5% Hydrochloric acid), 
and one drop of the cell suspension was dropped, using a fine tipped pastette, onto 
the surface of the slide, whereby the drop should spread evenly over the slide 
surface. The slides were left on the bench to air dry. Microscopy analysis using the 
X10 phase contrast objective was used to check for the mitotic index, spreading and 
fixation. Once the preparation was validated, 3 additional slides were made. The 




GIEMSA Staining of the Chromosomal Preparations 
The slides of chromosome preparations were allowed to age at room temperature for 
3-5 days. A coplin jar was filled with 2X SSC (0.3 M NaCl and 0.035 M Tri Sodium 
Citrate) and was incubated at 60°C for 20-30 minutes to allow the solution to warm 
up. The slides were then incubated in the 2X SSC at 60°C for 2-4 hours. The slides 
were individually washed with running tap water and incubated in 1% trypsin for 20-
30 seconds. The slides were washed once again and incubated in 5% GIEMSA (40ml 
GURRS buffer pH6.8 and 2 ml of GURRS R66 GIEMSA stain) for 8-10 minutes 
with a final wash in water. The slides were blotted dry and soaked in xylene for a 
few hours. DePeX was used to mount the slides once they were dry and they were 
left overnight to allow the coverslip to set completely. The slides were stored in the 
dark until analysed.  
 
2.3.4 ELISA ASSAYS  
L-15 medium (1ml) was added to the cells on days 14, 15 and 16 of the 
differentiation protocol and incubated for 24 hours at 37°C in 5% (v/v) CO2, 95% 
(v/v) air (n=3). The supernatants were collected after 24 hours and could be stored at 
-80°C for later use. High binding EIA plates were coated with rabbit anti-human 
antibodies specific for the protein overnight at 4°C (usual serum protein screen 
consists of fibrinogen (1:10000), fibronectin (1:1000) and thyroxin binding pre 
albumin (1:1000)). The sample supernatants were diluted 1:10 and pipetted into a 96 
well plate in triplicate followed by a 2-hour incubation at room temperature. 
Peroxidase conjugated rabbit anti-human antibody specific for the appropriate 
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protein was added to the wells and incubated at room temperature for 1 hour. O-
phenylenediamine was added into the wells for 5-15 minutes and the reaction was 
stopped by adding 0.5 M sulphuric acid. The plates were read at 490 nm with a 
reference wavelength of 630 nm using an MRX II plate reader. The data was then 
normalised to per mg protein as determined by the BCA Assay (Pierce, UK) (Hay et 
al., 2008). 
 
2.3.5 CYTOCHROME P450 ASSAYS  
Day 17 hESC (or another specified time point) derived HE and C3A cells were 
incubated with the luciferin conjugated specific Cyp 3A4 (1:40) and 1A2 (1:50) 
substrate (P450 P-Glo™ Luminescent Kit, Promega, UK) for 5 hours at 37°C (n=3). 
The tissue culture media was used as a negative control. The supernatants were then 
collected and could be stored at -80°C for later use. The Luciferin detection reagent 
was reconstituted by mixing the buffer into the bottle containing the lyophilized 
Luciferin detection reagent. 50 µl of the supernatant sample was mixed with 50 µl of 
the detection reagent in a white 96 well plate and incubated at room temperature in 
the dark for 20 minutes. The relative levels of basal activity were measured using a 
luminometer and were normalised to per mg protein as determined by the BCA 
Assay. 
 
2.3.6 UREAGENENSIS ASSAY  
hESC derived HE and the C3A cells at a defined time point were washed with 1 ml 
of PBS. 1 ml of PBS was added to each well and a final concentration of 16 µM of 
ammonium chloride solution was added to the tested wells. A PBS control was used. 
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The solutions were incubated for 4 hours at 37°C and the supernatants were 
subsequently collected and could be stored at -20°C for later use. 100 µl of the 
sample was added to a cuvette with 1 ml of buffer (150 ml PBS, 300 µl 0.1 M ADP, 
50 mg NADH and 750 µl of 0.5 M alpha keto glutarate pH 7.4) and read at 340 nm 
on a spectrophotometer. Glutamate dehydrogenase was diluted 1:5 with water and 10 
µl of the solution was added into the cuvette and mixed by inverting. The reaction 
was incubated at room temperature for 2 hours and the absorbance at 340 nm was 
read. Urease was diluted 1:3.5 with water and 10 µl was added into the cuvette. The 
reaction was inverted to allow mixing and incubated at room temperature for 2 hours. 
The absorbance was then measured as 340 nm. The urea concentration was 
calculated using the following formula: Urea (mmol/l)= Abs/6.22/2 (originated from 
the following formula Abs = ε x l x c where ε is the molar extinction coefficient 
which in this case is 6.22 mmol-1 cm-1 for NADH, l is the length of the cuvette and c 
is the concentration). The values were normalised to per mg of protein determined by 
the BCA assay.  
 
2.3.7 CASPASE 3/7 ASSAYS   
Apoptosis was measured using the Caspase 3/7 –Glo-Kit (Promega, UK). The 
caspase 3/7 buffer was combined with the lyophilized substrate and the solution was 
allowed to equilibrate to room temperature. 500 µl of the caspase 3/7 reagent was 
added to the cells containing 500 µl of their respective media and incubated for 1 
hour. The supernatants were collected and luminescence was measured using a 
luminometer. The measured readings were then normalised to per mg of protein 
determined by the BCA assay. 
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2.4 MOLECULAR TECHNIQUES 
2.4.1 RNA ISOLATION AND EXTRACTION 
The cells of interest were washed with PBS and 1 ml of TRIZOL reagent was added 
per well of a 6 well plate and left to incubate at room temperature for 5 minutes. The 
cells were collected and placed in a 1.5 ml eppendorf (stored at -80°C for later use if 
required). 0.5 ml of Chloroform was added to the eppendorf and mixed by inverting; 
this is done in a fume hood. The solution was centrifuged at 13,000 rpm for 15 
minutes at 4°C. The aqueous layer was collected and placed into a clean eppendorf. 1 
ml of isopropanol was added into each tube, mixed by inverting the tube and 
incubated at room temperature for 10 minutes to precipitate the RNA. The solution 
was centrifuged at 13,000 rpm for 10 minutes at 4°C. The supernatant was aspirated 
without disturbing the RNA pellet. 0.5 ml of 70% ethanol was used to wash the 
RNA. Following a 5 minute incubation at room temperature the RNA was 
centrifuged at 8,000 rpm for 5 minutes at 4°C. The ethanol was aspirated and the 
pellet was left to dry at room temperature for 5-10 minutes. Once all the ethanol had 
evaporated, the pellet was resuspended in 30 µl of deionised water and stored at -
80°C for later use. All RNA and DNA sequences were quantified using the 
Nanodrop, concentration and purity were measured.  
 
2.4.2 REVERSE TRANSCRIPTION AND POLYMERASE CHAIN REACTION (PCR) 
Reverse transcription (RT) was carried out using the Promega Reverse Transcription 
AMV kit (Promega, UK).  The purified RNA was converted to cDNA using the 
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reverse transcriptase enzyme AMV, as per the manufacturer’s instructions. A 
standard RT reaction was as follows:             
RNA template  
Random Hexamers 
Nucleotide mix (10 mM of each dNTP)          
AMV Reverse Transcriptase 
RNAsin 
5x AMV-RT Buffer 







Up to a final volume of 25 µl 
 
The resulting cDNA was used for further analysis carried out by PCR. PCR was 
employed using the Gold Ampli-Taq polymerase (Applied Biosciences, UK).  The 
PCR reactions were set up using specific primers and cycle conditions specified in 
Table 2.4 in conjunction with the manufacturer’s instructions. PCR was used to 
investigate the expression of specific genes within cells, this is defined as RT-PCR 
and utilises cDNA as the template. PCR was also employed to generate full gene 
sequences for vector cloning and subsequent protein expression, in this situation the 
DNA template was a gene specific image clone (Source Bioscience, UK). A standard 
PCR reaction was as follows: 
 
DNA template (50 ng/ml) 
Nucleotide mix (10 mM of each dNTP)          
Oligonucleotide 1 (10 pmol/µl) 
Oligonucleotide 2 (10 pmol/µl) 
Gold Ampli-Taq Polymerase 
Ampli-Taq 10x Buffer 
MgCl2 







Up to a final volume of 50 µl 
 
 
The polymerase enzyme mix amplifies the desired sequence by extending the 
annealed oligonucleotides to synthesise DNA from 3’ end of the oligonucleotide. 
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This process of denaturation, annealing and synthesis is repeated a number of times, 
whereby each newly synthesised DNA acts as a template for the next reaction. 
Agarose gel electrophoresis (section 2.4.3) was used to ensure that a PCR product 
was visible indicative of specific primers and a successful PCR reaction.  
 
2.4.3 GEL ELECTROPHORESIS 
Agarose gel electrophoresis was employed to visualise the amplified (PCR) and 
manipulated DNA (digests or ligations). A 1% (w/v) agarose gel solution in 1 x Tris 
base/Acetic acid/EDTA (TAE, Life Technologies, UK) buffer was prepared and the 
solution brought to the boil to dissolve the agarose.  On cooling, SYBR Safe (Life 
Technologies, UK) was added at a dilution of 1:10,000 and the agarose solution was 
poured into the gel rack containing the appropriate gel comb. Blue gel loading dye 
(New England Biolabs, UK) was diluted 1:6 and subsequently added to the DNA 
sample. The DNA samples were loaded into the gel, with a 1 Kb and 100 bp plus 
DNA markers (Life, Technologies, UK). DNA gels were run at 100 V in 1 x TAE 
buffer, and imaged using a UV light source.  
 
2.4.4 RESTRICTION DIGESTS 
Restriction endonucleases, supplied by New England Biolabs, were used to cleave 
specific restriction sites in plasmid vectors. This method was used for directional 
cloning, verifying the correct insert within a plasmid vector and for isolating the 
DNA sequence of interest. Double digests were only used when the enzyme buffers 
displayed sufficient compatibility. The digestion reactions were carried out for 2 
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hours at 37°C and were subsequently heat inactivated when possible. The digestion 
reactions consist of: 
 
Plasmid DNA 
Restriction enzyme 1 
Restriction enzyme 2  
10 X Enzyme Buffer  
BSA (10 mg/ml)* 
Sterile double distilled H2O 
1 µg plasmid DNA 
0.5 µl (enzymes 1/10 final volume) 
0.5 µl  
1 µl 
1 µl  
Up to a final volume of 10 µl 
 
*BSA was only added when required, as suggested by the manufacturer’s 
instructions. 
 
The digestion reaction efficiency was validated by gel electrophoresis (section 2.4.3). 
The DNA band was excised and gel purified using the QIAGEN gel extraction kit 
(section 2.4.5), (QIAGEN, UK) when the insert was required for subsequent cloning.  
 
2.4.5 DNA GEL EXTRACTION 
The QIAGEN gel extraction kit (QIAGEN, UK) was implemented for DNA 
purification from an agarose gel. The DNA band of interest was carefully excised 
using a scalpel and extracted as instructed by the manufacturer.   
 
2.4.6 LIGATION REACTIONS 
T4 DNA ligase is the ideal enzyme required for the efficient ligation of ‘sticky’ 
ended sequences, usually an insert of interest and a plasmid vector. The most 
optimum ligation ratio was found to be 1:3 (vector: insert), unless otherwise stated. 
The ligation reaction was incubated at room temperature for 1 hour, however in 
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special cases ligation was carried out at 16°C overnight. The ligation reaction was set 




T4 Ligation Buffer (2X) 
T4 DNA Ligase 





Up to a final volume of 10 µl 
 
Successfully ligated inserts were verified using gel electrophoresis (section 2.4.3), 
and were subsequently transformed into E.coli bacterial cells. 
 
2.4.7 TRANSFORMATION REACTIONS OF PLASMID DNA 
E.coli strains have been optimized to propagate plasmid DNA and express proteins 
of interest, each strain has unique properties required for effective function. The 
bacterial strains used are mentioned in Table 2.5. 10 µl of the ligation reaction was 
added to 50 µl of the competent cells at 4°C and was incubated for 10 minutes. The 
cells were then heat shocked in a 42°C water bath for 45 seconds followed by a 2 
minute incubation on ice. 0.25 ml of super optimal broth (SOC) media was added 
into the eppendorf and the bacterial cells were cultured at 37°C for 1 hour. Following 
bacterial propagation, the cell suspension was plated in 100 µl and 50 µl volumes on 
agar plates containing 0.1 mg/ml of the specific antibiotic. The plates were incubated 
overnight at 37°C. Selection pressure ensures that the bacterial cells retain the 





2.4.8 SITE DIRECTED POINT MUTAGENESIS 
The QuikChange II Site-Directed Mutagenesis Kit (Stratagene, UK) was utilized to 
make defined point mutations in vitro to cloned DNA, as noted by the 
manufacturer’s instructions. In this specific case, an extension time of 8 minutes was 
used (1 min per kb) and 18 cycles defined the PCR parameters. The reaction 
consisted of the following reagents: 




Nucleotide mix (10 mM of each dNTP) 
Pfu Ultra DNA polymerase 
Nuclease Free Water 
5 µl 
5 ng/µl of plasmid DNA 




Up to a final volume of 50 µl 
 
Agarose gel electrophoresis (section 2.4.3) verified the generation of a PCR product. 
DpnI (1 µl) restriction enzyme was added directly to each amplification reaction and 
was incubated at 37°C for 1 hour to digest the parental supercoiled dsDNA. The PCR 
product was subsequently transformed into XL-1 Blue super-competent E. coli cells 
(section 2.4.7). Blue white selection was employed, whereby the control 
pWhitescript™ plasmid was used to confirm successful mutagenesis, indicated by 
the blue colonies. The XL-1 Blue cells containing the mutagenesis control were 
plated on agar plates containing ampicillin selection in addition to IPTG and X-
galactocidase.  
 
2.4.9 PLASMID DNA PURIFICATION 
Small Scale 
The QIAprep Miniprep Kit (QIAGEN, UK) was used to isolate and purify plasmid 
DNA in a small scale according to the manufacturer’s instructions. A single colony of 
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transformed E.coli containing the DNA plasmid of interest was picked and used to 
inoculate a culture of 5 ml of LB medium, containing the appropriate antibiotic. The 
culture was incubated overnight at 37ºC with shaking at 200 rpm, allowing adequate 
propagation of the plasmid vector.  
 
The bacterial cells were harvested in 15 ml tubes by centrifugation at 5000 xg in a 
swinging bucket conventional table top centrifuge for 5 min at 4 ºC. The pelleted 
bacterial cells were re-suspended in 250 µl of Buffer P1 and transferred to a micro-
centrifuge tube. 250 µl of Buffer P2 was added and the tube inverted 4-6 times, 
followed by the addition of 350 µl of Buffer N3 and again the tube was inverted 4-6 
times. The solution was centrifuged at 13,000 xg in a micro-centrifuge for 10 min at 
room temperature. The supernatant was applied to a QIAprep spin column by pipetting 
and centrifuged for 30-60 sec, discarding the flow through. The QIA prep spin column 
was washed by the addition of 0.5 ml of Buffer PB and centrifuged for 30-60 sec, and 
again the flow through was discarded. The QIAprep spin column was further washed 
with 0.75 ml of Buffer PE and centrifuged for 30-60 sec, and the flow through 
discarded. To elute the DNA, the QIAprep column was placed in a clean 
microcentrifuge tube and 30 µl of Buffer EB added to the centre of the column. The 
column was allowed to stand for 1 min, followed by centrifugation for 1 min. 
 
Large Scale 
A single colony was picked from a freshly streaked selective plate and a starter 
culture of 2–5 ml LB medium containing the appropriate selective antibiotic was 
inoculated and incubated for 8 hours at 37°C with vigorous shaking (approx. 300 
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rpm). The starter culture was diluted 1:500 to 1:1000 into selective LB medium and 
were cultured at 37°C for 12–16 hours with vigorous shaking (approx. 300 rpm).  
 
The bacterial cells were harvested by centrifugation at 6000 x g for 15 min at 4°C, 
resuspended in 10 ml of Buffer P1 containing RNase A and inverted 4-6 times. 10 ml 
of Buffer P2 was added and the solutions were mixed thoroughly by vigorously 
inverting the sealed tube 4–6 times. The solutions were incubated at room 
temperature for 5 minutes to ensure efficient lysis. During the incubation period, the 
QIAfilter Cartridge was prepared by screwing the cap onto the outlet nozzle of the 
QIAfilter Maxi Cartridge. 10 ml of chilled Buffer P3 was added to the lysate, and 
mixed immediately by vigorously inverting the tube 4–6 times. The lysate was 
poured into the barrel of the QIAfilter Cartridge and incubated at room temperature 
for 10 minutes. A HiSpeed Maxi Tip was equilibrated by applying 10 ml Buffer QBT 
and the column was allowed to empty by gravity flow. The cap from the QIAfilter 
outlet nozzle was removed and the plunger was gently inserted into the QIAfilter 
Maxi Cartridge. The cell lysate was filtered into the previously equilibrated HiSpeed 
Tip and allowed to enter the resin by gravity flow. A  HiSpeed Maxi Tip was washed 
with 60 ml Buffer QC. The DNA was eluted with 15 ml of Buffer QF and collected 
in a 50 ml tube. The DNA was precipitated by adding 10.5 ml (0.7 volumes) of room 
temperature isopropanol. The solution was mixed and incubated at room temperature 
for 5 minutes. During incubation the plunger was removed from a 30 ml syringe and 
attached onto the outer nozzle of the QIAprecipitator Maxi Module. The 
QIAprecipitator was placed over a waste bottle and the eluate/isopropanol mixture 
was transferred into the 30 ml syringe. The plunger was then inserted and the mixture 
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was filtered through the QIAprecipitator using constant pressure. The 
QIAprecipitator was removed from the syringe and the plunger was pulled out. The 
QIAprecipitator was re-attached and 2 ml of 70% ethanol was added to the syringe. 
The DNA was washed by inserting the plunger and pressing the ethanol through the 
QIAprecipitator using constant pressure. The QIAprecipitator was once again 
removed from the syringe and the plunger was pulled out. The QIAprecipitator was 
attached to the syringe again, the plunger was re-inserted, and the membrane was 
dried by pressing air through the QIAprecipitator quickly and forcefully. This step 
was repeated. The outlet nozzle of the QIAprecipitator was dried with absorbent 
paper to prevent ethanol carryover. The plunger was removed from a new 5 ml 
syringe and attached onto the outlet nozzle of the QIAprecipitator. The outlet of the 
QIAprecipitator was held over a 1.5 ml collection tube and 0.5 ml of Buffer TE was 
added to the 5 ml syringe. The plunger was inserted and the DNA was eluted into the 
collection tube using constant pressure. The QIAprecipitator was removed from the 5 
ml syringe, the plunger was pulled out and the QIAprecipitator was re-attached to the 
5 ml syringe. The initial eluted solution was transferred into the syringe for a second 
elution to ensure high yields of the DNA. 
 
2.4.10 DNA SEQUENCING 
 MWG Eurofins Operon, Germany, carried out the sequencing reactions. Sequencing 
utilized specified primers provided by the company or custom designed primers 
when unavailable. The DNA sequences were analysed with Invitrogen Vector NTI 




SOLEXA is a deep sequencing technique used to measure the absolute levels of 
transcript expression within cells. The cDNA obtained from the purified RNA is 
initially cleaved to a uniform length between 200 and 500 bases and then tagged 
using unique adapters which then bind to the flow cell in clusters. The flow cell 
consists of 8 lanes whereby each set of samples can be run simultaneously. The 
cDNA is then sequenced, whereby each cycle adds a nucleotide to the sequence. A 
fixed camera with laser capabilities reads the nucleotide using illumination. The base 
addition cycle is repeated after de-blocking and fluorophore removal from the 
terminal base. The final sequence is a result of aligning 18-50 sets of reads. Paired 
end reads were carried out in this run, generating 50 base reads from both ends of the 
template. Pair end sequencing is useful for differentiating gene splice variants within 
a sample. The data is then analysed using specific software programs and normalised 
to allow definitive comparisons of the genes between the six samples. Two types for 
normalisation were used. Firstly, the raw count of reads for each gene was divided by 
the total number of reads aligned and multiplied by one million, thus accounting for 
the depth of sequencing. Secondly, the results were divided by the length of the gene 
multiplied by one thousand to obtain a read per kilo bases per million reads value, 
RPKM value.  
 
2.5 PROTEIN BIOCHEMISTRY TECHNIQUES 
2.5.1 CELLULAR PROTEIN EXTRACTION 
Cells grown in a 6 well plate were lysed in 150 µl of SUMO lysis buffer (2% SDS 
(Sigma Aldrich), 50 mM Tris pH 8 (Sigma Aldrich), 1 mM 
ethylenediaminetetraacetic acid (EDTA, Sigma Aldrich) and 10 mM iodoacetamide 
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(Sigma Aldrich)) for 5 minutes at room temperature. The cell extracts were sonicated 
and stored at -80°C for later use. 
 
2.5.2 MEASURING PROTEIN CONCENTRATION 
The Pierce BCA (bicinchoninic acid) protein assay was used to quantify the protein 
concentration in the cell protein extract samples. Protein extracts were diluted 1:5 
using nuclease free water (2 µl of sample extract and 8 µl of water) in a 96 well plate, 
each sample was pipetted in duplicate. Reagents A and B were mixed at a 50:1 ratio 
and a volume of 200 µl was transferred into each sample well in addition to wells 
containing the bovine serum albumin standards ranging from 20-2000 µg/ml, as per 
the manufacturer’s instructions. The plate was incubated at 37°C for 10 minutes and 
the absorbance was read at 562nm. The protein concentrations were calculated by 
linear extrapolation using the standard curve generated from the protein standards. 
 
 2.5.3 SDS-NUPAGE® POLYACRYLAMIDE GEL ELECTROPHORESIS 
The SDS-NuPage® gel electrophoresis (SDS-PAGE) was used to separate proteins 
of varying molecular weights.  The XCell SureLock® Mini-Cell system (Life 
Technologies, UK) was used with 4-12% Bis-Tris pre-cast polyacrylamide gels (Life 
Technologies, UK). The samples were denatured at 70 ºC for 10 minutes in 4 x LDS 
sample buffer ( Table 2.1). Once the gel was fitted in the chamber, the tank was filled 
with 1x NuPage® MES-SDS running buffer in addition to 0.5 ml of antioxidant (Life 
Technologies, UK) in the inner chamber. The samples were loaded, including 
kaleidoscope® Precision Plus Protein Standards marker (Biorad, UK). A current of 
200 V was applied and the samples were run for approximately 1 hour. The gels 
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containing the separated proteins were carefully removed from the cassette and were 
either Commassie stained  (section 2.5.5), or used in western blotting (section 2.5.4). 
 
2.5.4 WESTERN IMMUNOBLOTTING 
Protein Transfer 
Western blotting was used to detect the presence of specific proteins in samples 
extracts using the XCell SureLock® Mini-Cell system, as per the manufacturer’s 
instructions. Proteins were separated via SDS-PAGE followed by subsequent transfer 
from the polyacrylamide gel to the Polyvinylidene fluoride (PVDF) membrane, 
prevents protein cross over if the transfer time was over run and provides long-term 
durability (Millipore, UK). The membrane was then probed with antibodies specific 
to the target protein. The transfer stack was assembled in the following order from 
cathode to anode: 2x sponge; filter paper soaked in 1x transfer buffer; SDS-PAGE 
gel; PVDF membrane pre-soaked in methanol and then transfer buffer on top of the 
gel; filter paper soaked in transfer buffer; 3x sponge, and the beginning sequence was 
repeated for a second gel. It is vital that the membrane is positioned accurately 
between the gel and the anode as the samples and current will be moving in that 
direction. The stack was assembled in the XCell Blot II module and was tightly 
sealed and placed into the transfer SureLock® tank containing 1x transfer buffer 
(Table 2.1) and 0.25 ml of antioxidant in the inner chamber and cold water in the 






Once the proteins have been successfully transferred onto the PVDF membrane, the 
membrane was blocked to prevent non specific antibody binding. The membrane was 
blocked in 30 ml of 5-10% (w/v) dried milk, depending on the specificity of the 
antibody, in 0.1% (v/v) PBS Tween (PBST) for 1 hour with gentle agitation at room 
temperature. The primary antibody was added to 3 ml of the milk + PBST at the 
appropriate dilution for the antibody (Table 2.3), and incubated overnight at 4°C with 
gentle agitation. Unbound antibody was removed by three, 5-minute washes with 50 
ml of PBST. A horseradish peroxidase (HRP) -conjugated secondary antibody was 
diluted in 10 ml of 5% dried milk in 0.1% PBST at a dilution of 1:2000, and 
incubated for 1 hour with gentle agitation at room temperature. Unbound antibody 
was, once again, removed by three, 5-minute washes with 50 ml PBST. 
 
Enhanced Chemiluminescence (ECL)  
 The proteins of interest were detected using enhanced chemiluminescence (ECL). 
The HRP substrate reacts with the conjugated HRP group present on the secondary 
antibody specifying the target protein, whereby x-ray films detect the signal released.   
Protein bands were visualised using the Peirce enhanced chemiluminescence reagent 
kit (Pierce, UK). Peroxide Buffer and the Luminol/Enhancer Solution was mixed at a 
1:1 ratio and spotted on to the membrane (2 ml for each membrane), ensuring it was 
evenly spread. In the dark room, the membrane was exposed to Kodak 
chemiluminescence BioMax MS x-ray film for the appropriate length of time, 
typically 1-30 minutes. The exposed film was developed using a film developer 
containing the fixative, developer and water solutions. 
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2.5.5 COMMASSIE GEL STAINING 
Proteins were visualised by Coomassie Brilliant Blue R-250 staining after separation 
using SDS-PAGE electrophoresis. The SDS-PAGE gel was placed in a glass 
container containing 5 ml of Commassie stain (Table 2.1). The gel was incubated 
with stain for approximately 1-2 hours with gentle agitation at room temperature. 
Longer staining periods were used if more pronounced bands were required. The gels 
were washed with water and placed in destain solution (Table 2.1) until all 
background staining was removed. The gels were once again washed with water and 
pictures were taken to record the protein patterns. 
 
2.5.6 CROSS LINKING ANTIBODIES 
Cross-linking antibodies to beads allows specific pull down of the protein of interest 
leaving behind all non-specific bound proteins. The HNF4α antibody was cross 
linked to protein A beads (Generon) using the protocol stated in the book ‘Using 
Antibodies: a laboratory manual’ by Ed Harlow, 1999. The antibodies and beads 
were incubated for 1 hour at room temperature. The beads were washed with 0.2 M 
sodium borate solution and were further incubated with dimethyl pimelimidate for 30 
minutes at room temperature to allow cross links to form. Ethanolamine was used to 
stop the reaction and the beads were washed with 0.01% Merthiolate PBS. Coupling 
efficiency was verified using SDS-PAGE and Commassie gel staining to confirm the 






The cell extract was diluted using buffer (50 mM Tris pH 8, 150 mM NaCl, 5 mM 
EDTA and 2 mM DTT, and 1% Nonidet-P40 (NP40), all Sigma Aldrich). The cell 
extract was incubated with the 1.5 μg of the HNF4 α antibody (Santa Cruz) and a 
rabbit IgG (Santa Cruz) was used as a control, for 3 hours at 4°C.  Protein A beads 
(Sigma Aldrich) were prepared in NP40 buffer (50mM Tris pH8, 150mM NaCl, 
5mM EDTA and 1%NP40, all Sigma Aldrich). 20 µl of beads were added to each 
sample and left overnight at 4°C under constant rotation. The samples were spun 
down at 3500 rpm for 2 minutes, washed 3 times with NP40 buffer and eluted with 
2X boiling mix at 100°C for 2 minutes. The samples were then spun at 13,000 rpm 
for 5 minutes and analysed by Western Blot (SUMO 2 antibody). 
 
2.5.8 PROTEIN EXPRESSION  
HNF4 α wild type protein was kindly provided to us by Primorigen Inc. C and N 
terminal deletions and the point mutant sequences of the HNF4 α were generated by 
amplifying the respective fragment using primer specific PCR; please refer to Table 
2.4 for primer details. A two cycle PCR program was used where initially the 
specific sequence was generated to be the predominant template in the reaction 
(50°C for 7 cycles) followed by amplification of the sequence (60°C for 20 cycles) 
(section 2.4.1). The C terminal deletion lacked the last 115 amino acids whilst the N 
terminal deletion lacked the first 140 amino acids, as did the point mutant. The 
fragments were cloned into the pET15b Vector (Novagen, UK), using specific Bam 
HI and Nde I restriction sites (section 2.4.4-2.4.6). All mutants contained a His tag to 
confirm the expression and aid in the purification process.  The constructs were then 
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transformed into BL21 E-coli (Stratagene, UK) using chemical induced 
transformation (section 2.4.7). The BL21 cells were grown at 37˚C until they reached 
an optical density of 0.5 and were induced with 0.5 mM IPTG (Life Technologies, 
UK) and left for 1 hour. The cells were spun down and were lysed in SUMO lysis 
buffer. The proteins were then purified as previously described by Hoffman et al. 
(Hoffmann et al., 1991) using specific nickel-agarose beads for His tagged protein 
pull down (section 2.5.9). Point Mutagenesis was carried out as directed by the 
Quick Change II manual (section 2.4.8) (Stratagene, UK), and the protein was 
expressed and purified as described above.  
 
2.5.9 PROTEIN PURIFICATION 
All protein purification steps were carried out at 4oC. The bacterial cells were 
harvested by centrifugation and resuspended in 30 ml of low salt buffer (Table 2.1), 
supplemented with protease inhibitors. N-P40 was added to a final concentration of 
1% and the cell suspensions were mixed thoroughly and incubated for 3 minutes to 
ensure good cell lysis. The lysed cells were sonicated on ice repeatedly, followed by 
centrifugation at 16,000 g for 30 min. The supernatant was carefully transferred into 
a fresh falcon tube and maintained on ice. The remaining pellet was fast frozen on 
dry ice and stored at -80oC. Immidazole was added to the cleared lysate to a final 
concentration of 5 mM. The solution was then applied to pre-equilibrated nickel 
agarose (1 ml of resin) and incubated for 1 hour at 4oC with constant rotation. The 
resin was transferred into a fresh column and was allowed to pack down using 
gravity. The bound protein was washed with 50 bed volumes of chilled CB100 
followed by 50 bed volumes of chilled CB1000 (Table 2.1). The protein was eluted 
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using 10 ml of chilled elution buffer (Table 2.1) and 0.5 ml fractions were collected 
in 15-20 eppendorf tubes. 10 µl of each fraction was transferred into a well of a 96 
well plate with the elution buffer used as a negative control. 90 µl of Bradford 
reagent (Life Technologies, UK) was added into each well. The fractions containing 
the eluted protein turned blue. The fractions were then pooled together and dialyzed 
overnight at 4oC in dialysis buffer (Table 2.1), with constant stirring. The remaining 
purified protein was aliquoted and stored at -80 oC for later use.  
 
2.6 IMMUNOHISTOCHEMISTRY – SECTION STAINING 
IHC was used to stain for specific proteins expressed in adult liver sections. DAB 
staining was preferred over fluorescence, as fluorescence results in high background 
signal due to non-specific binding of the secondary antibody. 3,3'-Diaminobenzidine 
(DAB) is an organic compound used as a positive indicator in 
immunohistochemistry. The secondary antibody is conjugated to a peroxidase 
enzyme which binds DAB as a substrate and results in its oxidization and a 
subsequent colour change to dark brown.  
 
Antigen Retrieval 
The wax sections on glass slides were placed in a slide holder and incubated in 
xylene for 10 minutes with intermittent agitation to allow adequate removal of the 
wax. The xylene solution was blotted off using paper towels and the slides were 
placed in 100% ethanol for 2 minutes with intermittent agitation. The slides were 
transferred into ethanol solutions with decreasing concentration; 90%, 80%, 70% and 
50%, and each incubation was 2 minutes with intermittent agitation, this resulted in 
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section re-hydration. The slides were finally placed in water, and it is essential that 
the slides never dry. 
 
Both enzymatic and heat antigen retrieval techniques were employed, however, with 
the RNF4 antibody in use, the trypsin based antigen retrieval method was found to be 
the most optimal. 1% Trypsin solution was made up in water containing 1% CaCl2 
and the slides were incubated for 15 minutes at room temperature.  
 
DAB Staining 
The slides were then blocked with 120 µl of hydrogen peroxidase blocking solution 
for 15 minutes at room temperature, this steps prevents any false positive signals. 
The slides were washed twice with PBS and 120 µl of blocking protein serum was 
added for 20 minutes at room temperature. The primary antibody was added at 1:20, 
diluted in DAKO serum diluent, and was incubated overnight at 4°C. After overnight 
incubation the slides were washed twice with PBS and 3 drops of the HRP anti 
Rabbit secondary antibody solution (Invision, UK) were added to the slides and 
incubated for 1 hour at room temperature. The slides were washed twice with PBS 
and DAB was placed onto the slide and left for 3-5 minutes at room temperature. The 
slides were counter-stained with hematoxin, which stains nuclei purple, for 25 
seconds at room temperature. The slides were dehydrated by incubation in increasing 
concentrations of ethanol solution followed by a 5-minute incubation in 100% 
ethanol at room temperature followed by another 5 minute incubation in xylene. 
DPX mountant was dropped onto the slides and covered with a coverslip and left to 
dry overnight. The sections were then observed using bright field microscopy. 
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2.7 IN VITRO PROTEIN ASSAYS 
2.7.1 IN VITRO SUMOYLATION ASSAY 
An in vitro SUMOylation assay was used to verify the ability of a protein to be 
SUMO modified in the presence of the SUMO conjugation machinery. 3 µg of each 
HNF4 α variant and the Ran GAP positive control was conjugated in a reaction 
containing: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM DTT, 5 mM MgCl2, 2 
mM ATP, 100 ng SAE2/SAE1, 400 ng Ubc9 and 2.5 µg SUMO-1 or SUMO-2 and 
incubated at 37°C for 3-4 hours. SUMOylation was verified using western blotting 
(section 2.5.3 and 2.5.4) (Tatham et al., 2008). 
 
2.7.2 IN VITRO SUMO DECONJUGATION ASSAY 
Deconjugation assays were employed as a further control to confirm sufficient 
SUMO conjugation. SENP enzymes were utilized to cleave any isopeptide bonds 
between SUMO and the target proteins. 10 mM of iodoacetamide was added to the 
completed conjugation reaction and left at room temperature for 30 minutes. DTT 
was added at 20 mM to the reaction and left for 15 minutes at room temperature. 10 
nM-50 nM of the respective SENP enzyme was added into the reaction and 
incubated for 1 hour at 37°C. Deconjugation was validated using western blotting 
(section 2.5.3 and 2.5.4) (Shen et al., 2009). 
 
2.7.3 IN VITRO UBIQUITINATION ASSAY 
1 μg of HNF4 α was either mono or poly-SUMOylated as described above. The 
ubiquitination machinery (8 µM of ubiquitin, 40 nM Uba1, 0.7 µM UbcH5a, 0.5 µM 
RNF4) was added to the reaction to make a total volume of 50 µl under the following 
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conditions: 50 mM Tris, 200 mM NaCl, 5 mM MgCl2, 1 mM DTT, 2 mM ATP and 
0.1% NP40. The reaction was incubated at 37°C for 3-4 hours. The HNF4α was 
immunoprecipitated (section 2.5.7), out of the reaction using the cross-linked beads 
specific to HNF4α and the elute was analysed using western blotting (section 2.5.3 
and 2.5.4).  
 
2.8 LENTIVIRAL BASED TECHNIQUES 
2.8.1 LENTIVIRAL KNOCK DOWN VECTOR CONSTRUCTION 
The BLOCK-iT™ Inducible Lentiviral RNAi System (Life Technologies, UK) was 
used to specifically knock down genes expressed in vivo. The vectors were generated 
as described by the manufacturer’s instructions. Specific shRNA sequences were 
designed (Table 2.4), and annealed at 95°C for 4 minutes in the following reaction:  
200 µM top strand oligonucleotide 
200 µM bottom strand oligonucleotide  
10X  Annealing Buffer  






The annealed sequences were ligated into the pENTR™/HI/TO entry vector in the 
reaction set up below, and the reaction was incubated for 1 hour at room temperature. 
5X Ligation Buffer  
pENTR™/H1/TO (0.75 ng/µl)  
Annealed reaction (5 nM; 1:10,000 
dilution)  
T4 DNA Ligase (1 U/µl) 
Nuclease Free Water 
4 µl  
2 µl  
1-5 µl  
 
1 µl 
to a final volume of 19 µl 
  
The ligation reaction was transformed into DH5α cells as previously described in 
section 2.4.7, and the vector containing the insert was purified as mentioned in 
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section 2.4.9. The ligated vectors containing the shRNA were verified by sequencing 
(section 2.4.10). 
 
The entry vector provides an efficient platform for inserting the shRNA sequences 
into the pLenti4/BLOCK-iT™-DEST vector. This was done by a recombination 
reaction set up as below: 
Entry clone (50–150 ng/reaction)  
pLenti4/BLOCK-iT™-DEST vector (150 
ng/µL)  
TE Buffer, pH 8.0  




Up to 8µl 
2µl 
 
The reaction was incubated at room temperature for 1 hour and subsequent stopped 
by the addition of 1 µl of Proteinase K solution, which was incubated at 37°C for 1 
hour. The recombined lentiviral vector was transformed into One Shot® Stbl3™ 
cells as described in section 2.4.7 and the plasmid DNA was isolated as described in 
Section 2.4.9. The final lentiviral vectors were validated using sequencing (section 
2.4.10). 
 
2.8.2 LENTIVIRAL OVER EXPRESSION VECTOR CONSTRUCTION 
The pLVX tight PURO lentiviral (Clontech, UK) vector was used for gene over 
expression in mammalian cells. The gene sequences were generated from image 
clones using specifically designed primers (Table 2.4), carried out by PCR (section 
2.4.2). The PCR reaction products were ligated into the PCR2.1 vector using the 
TOPO TA Ligation Kit (Life Technologies, UK) as per the manufacturer’s 
instructions. The vectors were propagated by transformation into DH5α cells (section 
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2.4.7) and the DNA was isolated using the QIAGEN mini prep kit (section 2.4.9).  
The gene sequences were verified using sequencing (section 2.4.10). 
 
The GOI sequences were digested from the PCR2.1 entry vector using specific 
combinations of restriction endonucleases as described in section 2.4.4 and ligated 





Bam HI and NotI 
NotI and MluI 
MluI and EcoRI 
EcoRI 
 
The ligated vector was transformed into Stabl3 cells as instructed in section 2.4.7 and 
subsequently purified (section 2.4.9). The final over expression vectors were 
validated using sequencing (section 2.4.10). 
 
2.8.3 LENTIVIRAL PACKAGING 
293FT cells were co-transfected with the ViraPower™ Packaging mix (Life 
Technologies, UK), containing the plasmid vectors that express the genes required 
for efficient viral packaging, and the pLenti4 lentiviral vector (LV). A no DNA and 
Lipofectamine® 2000 negative control was included in the experiment and was used 
to evaluate the results. 6 × 106 293FT cells were used for each a sample LV.  For 
each transfection sample, DNA-Lipofectamine® 2000 complexes were prepared as 
follows: 9 µg of the ViraPower™ Packaging Mix was mixed with 3 µg of pLenti-
based plasmid DNA (12 µg total) in 1.5 ml of Opti-MEM® I Medium without serum 
and was gently mixed. In a separate sterile 5 ml tube, Lipofectamine® 2000 was 
diluted by adding 36 µl into 1.5 ml of Opti-MEM® I Medium without serum, mixed 
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gently and incubated for 5 minutes at room temperature. The DNA was added to the 
diluted Lipofectamine® 2000 solution, mixed gently and incubated for 20 minutes at 
room temperature to allow the DNA: Lipofectamine® 2000 complexes to form. 
293FT cells were trypsonised, counted and resuspended at a density of 1.2 × 106 
cells/ml in Opti-MEM® I Medium containing serum. The DNA-Lipofectamine® 
2000 complexes were added to a 10 cm tissue culture plate containing 5 ml of Opti-
MEM® I Medium containing serum. 5 ml of the 293FT cell suspension (6 × 106 total 
cells) was added to the plate containing media and DNA-Lipofectamine® 2000 
complexes and mixed gently by rocking the plate back and forth. The cells were 
incubated overnight at 37°C in 5% (v/v) CO2, 95% (v/v) air. After 24 hours, the 
media containing the DNA-Lipofectamine® 2000 complexes was removed and 
replaced with complete culture medium. The virus-containing supernatants were 
harvested 48–72 hours post transfection by removing medium into a 15 ml sterile, 
capped, conical tube. The supernatants were centrifuged at 3000 rpm for 5 minutes at 
4°C to pellet cell debris and filtered using a 0.45 µm low protein-binding filter to 
further purify the viral supernatants. The viral supernatants were aliquoted in 1 ml 
volumes and stored at -80°C for later use. 
 
2.8.4 LENTIVIRAL TITRATION 
Viral titres are a measure of the number of infective viral particles present in the 
packaged supernatant. It allows the control of the number of integrated copies within 
the host genome and provides reproducible results. As such the viral titre was 
measured for each LV. The day before transduction (Day 1), 293FT cells were 
trypsinised and counted before they were plated into a 6-well plate generating 30–
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50% confluency at the time of transduction. The cells were incubated 37°C in 5% 
(v/v) CO2, 95% (v/v) air overnight. Twenty four hours later, the lentiviral stock was 
thawed and 10-fold serial dilutions ranging from 10-2 to 10-6 were prepared. For 
each dilution, the lentiviral construct was diluted into complete culture medium to a 
final volume of 1 ml. The culture medium was removed from the cells and the 
diluted virus were gently mixed by inversion and added to one well of cells. 6 µg/ml 
of Polybrene® was added to each well to improve transfection efficiency. The plate 
was swirled and incubated at 37°C in 5% (v/v) CO2, 95% (v/v) air overnight. The 
media containing virus was removed 24 hours later and replaced with 2 ml of 
complete culture medium. Twenty four hours later, the cells were trypsinised and the 
entire amount was re-plated into one 10 cm plate containing complete culture 
medium with the appropriate antibiotic to select for stably transduced cells. The 
medium was replaced with fresh medium containing antibiotic every 2–3 days. After 
10–12 days of selection, the medium was removed and the cells were washed twice 
with PBS. 10 ml of crystal violet solution was added and incubated for 10 minutes at 
room temperature. The crystal violet stain was removed and the cells were washed 
twice with PBS. The blue-stained colonies were counted and the titre of the lentiviral 
stock was measured. 
 
2.8.5 ANTIBIOTIC KILL CURVES 
Kill curves provide an accurate measure of the optimal concentration of the antibody 
required for cell selection. The respective cells were plated at approximately 25% 
confluence, 6 wells for each antibiotic was set up. The cells were left over night at 
37°C in 5% (v/v) CO2, 95% (v/v) air to allow them to adhere. Twenty four hours 
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later the media was changed and varying concentrations of the antibiotic were added 
to the media. The media was changed every other day and the percentage of 
surviving cells was observed. This was carried out for 14 days and the optimal 
concentration of the antibiotic was determined. 
 
2.8.6 MAMMALIAN CELL TRANSFECTION  
The cells of choice were plated in complete growth media as appropriate, for optimal 
transfection the cells were maintained at 30% confluency when possible. The 
Lenti4/BLOCK-iT™-DEST lentiviral stock was thawed and added into fresh 
complete medium at an MOI between 1 and 5, and was diluted if required. The total 
volume of medium containing virus was kept as low as possible to maximize 
transduction efficiency. Polybrene® was added to a final concentration of 6 µg/ml 
and the plate was swirled gently to mix. The cells were incubated at 37°C in 5% 
(v/v) CO2, 95% (v/v) air overnight. The medium containing the virus was removed 
and replaced with fresh media 24 hours later. The cells were incubated at 37°C in 5% 
(v/v) CO2, 95% (v/v) air overnight. The cells were maintained in the appropriate 
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DEFINING HUMAN EMBRYONIC STEM CELL CULTURE 
CONDITIONS AND THEIR SUBSEQUENT DIFFERENTIATION 
INTO HEPATIC ENDODERM 
 
3.1 INTRODUCTION 
3.1.1 PROPERTIES AND CHARACTERISTICS OF HESCS 
Human embryonic stem cells (hESCs) have the potential to provide an inexhaustible 
supply of a variety of human somatic cell types (Anna et al., 2005). These in turn can 
be used for applications such as disease modelling, drug discovery and cell therapy. 
hESCs can also be utilised for deciphering complex mechanisms throughout 
development and during organ formation (Vazin et al., 2010). Two properties make 
them ideal candidates for modelling and therapeutic applications; this includes their 
ability to indefinitely self renew and to differentiate into cell types from all three 
germ layers; the mesoderm, ectoderm and endoderm (Pera et al., 2000, Henrik, 
2005).  
 
hESCs are isolated from the inner cell mass of blastocyst stage embryos {Thomson, 
1998, Peura, 2007). Once an egg has been fertilized and a diploid zygote has formed 
during early embryogenesis, the blastocyst is generated.  The blastocyst has two 
layers; the outer layer referred to as the trophoblast and the inner layer defined as the 
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embryoblast, also known as the inner cell mass (ICM), which gives rise to the 
embryo. (Peura et al., 2011) The ICM is then dissociated from the embryo using 
either immunosurgery, mechanical or enzymatic dissection and is subsequently 
cultured in vitro using a variety of methods. The latter form of dissection is favoured 
as it prevents the contamination of animal derived products, maintaining the derived 
cells at a suitable grade for clinical applications. 
 
hESCs are characterised using an array of stem cell specific markers including; the 
expression of ES cell specific transcription factors; Octamer 4 (Oct 4) and Nanog, 
their cell surface expression of stage specific embryonic antigens (SSEA) 3 and 4, 
Tra 160 and 181 (Xu et al., 2001, Amit et al., 2006, Anna et al., 2005) and their 
morphology (Henrik, 2005). hESCs typically form tightly packed colonies with 
defined edges. The population of cells have a high nucleus to cytoplasm ratio with 
pronounced nucleoli (Pera et al., 2000). Karyotyping is frequently performed to 
ensure the correct chromosome number is present and that no major transpositions 
occurred (Campos et al., 2009). DNA microarrays, short tandem repeat analysis, 
fluorescent in situ hybridization and whole genome single nucleotide polymorphism 
can also be used to confirm the precise hESC signature within the population 
(Josephson et al., 2006, Brimble et al., 2004, Mitalipova et al., 2005). hESC 
pluripotency is measured by their ability to form embryoid bodies and subsequently  
spontaneously differentiate into cell types from all three germ layers (Hannoun et al., 
2010, Barbara S Mallon et al., 2006, Cai et al., 2006). Each germ layer is identified 
using a specific marker; the endoderm is usually defined by the presence of alpha 
feto protein (AFP), the ectoderm stains positive for β-tubulin and the mesoderm 
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usually contains smooth muscle actin (SMA) (Hannoun et al., 2010). hESCs can also 
be cultured in vitro for over 100 passages and have been directly differentiated into a 
variety of cell types such as; cardiomyocytes, neurons, epithelial cells and 
hepatocytes (Hannoun et al., 2010, Niebruegge et al., 2009, Van Hoof et al., 2009, 
Trounson, 2006, Hay et al., 2008). 
 
3.1.2 HESC CULTURE CONDITIONS  
hESCs are frequently maintained on mouse embryonic fibroblasts (MEFs) in the 
presence of serum replacement media and basic fibroblast growth factor (bFGF) 
(Barbara S Mallon et al., 2006, Henrik, 2005, Jean et al., 2006). The MEF feeder 
cells are able to supply the essential factors and cell attachment support that are 
required for healthy maintenance of undifferentiated pluripotent hESCs (Thomson et 
al., 1998). In an attempt to move away from the use of xeno related products in hESC 
culture, MEFs have been replaced by a variety of human derived fibroblasts and 
fibroblast like cells; ranging from fetal foreskin cells (Amit et al., 2003) to bone 
marrow cells (Cheng et al., 2003); all of which supported viable hESC growth.   
 
Due to the continuous requisite of using hESCs in a pure population and in a scalable 
manner, feeder free conditions were developed. hESCs were cultured on the 
basement membrane, Matrigel™; a membrane preparation extracted from a murine 
Englebreth-Holm-Swarm sarcoma (Xu et al., 2001, Amit et al., 2004), which 
provided the necessary attachment support for cell growth. Other extracellular 
matrices that have been successfully employed include fibronectin, vibronectin and 
laminin or a combination of the three (Braam et al., 2008, Amit et al., 2006, Rodin et 
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al., 2010).  Initially, MEF conditioned media (CM) was used to provide the required 
growth factors for healthy hESC maintenance on various extracellular matrices (He 
et al., 2005, Xu et al., 2001). Despite its advantages, CM culture systems suffer from 
lack of definition, batch to batch variability, presence of animal components and the 
labour intensity associated with CM production; all of which result in a poorly 
defined cellular model (Hannoun et al., 2010). 
 
3.1.3 HESC CULTURE DEFINITION 
In an attempt to create more defined conditions, a number of laboratories executed 
the characterisation of the essential components of maintenance media and extra 
cellular support matrices. Comparative proteomic analysis was performed on media 
before and after conditioning by various fibroblasts to try and isolate the important 
factors required for hESC maintenance.  A total of 34 proteins were regarded as 
significant as these were found in media conditioned by MEFs, human fetal and 
neonatal fibroblasts (Prowse et al., 2007). Overall various studies have confirmed the 
following proteins to be essential for hESC culture; bFGF (Wang et al., 2005), 
Activin A (Beattie et al., 2005), transforming growth factor beta-1 (TGF β-1) (James 
et al., 2005) and Noggin (Pera et al., 2004); used to repress the bone morphogenic 
protein (BMP). These factors were added to serum free media in various 
concentrations and combinations, depending on the research group. Overall, the 
correct signalling pathways required for the adequate maintenance of hESCs in a 
pluripotent non differentiated state seemed to be activated within these systems.  
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Chin and colleagues successfully managed to replace MEFs/CM with a cocktail of 
recombinant proteins including; plasminogen activator inhibitor, monocyte 
chemoattractant protein 1, insulin like growth factors binding proteins 2 and 7, 
interleukin 6 and pigment epithelium derived factor; supporting healthy growth of 
hESCs cultured on fibronectin (Chin et al., 2007). Another study has developed a 
defined media (RegES) containing only recombinant, synthetic or human derived 
components capable of maintaining hESCs in an undifferentiated state. The main 
ingredients consist of knock out Dulbecco’s modified Eagle’s medium (serum free 
basal media), human serum albumin, vitamins, antioxidants, trace minerals, amino 
acids and growth factors (Rajala et al., 2010). hESCs cultured in RegES maintained 
the expression of the ES markers Oct 4, Nanog and Sox 2 in conjunction with the 
expression of cell surface antigens SSEA 4 and Tra-160. RegES cultured hESCs 
retained the correct colony morphology and full pluripotency, indicated by forming 
cell types from all three germ layers via EB formation. Directed differentiation into 
cardiomyocytes and neural cell types was also achieved. (Rajala et al., 2010) 
 
To help standardise the culturing techniques of hESCs, various companies have 
released defined xeno free media into the market. The most popular media used to 
date are StemPro (Invitrogen), mTeSR 1 (Stem Cell Technologies), HEScGro 
(Millipore), NutriStem (Stemgent) and X-Vivo (Lonza). Research groups 
internationally have carried out trials to select the most effective media for culturing 
hESC using a number of different hESC lines and extra cellular matrices to help 
create the ideal environment (Chin et al., 2010, Melkoumian et al., 2010, Sugii et al., 
2010, Hannoun et al., 2010).  Despite claims that all of the above media are capable 
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of maintaining hESCs in vitro; the majority of the publications seem to have shown 
mTeSR and StemPro to be the most effective, including our own research, discussed 
in section 3.2. Recently, the new fully defined E8 media has been shown to promote 
efficient self-renewal and differentiation of hESCs and iPSCs (Chen et al, 2011).  
 
3.1.4 METHODS OF HESC EXPANSION 
Another aspect of hESC culture is their expansion. The rate of hESC growth is 
highly dependant on the culture conditions and the hESC line itself. Usually at 80-
95% confluency, the cells are disaggregated either mechanically or enzymatically; 
using collagenase, dispase and trypsin, all of which are animal derived making the 
cells unsuitable for the clinic (Hoffman et al., 2005). Recombinant human 
collagenase has been successfully utilised and has resulted in the improvement of the 
culture conditions towards good manufacturing practice (GMP) standards (Crook et 
al., 2007). Data has shown both methods to be successful in individual cases; 
however there is variation between the results. Mechanical passaging is labour 
intensive and can not be accurately reproduced. On the other hand, enzymatic 
dissection has also shown to result in genetic abnormalities within the cells (Brimble 
et al., 2004, Mitalipova et al., 2005). An automated approach is required to provide a 
reproducible and efficient method of hESC expansion whilst maintaining hESC 
pluripotency and karyotypic stability (Mitalipova et al., 2005).  
 
3.1.5 IMPORTANCE OF THE HESC MICROENVIRONMENT 
It is vital to recapitulate the surroundings of hESCs in vitro as observed in the in vivo 
niche. As such, cell: cell and cell: matrix interactions play an important role in hESC 
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culture and differentiation, mediated by specific integrin expression. Most hESC 
culture methods rely on two dimensional (2D) systems; however studies have shown 
that culturing hESCs in a three dimensional environment (3D) enhances cell 
proliferation and self renewal as it more accurately mimics the in vivo environments 
(Lee et al., 2007, Postovit et al., 2006). The hypothesised mechanism suggests the 
requirement for physical and mechanical cues in hESC growth. This has been shown 
by the activation of the GTPase Rac and the subsequent induction of the 
phosphoinositide 3-kinase (PI3K) pathway, resulting in the up regulation of Nanog 
expression, required for hESC self renewal (Nur-E-Kamal et al., 2006).  
 
A number of cases have successfully derived defined 2D matrices for the 
maintenance of hESCs. Melkoumian and colleagues synthesised a peptide- acrylate 
surface (PAS) whereby biologically active peptides; vibronectin, laminin, fibronectin 
and bone sialoprotein, required for hESC self renewal are conjugated to an acrylate 
surface (Melkoumian et al., 2010). The hESCs cultured on PAS in the presence on X 
Vivo 10 media supplemented with bFGF and TFG-1 retained all ES cell specific 
properties, as stated in section 3.1.1 (Melkoumian et al., 2010). The cells could 
subsequently be differentiated into functional cardiomyocytes in a scalable manner 
(Melkoumian et al., 2010). Similar observations were found when using another 
synthetic polymer, poly [2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl) 
ammonium hydroxide] (PMEDSAH) (Villa-Diaz et al., 2010). PMEDSAH supported 
long term self renewal of undifferentiated hESCs with retained pluripotency when 
cultured in a number of media; CM, human cell conditioned media (hCCM), mTeSR 
and StemPro (Villa-Diaz et al., 2010). Although successful 2D systems are 
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extensively used, it is probable that scalable and defined 3D culture systems will 
provide a method for large scale and cost effective manufacturing in the future. Such 
a scheme is required for the widespread use of hESCs as tools in research and cell 
based therapies in the clinic. 
 
3.1.6 EXPRESSION PROFILING OF HESCS 
Recent research has established the relationship between stem cell lines derived from 
early mouse and human embryos. The gene expression profiles of hESCs more 
closely resemble that of the epiblast over the inner cell mass, suggesting the epiblast 
nature of hESCs (Reijo Pera et al., 2009). The epiblast is formed at a later stage in 
development and is derived from the inner cell mass. Hence, hESCs with epiblast 
like properties are usually defined as cells generated from a later stage in 
development.   This is further supported by data showing similarity between mouse 
epiblast stem cells and hESCs, both on gene expression and phenotypic levels (Reijo 
Pera et al., 2009). On the other hand, mouse embryonic stem cells are fixed at an 
earlier stage in development and are more comparable to the inner cell mass (Brons 
et al., 2007, Tesar et al., 2007). However, recent studies have shown the importance 
of the microenvironment and culture conditions on defining the epiblast or pre-
epiblast stage of hESCs and hence their expression profiles (Tavakoli et al., 2009, 
Allegrucci et al., 2007).  It has also been noted that there are large differences in the 
gene expression profiles of different hES cell lines, further supporting the above 
hypothesis (Reijo Pera et al., 2009, Allegrucci et al., 2007).  The majority of 
differences associated between the various hESC lines can be attributed to epigenetic 
changes due to the surrounding environment (Brink et al., 2008). Extensive 
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characterisation of hESC lines has resulted in the isolation of genes affected by 
genetic imprinting via epigenetic regulation (Brink et al., 2008). Various epigenetic 
changes including distinctive methylation patterns and divergent histone 
modifications have been detected in hESC lines (Frost et al., 2011). Studies have 
accredited these differences to inconsistencies in the culture environments (Frost et 
al., 2011).  
 
During the past year, three groups have managed to alter the state of hESCs to 
behave more like mouse embryonic stem cells by activating reprogramming 
transgenes such as KLF4 (Hanna et al., 2010), or by the addition of LIF, a factor 
essential for mESC maintenance and other small molecules (Xu et al., 2010) or a 
combination of both (Buecker et al., 2010). The above data substantiates the dynamic 
and fluid nature of hESCs, an important property that should be considered when 
defining ideal culture systems.  
 
The above section summarises the important points associated with hESCs and the 
various culture techniques used to maintain the cells in an undifferentiated 
pluripotent state. The main challenges in defining hESC culture are integration of the 
media with the matrix support, scalability, reproducibility and limited knowledge of 
the underlying mechanisms. The next section of the chapter highlights the 
investigation carried out to help overcome the above issues. The employment of a 
defined, serum free commercially available media will improve the reproducibility of 
the culture system as it reduces batch-to-batch variation and allows for scalability.  
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Furthermore, this system could be implemented as an accurate model for 
understanding the mechanisms employed by hESCs.  
 
3.2 RESULTS 
 DEFINING HUMAN EMBRYONIC STEM CELL CULTURE CONDITIONS 
A large amount of time and effort has been invested in creating the ideal culture 
conditions for maintaining hESCs in a defined system. However, despite a number of 
successful approaches; a standardised, reproducible, scalable and efficient method 
has yet to be determined. This is the first step to providing a platform required to 
realise the full potential of hESCs. As such, a media trial was carried out to further 
refine hESC culture techniques. A more defined serum-free commercially available 
media, mTeSR (MT) (Ludwig et al., 2006) was employed to further standardise 
hESC maintenance using CM as the base control.  
 
3.2.1 CULTURE AND CHARACTERISATION OF HESCS MAINTAINED IN CM AND MT 
hESCs previously cultured in CM were gradually transitioned into MT over 14 days. 
At the first passage hESCs cultured in 100% CM, were transferred into a 
combination of CM and MT with an 80:20 ratio. At the second passage, the cells 
were cultured in a 60:40 ratio of CM and MT, respectively. At each following 
passage the cells were cultured in a mixture of CM:MT at the following ratios; 40:60, 
20:80 and finally 100% MT. The hESCs were then maintained in both CM and MT 
for a further 30 passages and then characterised for their ES cell identity and 
pluripotency accordingly.  hESC identity was assessed by their morphology, the 
identification of transcription factors ascribed to pluripotency; Oct4 and Nanog, and 
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their cell surface expression of stage specific embryonic antigens (SSEA) 3 and 4 
and Tra 16-0 and 1-81 (Hay et al., 2008). Furthermore, their pluripotency was 
measured by their ability to spontaneously differentiate into all three germ layers; the 
mesoderm, ectoderm and endoderm, and directly differentiate into hepatocytes using 
a standardised protocol (Hay et al., 2008, Fletcher et al., 2008), an elaborate 
description can be found in section 3.2.3. 
 
The first stage of assessing hESC identity was to compare the morphology between 
hESCs grown in CM and MT. hESCs grown in CM formed compact colonies with 
slightly loose edges, and little spontaneous differentiation was observed (Figure 3.1 
A, arrows). The colony morphology was maintained over 30 passages (Figure 3.1 a-
f, arrows). However, hESCs maintained in MT adopted a morphology similar to 
hESCs cultured in CM for approximately 10 passages (Figure 3.1 B, g and h). The 
hESCs then formed highly defined tightly packed dome-like colonies with no 
observable spontaneous cellular differentiation (Fig. 3.1 B, i-l, arrows). hESCs 





Figure 3.1 – Morphological Analysis of hESCs cultured in CM and MT. 
hESCs cultured in various media have been known to adopt various morphological properties. A displays hESCs cultured in 
conditioned media from 0 (a and b), 10 (c and d) and 30 (e and f) passages. As observed, there are no significant changes in the 
morphology of the colonies for over 30 passages, A.  hESCs cultured in CM form defined colonies with slightly loose edges as 
seen in b, d and f (arrows). Little differentiation is found between the colonies.  The hESCs maintain a large nucleus to 
cytoplasm ratio with defined nuclei. B depicts hESCs cultured in mTeSR. Morphological changes are noted between passages 0 
and 10. At passage 0 (g and h) the cells adopt a CM like morphology with defined colonies and loose edges. However, at 
passage 10 (i and j) the colonies pack in to form more dome like structures with fully defined edges as seen in h, j and l 
(arrows). The hESCs form more circular shaped colonies. This morphology is maintained for 30 passages (k and l). As with 
hESCs cultured in CM, MT cultured hESCs have high nuclear to cytoplasm ratios with defined nuclei and little to no 




Chromosomal abnormalities have been attributed to long-term culture of hESCs and 
the likelihood may be related to the media conditions employed.  As a result, we 
carried out karyotypic analysis on hESCs cultured in CM and MT to ensure 
chromosome integrity. Forty-eight hours after the hESCs were passaged; Colcemid 
(GIBCO, UK), a drug used to arrest cells at metaphase, was added to the cells, which 
were then harvested 1-2 hours later. Chromosome slides were then prepared and 
Giemsa stained (Section 2.3.3), a technique used to band the chromosomes. Figure 
3.2 confirms the correct number of paired chromosomes in hESCs cultured in both 
CM (a) and MT (b) with no detectable abnormalities (n=10). In conclusion, the 
hESCs cultured in CM and MT maintained a normal karyotype for over 30 passages, 





Further to morphological and karyotypic analysis, we investigated the stem cell 
nature of the hESCs cultured in both media. hESCs cultured in both CM and MT 
stained positive for Oct 4 protein expression as depicted by the immuno-fluorescence  
(Figure 3.3 A, a and b) and Nanog gene expression detected by PCR (Figure 3.3 B). 
hESCs cultured in MT displayed higher levels of Nanog expression (Figure 3.3 B) 
Figure 3.2 – Karyotypic Analysis of hESCs 
cultured in CM and MT. 
Chromosomal integrity is an important property required for 
healthy maintenance of hESCs especially during long-term 
culture. As such, after 30 passages CM and MT cultured 
hESCs were karyotyped to analyse their chromosomal 
structures, this was carried out using Giemsa banding.  The 
pictures display the chromosomes from hESCs cultured in CM 
(a) and MT (b). It can be noted that hESCs cultured in both 
MT (b) and CM (a) have the correct number of paired 
chromosomes with no detectable abnormalities (n=10). The 
images were captured at x100 magnification on a Leica Light 
microscope. Chromosome analysis was carried out in house.    
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which may correlate to a more homogenous stem cell population than that observed 
in hESCs cultured in CM. The high level of expression of Oct4 and Nanog, two main 
transcription factors associated with hESC ‘stemness’, confirmed the undifferentiated 
state of the hESCs whilst maintaining pluripotency; which will be analysed in more 
detail in section 3.2.2 and 3.2.3.  
 
Figure 3.3 – Characterisation of hESCs cultured in CM and MT. 
A hESCs cultured in both media are Octamer 4 (Oct4) positive as shown in conditioned medium (CM, panel a) and mTeSR 
(MT, panel b) at x20 magnification using a Nikon TE3000/U inverted microscope. This supports the efficient maintenance of 
hESCs by both MT and CM, as the hESCs expressed stem cell specific marker Oct4.  B indicates the expression of the hESC 
transcript Nanog (band at correct size), further supporting the stem cell status of hESCs maintained in both different media. B 
actin is used as a loading control and a negative RT was included  
 
Fluorescence activated cell sorting (FACS) was used to examine the expression of 
cell surface antigens, another technique employed to characterise the stem cell 
identity of hESCs. The surface markers used to identify hESCs within a population 
include SSEA 3 and 4 in conjunction with Tra 1-60 and 1-81. The Tra surface 
antigens have been suggested to be the more sensitive markers, as their expression 
decreases almost instantaneously when hESCs begin to differentiate. The results 
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displayed in figure 3.4 show background level of SSEA-1 expression (a 
differentiation marker) in both CM and MT cultured hESCs, as expected.   
 
Figure 3.4 – Investigation of Surface Marker Expression of hESCs cultured in CM and MT. 
The FACS plots show hESC surface marker expression levels as expected, including stage specific embryonic antigens (SSEA) 
and Tumour rejection antigens (Tra). SSEA 3, 4, Tra 1-60 and 1-81 are expressed at 92.11%, 27.26%, 90% and 98.62% in 
hESC cultured in CM and; 97.72%, 46.38%, 89.60% and 79.59% in hESCs cultured in MT; respectively. Negligible levels of 
SSEA-1 were detected further supporting the stem cell nature of these hESCs; 4.8% in CM and 18.2% in MT.  A negative 
staining control, secondary antibody only, was used to define levels of background staining.  
 
The levels of SSEA 3, Tra 1-60 and 1-81 expression was confirmed in greater than 
80% of the cells, confirming the undifferentiated state of the hESCs. It should be 
noted that the levels of SSEA-4 were lower than expected, but was to be due to the 
inefficiency of the antibody and not the hESCs themselves. In addition to the 
increased Nanog expression in hESCs cultured in MT, a higher level of Tra 1-60 
expression was observed, both correlating to the more stem cell nature of the cells. 
SSEA 3, 4 and Tra 1-81 expression are comparable between both media.  SSEA 3, 4, 
Tra 1-60 and 1-81 were expressed in 92.11%, 27.26%, 90% and 98.62% of hESCs 




In conclusion, hESCs cultured in both CM and MT exhibited the required 
characteristics that define the undifferentiated and pluripotent state of the cells. Both 
media could sustain hESCs self-renewal for over 30 passages maintaining the correct 
morphology (Figure 3.1), chromosome stability (Figure 3.2) and Oct 4 and Nanog 
expression (Figure 3.3). This data was additionally supported by the expression 
pattern of the cell surface antigens, refining their undifferentiated state. MT 
successfully maintained the undifferentiated hESC self renewal for over 30 passages, 
comparable to CM, and is therefore able to provide a stable environment for hESC 
culture. The next two sections will focus on the pluripotent properties of the hESCs 
cultured in CM and MT.   
 
3.2.2 INVESTIGATING PLURIPOTENCY OF HESCS CULTURE D IN CM AND MT 
Embryoid body (EB) formation is a standardised method for measuring hESC 
pluripotency (Xu et al., 2001). The technique assesses the ability of hESCs to 
differentiate into cell types from all three germ layers; the mesoderm, endoderm and 
ectoderm, which occurs spontaneously. The cell types associated with the germ 
layers are frequently identified using the following antibodies: alpha-feto protein 
(AFP) defines endodermal cells, smooth muscle actin (α SMA) depicts mesoderm 
and β tubulin III categorizes ectoderm. hESCs at 80-90% confluency were lifted and 
placed into a suspension suitable for promoting cell aggregation (Section 2.2.2) 
(Figure 3.5 A). After 7 days the EBs generated were well defined and vacuolated 
(Figure 3.5 B), suggesting efficient EB formation. The EBs were then re-plated on 
gelatin-coated wells and were allowed to spontaneously differentiate over a 14-day 
period. Two weeks provides adequate time to allow the hESCs to generate cell types 
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from all three germ layers. The resulting cell types are then fixed in ice cold 
methanol and are stained with antibodies that are specific to each individual lineage 
(Section 2.3.1) (Figure 3.6).  
 
Figure 3.5 – Investigation of pluripotency in hESCs cultured in CM and MT.  
A. Embryoid body formation is one method of investigating hESC pluripotency. hESCs at 80-90% confluency cultured on 
Matrigel™ are scraped off in large clumps and are allowed to aggregate in low culture attachment plates for 7 days in EB 
specific media, see material and methods for details. The EBs are then plated onto gelatine coated plates for a further 14 days 
where they spontaneously differentiated into cell types of all three germ layers; mesoderm, endoderm and ectoderm. The 
formation of these cell types indicated sufficient hESC pluripotency.  B.  These images display embryoid body formation by 
hESCs cultured in CM and MT at x4 and x10 magnifications. The EB’s are well defined and vacuolated, suggesting efficient 
EB formation in both media. The images were captured using a Nikon TE3000/U inverted microscope. 
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Figure 3.6 displays the resulting cell types formed following EB spontaneous 
differentiation from hESCs cultured in CM and MT.  The hESCs formed cell types 
that were positive for all three germ layers; AFP (endoderm), α SMA (mesoderm) 
and β tubulin III (ectoderm), and are comparable between both media. The cellular 
 
Figure 3.6 – Analysing the pluripotency of hESCs cultured in CM and MT.  
Immunocytochemical analysis shows that the hESCs are able to form cell types from all three germ layers after being cultured 
in CM and MT, indicative of their pluripotent abilities. AFP positive cells denote cells from the endoderm lineage, muscle actin 
is used to define mesodermal cells and beta tubulin III defines cells from the ectodermal lineage. These images were captured at 
x40 magnification using a Leica DMIRB inverted fluorescent microscope, all images are merged DAPI and FITC images, with 
IgG used as a negative control. Abbreviations: AFP – alpha-fetoprotein, α-SMA – alpha smooth muscle actin and β Tub III – 
Beta Tubulin III. 
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morphologies also corresponded to the germ layer formed; for example, cells 
positive for α SMA displayed streaky sheet like structures that are normally 
associated with muscle. This data demonstrates that the hESCs cultured in MT 
remain pluripotent for over 30 passages and are able to spontaneously differentiate 
into all three germ layers in a manner comparable to hESCs maintained in CM.  
 
3.2.3 DIRECTED DIFFERENTIATION AND CHARACTERISATION OF HESC DERIVED 
HEPATIC ENDODERM 
Efficiently directing hESC differentiation to the appropriate cell type is essential if 
stem cell-derived products are to be manufactured cost effectively. hESCs 
maintained in CM and MT were scaled up to the desired quantity and hepatic 
differentiation was driven using Activin A andWnt3a stimulation, Section 2.2.3.  
This protocol was employed over the Activin A and Sodium Butyrate method as it 
was more efficient at generating HE and displayed improved function specifically in 
ureagenensis and serum protein production; including proteins AFP and fibrinogen 
(Hay et al., 2008).   
 
The differentiation protocol mimics the stages observed throughout development, 
whereby the hESCs are primed towards definitive endoderm, followed by hepatic 
specification and maturation. Initially the hESCs are cultured in RPMI/B27 
supplemented with Activin A and Wnt3a, this stage primes the cells towards 
definitive endoderm. The cells are then cultured in SR/DMSO media, which induces 
hepatic specification. Subsequently, the cells are transferred to L15 supplemented 
with hepatocyte growth factor (HGF) and Oncostatin M (OSM) driving hepatic 
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maturation. The resulting hepatic endoderm (HE) is then characterised using 
morphological, transcriptional and functional analysis. This form of characterisation 
encompasses both the transcriptional and translational levels of the resulting HE, 
thus accurately defining the end product.  
 
hESCs cultured in MT and CM were differentiated using the above protocol; RNA 
and protein samples were collected at various time points which were then used for 
further analysis. The first stage was defining the transcriptional gene patterning of 
the differentiating cells.  
 
3.2.3.1 TRANSCRIPTIONAL ANALYSIS OF HESC DERIVED HE 
We investigated the expression of a number of genes required in hepatic 
differentiation using SOLEXA (Cuddapah et al., 2009), a method of quantifying 
absolute levels of gene transcription, Section 2.4.11. The key time points examined 
during the analysis were day 0; undifferentiated pluripotent hESCs, day 3; definitive 
endoderm, day 10; hepatoblast like cells, day 17; differentiated hepatocyte like cells 
which were compared to fetal and adult human hepatocytes.  
 
Figure 3.7 displays the expression pattern of stage specific genes involved in 
hepatocyte formation. As expected, peak Oct4 and Nanog (ESC specific transcription 
factors) expression levels were detected at day 0 and decreased as hESCs 
differentiated into primitive endoderm. No Oct4 and Nanog expression was detected 
in our control adult and fetal hepatocytes. As cells differentiated through the 
primitive streak towards definitive endoderm we detected the expression of 
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Brachyury followed by goosecoid and SOX 17 expression once definitive endoderm 
was generated. GATA 4 expression was noted at day 10 as the cells developed into 
foregut endodermal like cells, specifying hepatic commitment.  
 
In conclusion, the gene patterning observed in our HE differentiation model is 
comparable to the expression pattern noted in the developing liver during 
embryogenesis. This supports that the differentiation model and the resulting HE are 
accurate representations of the in vivo system. 
 
 
Figure 3.7 – Transcriptional Analysis of Hepatic Differentiation  
In conjunction with analysing pathways at a translational level, SOLEXA was carried out to observe changes in gene expression 
at specific time points. Panel A depicts gene expression changes from day 0, 3, 10 and 17 hESC derived HE as well as fetal and 
adult human hepatocytes. At each stage of differentiation key genes were chosen and analysed. Oct 4 and Nanog were used to 
define the undifferentiated state of the cells (Nichols et al., 1998, Hoffman et al, 2005). Brachyury defined the primitive streak 
(Tam et al., 2003, Vaillancourt et al., 2009) followed by Goosecoid and SOX 17 that define the anterior definitive endoderm 
(Hannoun et al., 2010). As the cells commit to the hepatic lineage GATA 4 was used to define the foregut endoderm (Duncan, 







3.2.3.2 CHARACTERISATION OF HESC DERIVED HE 
In addition to gene expression profiling, we noted the various morphological changes 
associated with hepatic differentiation in hESCs cultured in CM and MT, Figure 3.8 
A (CM) and B (MT).  
 
At approximately 20-30% confluency, hESCs cultured in CM and MT were directly 
differentiated to HE. Images were captured at days 0, 3 and 17 to note the 
morphological changes throughout hepatic differentiation. At day 0 both CM and 
MT cultured hESCs maintain the expected colony structure as described in section 
3.2.1. As the cells are primed using Activin A and Wnt3a, they begin to proliferate 
and develop a more definitive endoderm like structure, day 3 (Figure 3.8 A and B). 
 
The cells commit to hepatic specification, days 5-10, and being maturing, day 13. At 
day 17, the HE displays morphological traits associated with mature hepatocyte. The 
HE consisted of large hexagonal shaped cells with canaliculi like structures 
surrounding them. The hepatic nuclei are large and well defined, another property 
correlated to hepatic maturity. In conclusion, the morphological changes observed 













Figure 3.8 – Morphological Analysis of hESCs Derived HE, cultured in CM and MT. 
Directly differentiating hESCs down the hepatic lineage is associated with significant morphological changes within the cells. 
Each morphological change is defined by a specific stage in the differentiation protocol. The images display the morphological 
alterations of hESCs cultured in CM (A) and MT (B) as they are differentiated into hepatic endoderm (HE).  Similar patterns 
are observed between CM and MT derived HE. At day 0 the hESCs maintain normal ES cell morphology. Once stimulated to 
differentiate down the endodermal lineage, the cells adopt a definitive endoderm like shape at day 3. The differentiating cells 
then commit towards the hepatic lineage followed by maturation between days 15 and 17. The cells adopt a hexagonal shape 
and are surrounded by canaliculi like structures. These properties are similar to those observed in primary adult hepatocytes, 
suggesting successful differentiation into HE. The images were captured using a Nikon TE3000/U inverted microscope at x4 
and x 10 magnification. 
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To further characterise our in vitro-derived HE, we assessed the repertoire of hepatic 
gene expression by RT-PCR (Section 2.4.2, 2.4.3). HE derived from hESCs cultured 
in MT expressed a number of hepatic transcripts; including HNF4 α, albumin and 
tryptophan oxidase (TO) indicative of hepatic maturity within the differentiated 
hepatocytes, comparative to the morphological data (Fletcher et al., 2008) (Hay et al., 




At day 17 of differentiation the purity of hESC-derived HE was quantified using an 
adult liver marker, albumin, and an IgG antibody was used as a negative control. 
hESC-derived HE purity was determined by the percentage of albumin-positive cells 
in differentiating cultures and estimated using four random fields of view with 500 
cells per field of view. This data was further supported by estimating the percentage 
Figure 3.9 – Characterisation of HE derived 
from hESCs cultured in CM and MT. 
Gene expression profiling demonstrates hepatic gene 
expression in HE derived from CM and MT cultured cells, 
which was carried out using RT PCR. HE derived from hESC 
cultured in both medias show comparable levels of hepatic 
gene expression, using a –ve RT as a control. Abbreviations: 
AFP – alpha fetoprotein; ALB – albumin; HNF4 – 
hepatocyte nuclear factor 4 alpha; CYP3A4 – cytochrome 
p450 3A4; TAT – tyrosine amino transferase; TO – tryptophan 
oxidase; APOF – apolipoprotein F; CYP7A1 – cytochrome 
p450 7A1 
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of HE generated in 20 random fields of view per well based on morphology using 
phase contrast microscopy (n=3). We did not observe any significant differences 
regarding HE generation, in vitro, between each of the different media (Figure 3.10, 
graphs A and B). The CM control formed 96.5% (+/-1.5) HE and hESCs cultured in 
MT resulted in 98.6% HE (+/-0.38).  
 
In addition to PCR, we confirmed hepatic gene expression by immunostaining fixed 
hESC-derived HE monolayers for a number of proteins involved in hepatic 
maintenance and function, (Section 2.3.1) Figure 3.10 A and B. hESC-derived HE 
maintained in CM and MT were fixed on day 17, and were stained with antibodies to 
albumin (ALB), alpha-feto protein (AFP), cytochrome p450 3A4 (Cyp 3A4), E-
Cadherin, and hepatocyte nuclear factor 4 α (HNF4 α). Figure 3.10 displays the 
positive staining of the hepatic markers in HE derived from hESCs culture in CM 
(A) and MT (B). For antibody details please refer to table 2.3. Immunostaining was 
controlled using an IgG negative control. 
 
The data presented demonstrates that hESCs cultured in MT can undergo efficient 
spontaneous and directed differentiation to human HE in vitro in a manner similar to 




Figure 3.10 – Immunocytochemical Analysis of HE formed from hESCs cultured in CM and 
MT.  
The graphs demonstrate the percentage yield of hepatic endoderm (HE) derived from hESCs cultured in the various media. 
Each media generated similar levels of HE. hESCs cultured in MT generated (B) 98.6% (+/- 0.38) HE and CM (A) 96.5% (+/- 
1.5) HE. Four fields of view were counted, 500 cells in each view, and an additional 20 fields of view of phase contrast images 
were measured (n=3). IgG was used as a negative control. The images depict HE generated from hESCs cultured in CM (A) and 
MT (B). hESC-derived HE (Day 17) was stained for various hepatocyte markers, including albumin (ALB), alpha-feto protein 
(AFP), Cytochrome p450 3A4 (Cyp 3A4), E- Cadherin (E-Cad), hepatocyte nuclear factor 4-α (HNF4a) and an IgG control. 
Immunostaining was recorded using a Leica DMIRB inverted microscope, all images were captured at a x40 magnification. 
96.5% (+/- 1.5) 
98.6% (+/- 0.38) 
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3.2.3.3 FUNCTIONAL CHARACTERISATION OF HESC DERIVED HE  IN VITRO 
The production of functional HE from hESCs is essential for a number of 
downstream applications ranging from in vitro models to the bio-artificial liver and 
cell-based therapies. Following hepatic differentiation, we focussed on characterising 
hepatic function that would have direct application to the generation of predictive 
toxicology tools and extra-corporeal support devices. As such, we investigated a 
number of important liver functions including cytochrome p450 function (CYP3A4 
and CYP1A2) (Section 2.3.5), ureagenensis (Section 2.3.6) and serum protein 
production, analysed using ELISA (Section 2.3.4).  
 
 
Figure 3.11 – Functional 
Analysis of HE derived 
from hESCs cultured in 
CM and MT, Cyp 
Activity.   
hESC-derived HE cytochrome 
p450 function, Cyp3A4 and 
Cyp1A2 were assessed using the 
pGlo systems; (n=3) (Promega). 
A. Cyp3A4 activity, was 
approximately 2 fold greater than 
CM, observed in HE cultured in 
MT suggesting more mature 
hepatocytes with improved 
function , p<0.002 (ANOVA, 
F=50.7 and R 2= 0.94). B. hESC 
derived HE from MT cultures 
exhibited Cyp1A2 activity which 
was greater than that from CM 
cultures, p<0.0001 (ANOVA; F = 
64.68 and R2= 0.96). The values 
for Cyp3A4 and Cyp1A2 activity 
in CM and MT are as follows; 
2646.7 RLU/mg (+/- 174) and 
1822.9 RLU/mg (+/- 53), 4909.18 
RLU/mg (+/- 630) and 3029.25 
RLU/mg (+/- 259), respectively. 
The significance between 
differences in function of the 
various media was measured 
using ANOVA, and denoted on 
the graphs by an asterisk (*).  
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Both Cyp3A4 and 1A2 activity were observed in hESC-derived HE from cells 
maintained in CM and MT (Figure 3.11 A and B). Maximal CYP3A4 activity was 
detected in hESCs maintained in MT that was two fold higher than in CM-derived 
HE; (p<0.0002, ANOVA) (Figure 3.11 A). CYP1A2 activity was significantly 
greater in MT than that observed for CM; p<0.0001 (Figure 3.11 B). The values for 
Cyp3A4 and Cyp1A2 activity in CM and MT are as follows (+/- standard deviation); 
2646.7 RLU/mg (+/- 174) and 1822.9 RLU/mg (+/- 53), 4909.18 RLU/mg (+/- 630) 
and 3029.25 RLU/mg (+/- 259), respectively.  
 
Urease activity was measured as previously carried out (Filippi et al., 2004). Urea 
production was 1.5 fold greater in MT than CM maintained hESCs; (p<0.015) 
(Figure 3.12). Urease activity in HE derived from hESCs cultured in CM and MT 
was measured to be 53.5 µmol/mg/hr (+/- 8.5) and 75.42 µmol/mg/hr (+/- 4.11), 
respectively, (+/- standard deviation).  
 
Serum protein production is another vital function of mature hepatocytes required for 
healthy liver metabolism and homeostasis. Day 16 and 17 HE supernatants were 
collected and analysed for production and secretion of albumin, thyroxin binding pre 
albumin (TBPA) and fibrinogen; using ELISA. 
Figure 3.12 – Functional Analysis 
of HE derived from hESCs 
cultured in CM and MT, Urea 
Activity.   
Urease function in HE derived from hESCs 
cultured in the various media is shown in the 
graph displayed. The level of ureagenesis was 
1.5 higher in MT when compared to CM, 
p=0.0118, (ANOVA F= 27.4 and R 2= 0.95).  
This further suggests that MT derived HE is 
not only generated more efficiently but also 
shows increased function when compared to 






Figure 3.13 – Functional Analysis of hESC derived HE cultured in CM and MT, Serum Protein 
Production.   
Serum protein production is another effective method to measure the maturity of hESC derived HE. The graphs displayed show 
the levels of Albumin (A) and fibrinogen (B) secreted by HE derived from hESCs cultures in CM and MT. These proteins are 
good indicators of hepatic maturity as they are uniquely produced by hepatocytes. As seen in both graphs, serum protein 
production for each protein is significantly higher in MT derived HE than CM, on both days 16 and 17 (p<0.0001). This defines 
MT derived HE as more functional than CM derived HE. The relative levels of serum protein production for CM derived HE 
are as follows; Albumin: D16 – 19 ng/ml/mg (+/- 0.29) and D17 - 26.91 ng/ml/mg (+/- 0.16), Fibrinogen: D16 – 
377.86ng/ml/mg (+/- 0.6) and D17 – 401.18 ng/ml/mg (+/- 0.05). The relative levels of serum protein production for MT 
derived HE are as follows; Albumin: D16 – 44.33 ng/ml/mg (+/- 0.15) and D17 – 69.42 ng/ml/mg (+/- 0.12), Fibrinogen: D16 – 
560 ng/ml/mg (+/- 0.06) and D17 – 581 ng/ml/mg (+/- 0.1). 
 
Figure 3.13 demonstrates protein production for two proteins in HE derived from 
hESCs cultured in both CM and MT. The levels of albumin production increased 
significantly in both media from day 16 to 17, whilst fibrinogen levels were 
maintained over both days. The levels of albumin and fibrinogen were significantly 
higher in MT derived HE when compared to CM, (p<0.0001). The level of albumin 
B 
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produced at day 17 was 2.6 fold higher in MT than CM and fibrinogen were 1.2 fold 
and 1.4 higher, respectively. This suggests that MT derived HE demonstrates 
increased function when compared to CM. The relative levels of serum protein 
production for CM derived HE are mentioned in Figure legend 3.13. 
 
Sufficient levels of function was observed in HE derived from both media and were 
comparable to previous investigations. However, taken together, the data 
demonstrates that the introduction of a more defined cell culture technology not only 
permits scalable and reproducible hESC-derived HE, but also improves hepatic 
function when compared to CM-derived HE.  
 
3.2.3.4 IN DEPTH PHENOTYPING OF HESC DERIVED HE 
In order for hESC derived HE to be of use in an applied setting, they should acquire 
the majority of features associated with adult hepatocytes. As such, the genes 
expressed in hESC derived HE, fetal and adult hepatocytes were pooled and a 
comparative gene expression profile was generated. Initially, parameters were set to 
normalise and process the raw data, Figure 3.14 A. The total number of reads were 
measured followed by the total number of alignments, which generates a base 
number for further calculations. The aligned reads are then measured to signify a 
positive result, as it confirms that an mRNA strand were successfully aligned to a 
known gene. Unaligned reads are stands of mRNA sequences that could not be 
associated with any known gene, and this could be due to errors in the amplification 
stage or the integrity of the sequence itself. Discarded reads are not utilised as they 
are not an accurate representation of the mRNA.  
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Figure 3.14 – Further Analysis of Gene Expression at Various Time Points.  
A. The table displays a range of parameters and subsequent values used in defining gene expression at various time points 
throughout differentiation. B. The Venn diagram compares the genes expressed at the different time points. As observed; day 0, 
3 and 10 have a few genes expressed in all three stages. However, when comparing day 17, fetal and adult samples, an increase 
in overlapping gene expression is observed. C. Sample clustering shows the relative levels of similarity in gene expression 
between the samples.  Red defines close correlation whilst green defines distinct expression patterns. 
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Interestingly, there is a significantly higher number of non-aligned reads in the hESC 
sample. This could be due to the open chromatin structure usually associated with 
hESCs. As a result, RNA polymerase non specifically binds to DNA sequences, most 
likely non transcribed regions of the genome, and loosely expresses random DNA 
sequences. 
 
The positive aligned reads each correspond to a gene, and are hence used to generate 
an expression pattern. The genes expressed in each of the samples were then 
compared, Figure 3.14 B and C. The Venn diagram, Figure 3.14 B, supports the 
differential gene expression patterns occurring at each specific time point. The 
samples were segregated into two groups; group one consisted of day 0, 3 and 10 
samples whilst group 2 contained day 17, fetal and adult hepatocytes. As expected, 
only 0.5% gene expression similarity was detected between all three group 1 
samples, attributed by the induction of a lineage change i.e.: converting hESCs into 
definitive endoderm, resulting in considerable alteration of the genes being activated. 
hESCs had approximately 3.6% and 4.6% gene expression similarity with the sample 
exhibiting primitive streak expression patterning and the sample expression genes 
observed in definitive endoderm formation, respectively. The comparative 
expression doubled to 7.3%, when comparing day 3 and 10 samples, which is due to 
the activation and maintenance of hepatic specification pathways required for 
differentiation in both samples.   
 
The similarity in the expression pattern of all three group 2 samples increased by 10 
fold when compared to group 1 samples, 4.9%, indicative of the constant expression 
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of signalling pathways vital for the maintenance of the mature hepatic phenotype. 
Interestingly, gene expression between day 17 hepatocytes was comparable to the 
fetal and adult hepatocyte samples, 9.9% and 9.1%, respectively, which rose to 
30.1% when fetal and adult hepatocyte samples were compared. Therefore, Day 17 
hepatocytes display comparable gene expression patterns to both the fetal and adult 
liver, contrary to the functional data previously noted in Section 3.2.3.3. It can be 
postulated that day 17 hepatocytes possess the correct gene expression pathways 
however, due to variations in translational processing the hepatic function is 
maintained at a more fetal than adult nature. In addition, the fetal expression patterns 
may be stalled in day 17 HE and an environmental cue is vital to drive maturation 
forward. 
 
The data was also used to generate a heat map, Figure 3.14 C. The sample cluster 
shows that day 0, 3 and 10 samples show differential profiles of gene expression, 
displayed in red, which then changes as the cells differentiate towards hepatocytes 
suggesting similar gene expression patterns, marked by a colour change to green. As 
observed, day 17, fetal and adult hepatocytes cluster close together due to the 
similarity in their expression profiles. As the cells adopt a more hepatic nature, the 
majority of pluripotency genes are fully repressed and the expression of a large 
number of hepatic specific genes required for function and maturity are maintained; 
such as albumin, HNF4 α, HNF 6 and FOX A1 and thus the samples cluster together 
(day 17, adult and fetal). On the other hand, as hESCs differentiate into definitive 
endoderm, there is a significant modification in gene expression before the cells 
specialise down the hepatic lineage, post day 10, and therefore the samples exhibit 
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considerable difference in their gene expression patterns. Between days 0 and 10, the 
cellular phenotype is altered entirely, whereby genes required for pluripotency, Oct 4 
and Nanog, begin to be repressed and genes required to initiate definitive endoderm 
differentiation are activated, GATA4 and FOXA1. Therefore, a differential gene 
expression pattern is generated between each sample (Day 0, 3 and 10) in 
conjugation with no similarity with the day 17, fetal and adult hepatocyte cluster. 
 
Overall, the gene expression patterns within our hepatic differentiation model match 
those documented for human liver development, which supports its use as a reliable 
and accurate tool for investigation and as a robust starting point. Interestingly, the 
gene expression pattern of our hESC-derived hepatocytes is comparable to both fetal 
and adult gene expression suggesting the requirement of a switch to drive the 
complete maturation of day 17 HE. Therefore, modelling signalling pathways at a 
transcriptional and translational level will provide insight into the various methods of 
signalling regulation, whether transcriptional, translational or a combination of both. 
 
3.3 DISCUSSION 
Primary human hepatocytes are a limited resource with variable function that 
decreases with time in culture (Wege et al., 2003, Hay et al. 2007, Hay et al., 2008). 
Consequently, their use in therapeutic and clinical applications is restricted. As a 
result, other sources of hepatocytes have been explored to alleviate the dependence 
on primary hepatocytes. These sources include hepatocytes isolated from animal 
livers, hepatocarcinoma cell lines and derivates from adult stem cells (Medine et al., 
2010). Unfortunately, each individual substitute has their disadvantages. The use of 
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animal hepatocytes, specifically porcine hepatocytes, in clinical applications may 
result in the risk of disease and xeno-genicity; as well as being an inaccurate 
representation when modelling human disease (Bonavita et al., 2010). 
Hepatocarcinoma cell lines can not be used for therapeutic or clinical purposes and 
have limited function in vitro (Iyer et al., 2010). The use of adult stem cells, such as 
hepatoblasts, is limited due to highly inefficient isolation and sub optimal 
purification. As a result, the derived hepatocytes are limited with unreliable function 
(Fiegel et al., 2006, Vessey et al., 2001, Alison et al., 2007).  
 
Human embryonic stem cells (hESCs), on the other hand, have the potential to 
provide an inexhaustible supply of functional hepatic endoderm (HE) which, can 
then be used for applications such as drug discovery, disease modelling and cell 
therapy (Hannoun et al., 2010, Hay et al., 2008, Sharma et al., 2010). As a result, 
large amounts of time and resources, including our research group, have been 
invested into defining a standardised protocol for differentiating hESCs into 
functional and viable HE.  
 
In vivo and in vitro formation of hepatic endoderm is a complex process regulated by 
growth factors, cytokines, transcription factors and the cellular adhesions. The 
essential factors include; FGF; a stimulator of hepatic gene expression and nascent 
hepatocyte stability via the activation of the RAS/MAP kinase pathway (MAPK) 
(Shin et al., 2007, Calmont et al., 2006). BMP signalling coincides with FGF 
signalling to sustain complete induction of hepatic endoderm. Co-operation between 
FGF and BMP 2 and 4, produced by the septum transversum mesenchyme, promotes 
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both competence and specification of the primitive endoderm down the hepatic 
lineage by induction of the transcription factor GATA4 (Huang et al., 2008). Wnt 
and β-Catenin are involved in both differentiation and proliferation of pre-hepatic 
endodermal cells (Burke et al., 2006, McLin et al., 2007, Fletcher et al., 2008). HGF 
binds to the c-Met receptor, activating both the SEK1/MKK4 and c-Jun signalling 
cascades resulting in Glucose-6-phosphate, Tyrosine amino transferase, Carbamoyl-
phosphate synthase and Albumin expression, all of which are associated with mature 
liver (Duncan, 2003, Fiegel et al., 2008, Zaret, 2001). FOXA1, also known as 
hepatocyte nuclear factor HNF3α, is responsible for activating the expression of a 
large number of hepatocyte specific genes (Cereghini, 1996, Cirillo et al., 2002, 
Costa et al., 2003, Kaestner, 2000). The hepatocyte nuclear factors 1, 4 and 6 play a 
vital role in liver development (Odom et al., 2004, Lemaigre et al., 2004, Lokmane et 
al., 2008). Each factor has a specific function in hepatic specification, differentiation, 
maintenance and metabolic activity.   
 
Elucidating the key pathways involved in hepatic endoderm formation in vivo has 
allowed us to apply these to the in vitro situation. There are a large number of 
protocols for HE formation ranging from embryoid body (EB) derivation in fetal 
bovine serum (FBS) (Rambhatla et al., 2003), to differentiating hESCs utilising 2-D 
systems using collagen, gelatin or Matrigel™ as the basement membrane. Agarwal 
and colleague’s cultured hESCs on collagen in the presence of FBS, knockout serum 
replacement (KOSR) and bovine serum albumin (BSA) supplemented with Activin 
A (AA), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), oncostatin 
M (OSM) and dexamethasone. The resulting HE expressed a number of hepatocyte 
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specific markers including albumin, alpha-fetoprotein (AFP), CYP3A4, CYP7A1 
and was also capable of glycogen storage and albumin secretion (Agarwal et al., 
2008, Hay et al., 2008). Schwartz and colleagues generated HE solely in the presence 
of FGF and HGF on collagen, expressing GATA4 and HNF1α and 3β; secreted 
human serum albumin, processed ammonia to urea production and exhibited 
Cytochrome P450 activity after treatment with Phenobarbital (Schwarts, 2005). HE 
has also been formed on collagen in the presence of FBS supplemented with insulin, 
dexamethasone, transferrin and selenious acid, where expression of albumin, 
transthyretin and albumin serum protein production was observed (Shirahashi et al., 
2004). Hay and colleagues demonstrated that treatment with either Activin A/Wnt or 
sodium butyrate followed by treatment with dimethylsulfoxide (DMSO) generated 
immature hepatocytes. These hepatocytes could be matured with HGF, insulin, OSM 
and hydrocortisone to generate HE that expressed the majority of hepatocyte specific 
genes, were capable of glycogen storage, produced significant levels of hepatic 
serum proteins and had inducible Cyp P450 activity (Hay et al., 2008, Fletcher et al., 
2008, Hay et al., 2007). These models all utilize factors associated with HE 
formation; however, each method differs in the factors used. Another difference 
between these systems is the varied use of the extra-cellular matrices. This highlights 
the importance of standardizing the differentiation process to allow for accurate 
reproducibility and modelling. 
 
Culture of HE in 3-D environments will undoubtedly enhance HE function; as this 
potentially mimics in vivo development more accurately. It has been proposed that 
culturing hepatocytes between double layers of ECM in 3-D structures will establish 
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polarity and enhance hepatic function and viability mimicking the in vivo situation. 
One group has successfully differentiated hESCs into HE in a 3-D environment. 
Baharvand et al., cultured hESCs in self renewing conditions and using the hanging 
drop method formed EBs. These EBs were then seeded onto collagen coated 3-D 
scaffold in culture medium supplemented with FGF, HGF, OSM, insulin, 
dexamethasone, transferrin and selenium. The HE expressed a number of hepatic 
specific genes and produced significant levels of both urea and albumin (Baharvand 
et al., 2006). Du and colleagues successfully constructed an ECM free synthetic 
culture by sandwiching a hepatocyte monolayer between two membrane-like 
structures. The top support system consisted of a glycine - arginine - aspartic acid - 
serine (GRGDS) modified polyethylene terephthalate (PET) membrane. The bottom 
substratum consisted of a galactosylated PET membrane. This resulted in hepatic 
polarity including biliary excretion and enhanced function when compared to 2-D 
collagen coated cultures using HE derived from hESCs (Du et al., 2008). Ng and 
colleagues successfully combined methylated and galactosylated collagen nano-
fibres that optimized the interactions required for the maintenance of functional 
hepatocytes. This enhanced interactions between the nano-fibres and the asialogly-
coprotein receptor (ASGPR), hence promoting hepatic function (Ng et al., 2005, Yin 
et al., 2003, Lu et al., 2003). Hay and colleagues screened 380 polyurethanes and 
polyacrylates in order to identify a matrix that supported and promoted HE function 
and viability.  Polyurethane 134 was found to not only enhance HE function but also 
permitted drug dependant induction of Cyp 3A4 with increased sensitivity over fresh 
isolated primary human hepatocytes (Hay et al., 2010). These results signify the 
importance of ECM interactions for maintaining hepatic functionality. Sufficient 
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differentiation has been achieved on 2-D culture systems. However, one can 
speculate that HE differentiation will never reach its full potential until culture 
systems incorporate the correct signalling factors and ECM. 
 
Basma and colleagues established an efficient protocol for the purification of a 
hepatocyte population from a heterogeneous endodermal population. The hESCs 
derived EBs were plated onto Matrigel™ and treated with Activin A and FGF 2. The 
cells were then placed into defined media supplemented with HGF followed by 
dexamethasone. The resulting HE was further enriched by FACS sorting for ASGPR 
positive cells, a specific feature of mature hepatocytes. The pure population of HE 
expressed hepatic gene function comparable to adult hepatocytes (Basma et al., 
2009). 
 
Cai and colleagues developed a physiological protocol that mimicked the in vivo 
situation. This involves priming hESCs with Activin A to direct them towards 
definitive endoderm, followed by BMP and FGF generating hepatic endoderm. The 
resulting HE was matured using HGF, OSM and dexamethasone. The HE expressed 
a range of mature hepatic genes; however there was no expression of AFP, indicative 
that the HE produced is more mature than those derived using other protocols. The 
HE produced significant albumin and interestingly was susceptible to infection by 
the hepatitis virus (Cai et al., 2007). 
 
As the field of regenerative medicine advances there will be a requirement for more 
defined and reproducible culture systems. This has been the goal of our lab, as 
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described in the above sections, and Baharvand and colleagues. hESCs have been 
grown on Matrigel™ under serum free conditions and treated with a series of defined 
factors to produce HE. The resulting HE expresses hepatic genes, produce serum 
protein, display, urease activity, glycogen storage and uptake of low density of 
lipoproteins (Baharvand et al., 2008, Hannoun et al., 2010). 
 
A combination of studies, including our own, has demonstrated that MT is a suitable 
and more defined media than CM for culturing hESCs. hESCs maintained in MT 
retained all embryonic stem cell specific phenotypes, Figures 3.1 – 3.4, and in our 
system demonstrated an increased capacity to form hepatocytes with improved 
function, Figures 3.7 - 3.13. In conjunction with the functional data, we observed the 
expected patterns in gene expression when compared to liver development in vivo, 
Figure 3.7. This model provided a starting point to further elucidate the important 
pathways required for efficient hepatocyte differentiation. 
 
A large number of factors affect the generation, function and viability of hepatic 
endodermal cells. As a result, isolating a few vital elements to fine tune our system 
has proven difficult. However, preliminary data in conjunction with a thorough 
literature review has deemed hepatocyte nuclear factor 4 α (HNF4 α) as a possible 
candidate. The next chapter focuses on HNF4 α, an essential factor required for both 
liver development and metabolism, and its role and subsequent use in refining our 
























THE IMPORTANCE OF HEPATOCYTE 







THE IMPORTANCE OF HEPATOCYTE NUCLEAR FACTOR 4 α 
IN HEPATIC ENDODERM DIFFERENTIATION 
 
4.1 INTRODUCTION 
4.1.1 PROPERTIES AND CHARACTERISTICS OF HNF4 α 
Hepatocyte nuclear factor 4 α is a member of the nuclear hormone receptor family 
(Watt et al., 2003) and is highly conserved (Sladek et al., 1990). It is known as an 
orphan receptor as there is no known ligand and has been defined as constitutively 
active (Sladek et al., 1990, Dhe-Paganon et al., 2002). The protein is predominately 
expressed in the liver, pancreas, kidney, colon and intestine. HNF4 α induces gene 
expression by binding to a 6 base pair repeat (AGGTCA), known as direct repeat 1 
(DR1) located upstream to  its target genes and binds strictly as a homodimer (Harish 
et al., 2001, Peiler et al., 2000). Unlike other nuclear receptors, it cannot form 
heterodimers (Jiang et al., 1997, Bogan et al., 2000). Studies have shown that HNF4 
α is essential during liver development (Hayhurst et al., 2008, Ryffel, 2001). 
Knocking out HNF4 α during development inhibits liver formation and severely 
disrupts extra embryonic endoderm generation (Chen et al., 1994, Peiler et al., 2000). 
HNF4 α expression is also crucial in the adult liver; controlling the expression of a 
large number of genes, approximately 50% of the hepatic transcripts, required for 
normal metabolic functions (Li et al., 2000). HNF4 α regulates the expression of 
genes associated with functions such as; urea production, drug metabolism, bile acid 
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synthesis, fat metabolism and glucose homeostasis (Li et al., 2000, Watt et al., 2003, 
Wortham et al., 2007, Ellard S FAU - Colclough et al., )) 
 
4.1.2 THE STRUCTURE OF HNF4 α 
HNF4 α possesses a molecular structure common to other transcription factors, some 
of which are nuclear receptors. Amino acid residues 1-50 contain an activation 
domain responsible for transcriptional activation (AD-1), followed by the DNA 
binding (DNA BD) domain which is conserved in most nuclear receptors, located 
between residues 50-140, (Figure 4.1 A). The DNA BD consists of two zinc fingers 
joined by a hinge region to allow conformational flexibility required for function. 
The ligand binding domain (LBD) consists of alpha helix 9 and 10, spanning 
residues 141-368, and is proceeded by another activation domain (AD2) (Figure 4.1 
A). Residues 369 to 465 contain the repression domain, of which its effect may be 
circumstantially alleviated (Sladek et al., 1999, Hadzopoulou-Cladaras et al., 1997). 
The LBD is important for transcriptional activity and has two distinct conformations, 
open and closed, differing by the position of helix 12 (the AF-2 domain) (Figure 4.1 
B). Helix 12 is extended co-linearly with helices 10 and 11 in the open 
configuration. This renders the ligand binding pocket accessible, however, this open 
structure prevents the binding of co-activator molecules; thus HNF4 α is in an 
inactive form. The 12 helix folds back onto the LBD in the closed conformation, 
restricting access to the ligand binding pocket. The closed state of HNF4 α allows 
interactions with co-activators such as C/EBP, creating the HNF4 α active state. 
Duda et al has provided evidence that although HNF4 α ligand binding and co-
activator binding both stabilize the LBD, it is co-activator binding that locks HNF4 α 
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in the active state. HNF4 α has also been shown to reversibly bind to a single fatty 
acid, linoleic acid, suggesting the potential use of HNF4 α as a drug target for 
various liver disorders. (Bogan et al., 2000, Dhe-Paganon et al., 2002, Duda et al., 
2004, Ryffel, 2001, Sladek et al., 1990) 
 
Figure 4.1 – Structure and 3D Schematic of Hepatocyte Nuclear Factor 4 α.  
A. The diagram shows the functional groups of HNF4 α, including the activation domain (AD), the ligand binding domain 
(LBD), the DNA binding domain (DNA BD) and the repression domain (RD).  (Bogan et al., 2000, Sladek et al., 1990) B.  The 
3D schematic of the HNF4 α heterodimer shows the subunits in the open conformation allowing for ligand binding, as helix 
twelve is aligned with helix 10 leaving the binding domain accessible. (Dhe-Paganon et al., 2002) 
 
4.1.3 HNF4 α FUNCTION IN THE CELL 
HNF4 α has been implicated in processes essential for development, hepatic 
differentiation and normal adult liver metabolism (Sladek et al., 1999). HNF4 α  was 
found to bind to 80% of the genes expressed in hepatocytes, when analysed using the 
Hu13K Microarray, with 42% of these genes also being occupied by RNA 
polymerase II, confirming its crucial role in hepatocytes (Odom et al., 2004). Studies 
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show that embryos deficient in HNF4 α die during gastrulation (Chen et al., 1994). 
This can be circumvented using conditional knockouts, whereby mice containing lox 
p sites flanking exon 2 of the HNF4 α gene were mated with mice expressing Cre 
recombinase in the fetal liver under the control of the albumin promoter and the AFP 
enhancer region. Heterozygous double breeding resulted in the formation of embryos 
containing the lox p flanked HNF4 α gene in addition to the Cre recombinase gene 
regulated by albumin and AFP expression. However, this resulted in the formation of 
embryonic livers containing large red lesions, with discontinuous parenchyma 
(Parviz et al., 2003). In addition, HNF4 α directly activates the expression of 
hundreds of genes; especially those prevailing in processes such as drug metabolism 
and glucose and fatty acid regulation (Odom et al., 2004). The deletion of HNF4 α 
has deleterious effects for hepatocyte differentiation, including metabolic function 
and altered cell morphology and adhesions (Parviz et al., 2003). HNF4 α has also 
been associated with healthy pancreatic function, indicative of its importance  in 
regulating endodermal differentiation as opposed to just hepatic.  Mutations in the 
HNF4 α gene in the pancreas results in Maturity Onset Diabetes of the Young 
(MODY1) (Yamagata et al., 1996). This disease is a form of type 2 diabetes, 
characterised by high levels of glucose in the blood due to insulin deficiency and 
resistance (Yamagata et al., 1996). Another effect of an HNF4 α mutation includes 
increased body weight, hyperglycaemia and hyperinsulinemia in HNF4 α 
heterozygous children at birth (Lemaigre et al., 2004). Additionally, various 
mutations in the HNF4 α gene have been detected in patients suffering from diabetes 
(Stanger, 2008).   
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4.1.4 REGULATING HNF4 α FUNCTION 
HNF4 α is known to be constitutively active and found in the nucleus at a steady 
state; however, the regulatory mechanisms which govern HNF4 α activity are poorly 
understood. Nonetheless, data has depicted the importance of HNF4 α 
phosphorylation in transcriptional activation (Sun et al., 2007). HNF4 α contains a 
conserved serine residue, S78, which is phosphorylated by protein kinase C (PKC), 
in vitro (Sun et al., 2007). Generation of a phosphomimetic mutant leads to reduced 
DNA binding, decreased transcriptional activity, re-localisation to the cytoplasm and 
enhanced proteasome mediated degradation of the HNF4 α (Sun et al., 2007). Similar 
observations have been noted when HNF4 α is phosphorylated by protein kinase A 
(Viollet et al., 1997), AMP activated protein kinase resulting in reduced dimer 
formation (Hong et al., 2003) and p38 a vital factor in the inflammatory response 
(Guo et al., 2006).  Various HNF4 α co-activators have been established such as; 
p300, CBP, GRIP 1 and SRC1a (Sladek et al., 1999). Another study correlated 
phosphorylation of another serine residue, S158, in response to oxidative stress and 
IL-β1 resulting in the enhancement of transcriptional activity (Guo et al., 2006). 
Various investigations have identified fatty acids as a target ligand for HNF4 α  and 
in turn affect its activity (Dhe-Paganon et al., 2002, Wisely et al., 2002, Hertz et al., 
1998). Furthermore, Yuan and colleagues demonstrated the reversible binding of the 
fatty acid, linoleic acid, with no effect on transcriptional activity (Yuan et al., 2009). 
Despite the above information, the complete mechanisms behind HNF4 α regulation 
and function are yet to be elucidated, more specifically its role in hepatic 
differentiation and the maintenance of HE viability, which has become the focus of 
this thesis. 
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4.1.5 HNF4 α SPLICE VARIANTS 
The presence of two HNF4 α  promoters within the gene results in the expression of 
six known splice variants (Harries et al., 2009, Drewes et al., 1996). Variants 1, 2 
and 3 are usually expressed in the liver, whilst variants 4, 5 and 6 (also referred to as 
7, 8 and 9) are found in the pancreas, figure 4.2 (Harries et al., 2009). As depicted in 
figure 4.2, HNF4 α variants 1, 2 and 3 rely on promoter P1 for expression, differing 
from v 4, 5 and 6 that utilise P2, also present in the fetal liver, established in murine 
development (Harries et al., 2008, Drewes et al., 1996, Eeckhoute et al., 2003). The 
presence of two promoter regions also allows spatial and time dependant induction of 
HNF4 α expression. The expression of both P1 and P2 transcripts occur during 
development; however, P1 transcripts are expressed exclusively in the adult liver 
with significant down regulation of P2 driven transcripts, in the mouse (Stoffel et al., 
1997) (Briancon et al., 2004). The switch between HNF4 α promoters has been 
suggested to be key in achieving a mature hepatic phenotype. The expression of P1 
promoter driven transcripts are dependant on HNF 1α and 1β, GATA-6, HNF 6 and 
RXR/RAR. In addition, the HNF4 α enhancer region has been found to be bound by 
HNF 3, HNF 1α and 1β, HNF4 α and C/EBP α (Stoffel et al., 1997). On the other 
hand, studies have shown that HNF4 α v1 is responsible for repressing the 
transcriptional activation of the P2 driven variants within the adult liver (Briancon et 
al., 2004). The mechanism proposed relies on negative feedback regulation whereby 
the initial activation of P1 HNF4 α variants in the fetal liver results in the repression 
of the P2 variants in the adult liver, indicative of the importance of the promoter 
switch. In addition, HNF4 α P1 variants promote self-transcription by binding to the 
P1 enhancer region, resulting in sustained expression of HNF4 α required in the adult 
 151
liver (Ribeiro et al., 2007). Interestingly, there is no published data specifying the 
variant expression pattern observed in the human fetal and adult liver. 
 
The structure of HNF4 α has been demonstrated to play a key role in regulating its 
functional activity. The LBD and DNA BD are conserved between all six variants; 
however variants differ in their activation domain (AD) and their repression domains 
(RD) (Figure 4.2) (Drewes et al., 1996, Sladek et al., 1990, Duda et al., 2004, Sladek 
et al., 1999). This difference may be responsible for altering the repertoire of genes 




Figure 4.2 – The Different HNF4 α Splice Variants.  
The diagram above shows the changes in the HNF4 α structure between the six different splice variants. All variants contain the 
ligand and DNA binding domains and differ in their activation and repression domains. Variants 1, 2 and 3 rely on promoter 
one for expression, used in the adult liver whilst variants 4, 5 and 6 rely on promoter two, used in the fetal liver. (Sladek et al., 
1990) 
 
the fetal liver, pancreas and adult liver. Studies indicate an anti tumorigenic role for 
P1 driven HNF4 α variants; moreover, over expression of these variants reduces the 
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proliferation of renal cells demonstrated in HEK293 cells (Lucas et al., 2005) as well 
as hepatocellular carcinomas observed in the murine embryo tumorigenic cell line, 
F9 (Chiba et al., 2005). On the other hand, high levels of the P2 driven variants were 
detected in cancerous regions (Tanaka et al., 2006). Variant five, a P2 promoter 
driven product, displays limited transactivation capabilities when compared to 
variant 2, this may be due to differences in the N terminal activation region and the C 
terminal repressor domain (Ihara et al., 2005). When comparing variants 1 and 4, the 
only notable splicing difference is the lack of the AD-1 domain in variant 4, which 
results in a dramatic change in function, whereby specific co-activators are not able 
to enhance HNF4 α functional activity (Torres-Padilla et al., 2002). The collection of 
this data suggests that each variant may have a specific function, differing not only in 
their target genes but also in tissue specificity. This emphasises the lack of 
redundancy within the HNF4 α signalling pathway, further supporting the 
importance of HNF4 α as a key factor in hepatic differentiation, postnatal liver 
function and tissue homeostasis.   
 
4.1.6 THE HNF 1, HNF 4 α AND HNF 6 SIGNALLING NETWORKS 
Signalling networks in hepatocytes and pancreatic cells have been thoroughly 
investigated. Three key factors play major roles in both the development and healthy 
function of the liver and pancreas; HNF4 α, HNF1 α and HNF 6. For the purpose of 
this thesis, I will only focus on their roles in the liver. As previously mentioned, 
HNF4 α is part of the nuclear receptor superfamily that strictly binds DNA as a 
homo-dimer. HNF1 α is a POU homeodomain protein that binds DNA as a homo and 
hetero-dimer (Costa et al., 2003) and binds to genes involved in lipid metabolism, 
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serum protein production and detoxification. HNF6 is a ONECUT transcription 
factor where it binds DNA with its cut-homeodomain as a monomer (Costa et al., 
2003) and alters the expression of genes vital for cell cycle regulation and acts as a 
master regulator for feed-forward mechanisms in the liver. All three-transcription 
factors contain DNA binding domains; however, they differ significantly in their 
structure, although each DNA BD is conserved within each protein. HNF1 α dimers 
form a unique four helix domain required for DNA binding and co-activator 
interaction (Rose et al., 2000). HNF 6, on the other hand, binds DNA as a single 
protein via the cut domain (Sheng et al., 2004). HNF 6 also contains another DNA 
binding homeodomain; however, it can only bind DNA if the cut region is already 
bound (Sheng et al., 2004). HNF4 α, like HNF1 α, can only bind DNA as a dimer via 
two zinc fingers. Both HNF1 α and 4 α also contain transactivation domains (Navas 
et al., 1999). 
 
HNF4 α and HNF1 α bind to each others promoter regions, creating a 
multicompentent loop, (Figure 4.3 B) (Odom et al., 2004). This mechanism allows 
for feedback control and the flexibility within the system to switch between the two 
different states. HNF1 α, 4 α and 6 also control HNF4 α gene expression (Figure 4.3 
A). However, it has also been observed that HNF4 α and HNF6 interact and 
cooperatively bind promoter regions of genes required for gluconeogenesis (Odom et 
al., 2004). Another set of genes require all three-transcription factors to be bound to 
its promoter region for expression, whereby inhibiting the binding of one factor 
inhibits its transcription (Odom et al., 2004). These genes include histamine N-
methyltransferase and the alpha-1-microglobulin/bikunin precursor both of which are 
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involved in the inflammatory response. The complex networking between these 
transcription factors allows for intricate regulation of the processes required for 




Figure 4.3 – The Transcriptional Networking Between HNF 1 α, 4 α and 6.  
Diagram A shows the transcriptional network of HNF1α, HNF6, and HNF4α. The blue circles depict target genes and the red 
boxes represent their target proteins. Solid arrows show DNA- protein interactions, whilst dashed lines indicate proteins 
regulated by the transcriptional products of the genes. Overall, these genes regulate a large number of genes and do so in a 




Given the key role of HNF4 α in hepatic differentiation, hepatocyte function and 
viability, it was vital to elucidate the exact mechanisms behind the regulation and 
function of HNF4 α within our in vitro model. Furthermore, regulating the levels of 






4.2.1 HNF4 α PATTERNING IN LIVER DIFFERENTIATION 
hESCs cultured in both CM and MT were differentiated using standardised protocols 
(Hay et al., 2008) and cell extracts were collected at key time points throughout the 
differentiation process. The cells were lysed with a SUMO specific lysis buffer 
(Table 2.1) containing iodoacetamide, a compound that specifically inhibits SUMO 
proteases. The cell extracts were then separated using SDS PAGE and probed with 
specific antibodies targeting key proteins for each time point using standard western 
blotting. The hepatocyte nuclear factor 4 α (HNF4 α) antibody was used to detect HE 
specification (Figure 4.4). Similar patterns were observed in both hESC derived HE 
cultured in CM, (Figure 4.4 A) and MT (Figure 4.4 B). 
 
Figure 4.4 – Investigating HNF4 α in HE derived from hESCs Cultured in CM and MT.   
Cell extracts were collected at various time points throughout the differentiation protocol (Hay et al., 2008) and were probed 
with hepatocyte nuclear factor 4 α (HNF4α) antibody using standard western blotting. HNF4α depicts hepatocyte specification. 
A decrease in the levels of HNF4α was observed as the hepatocytes mature. Similar patterns are observed in both medias, 
however, HNF4 α expression is induced at day 7 in CM (A) and day 9 in MT (B). Panel A shows extracts from hESC derived 
HE cultured CM and panel B displays hESC derived HE cultured in MT. β actin was used as a loading control.  
 
Peak levels of HNF4 α, an important transcription factor in both the developing and 
adult liver, were noted at day 7 in CM and day 9 in MT; the stage of hepatic 
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commitment. High levels of HNF4 α have also been documented within the 
developing liver at the point of hepatic specification and commitment. In conjunction 
with this observation, it was noticed that the levels of HNF4 α decreased to levels 
required to activate mature factor expression, as noted in the developing liver. 
Interestingly, the secreted levels of thyroxin binding pre-albumin (TBPA), increased 
by more than 2-fold, and fibrinogen, both HNF4 α targets, increased by less than 2-
fold between days 15 and 17 coinciding with the decrease in HNF4 α (Figure 4.5) 
suggesting a possible role of HNF4 α in regulating metabolic functions in our 
differentiation system.  However, levels of HNF4 α were barely detectable at day 17, 
which suggests that HNF4 α may play a significant role in HE de-differentiation and 
decreased cell viability.  
 
Figure 4.5 – Investigating the Effect of HNF4 α on HE Function.   
Serum protein production of fibrinogen and thyroxin binding pre albumin (TBPA), known targets of HNF4 α, were measured at 
day 15, 16 and 17. The levels fibrinogen increased by less than 2 fold and TBPA increased by more than 2-fold from day 15-17 
coinciding with the decrease in HNF4 α. The serum protein concentrations were measured using ELISA. For details please refer 
to (Hay et al., 2008). 
 
 
In conclusion, HNF4 α expression patterns within our differentiation protocol 
mimics changes noted throughout liver development (Lemaigre et al., 2004, Costa et 
al., 2003), illustrating the accuracy of our differentiation model. However, unlike the 
adult liver, the levels of HNF4 α at day 17 HE are notably low; which is also 
observed in day 5-7 old adult hepatocytes in vitro (data not shown), as the levels of 
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HNF4 α decrease with time in culture. During liver development, the levels of HNF4 
α expression significantly decrease between the fetal and adult liver. Nonetheless, the 
levels never decrease to the point observed in day 17 HE. The considerably low 
levels of HNF4 α in day 17 HE and the in vitro cultured primary hepatocytes may 
account for their limited viability, in vitro. In theory, stabilising HNF4 α within our 
hepatocytes may prevent their de-differentiation and subsequent death in long-term 
in vitro culture. This hypothesis forms the basis of my thesis.  
 
4.2.2 INVESTIGATING HNF4 α SPLICE VARIANT EXPRESSION IN HE 
DIFFERENTIATION  
Section 4.1.5 highlights the importance of the different HNF4 α variants in regulating 
cellular phenotype, however limited knowledge is available in the expression pattern 
in the adult and fetal liver in humans. Consequently, the expression patterns of the 
HNF4 α variants within our system was examined to enhance our understanding of 
signalling with our model. This was carried out using reverse transcription (RT) 
PCR. Initially, positive controls for each variant were generated by designing variant 
specific primers. The primers were then used to amplify variant specific sequences 
from an HNF4 α image clone (IC:9021539) using the standard PCR technique 
(Figure 4.6 A), thus generating the positive controls. The products were then run on 
an agarose gel, purified using a gel extraction kit, ligated into the PCR 2.1 vector and 
subsequently amplified and purified using the QIAGEN mini prep kit. PCR 




Figure 4.6 – Analysis of HNF4α Variants in Various Cell Types.  
A. The PCR gel displayed shows the positive controls generated to test each specific primer set that should recognise the 
individual HNF4α variants. B. Panel B displays the HNF4 α variants present in human embryonic stem cells (H), adult 
hepatocytes (A) and day 17 HE (C). Variant 1, 2, 5 and 6 are expressed at equivalent levels in adult hepatocytes and in HE 
variants 5 and 6 seem to be slightly up regulated. A band present in primer set 5 in the hESC suggests a false positive. C. The 
gel displays the analysis of the HNF4 α variants throughout the differentiation protocol. All variants are initially expressed at 




specificity in conjunction with cycle number to ensure the product was not at 
saturated levels. This allows direct comparisons between the samples.  Once the PCR 
conditions were optimised, RNA was extracted from hESCs (H), adult liver (A) and 
hESC derived HE (C) and transcripts amplified using the variant specific primers. 
The products were run on a gel as well as the positive and negative controls (Figure 
4.6 B).  
 
The gel shows positive expression for all variants in the adult and HE samples and a 
slight expression of v3, 4 and 5 in hESCs. This could be due to spontaneous 
differentiation within our hESC cultures. RNA was also extracted from various time 
points throughout the HE differentiation and transcripts amplified as previously 
mentioned. The gel in figure 4.6 C shows expression of variants 1-5 from day 3 
onwards and no real difference between the variants themselves. Variant 6 was 
unable to be amplified again in the samples and positive control despite repeated 
attempts and optimisation efforts, which may be due to primer annealing issues. 
Variants 4 and 5 are expressed in our HE, which could explain the fetal nature of the 
hepatocytes supporting previous data (Chapter 3). The switch between HNF4 α 
variants may be key in generating mature hepatocytes, as observed in mice (Sladek et 
al, 2000). However, due to the inaccuracy of RT-PCR for transcript quantification, 
no definitive conclusions were drawn. In order to quantify the expression of the 
HNF4 α variants, SOLEXA was employed. The data generated by SOLEXA allows 




4.2.3 ANALYSING HNF4 α SPLICE VARIANT EXPRESSION USING SOLEXA 
SOLEXA analysis was used not only to identify the expression pattern of the HNF4 
α variants within our differentiation model but to also identify the pattern between 
fetal and adult hepatocytes. hESCs were differentiated into HE using the 
standardised procedure and RNA was collected at day 0, 3, 10 and 17. The cells 
adopted the expected morphology of primitive endoderm, day 3; hepatic 
specification, day 10 and maturity, day 17 (Figure 4.7). Day 17 hepatocytes were 
positive for albumin expression, with 91% (as calculated in section 3.2.3) HE 
suggesting a pure population, a pre-requisite for accurate transcript quantification 
(Figure 4.8).  
 
 
The RNA was extracted from samples collected at days 0, 3, 10 and 17, as well as 
fetal and adult hepatocytes and was isolated using the technique described in section 
2.4.1 and sequenced using SOLEXA. The SOLEXA technology relies on the ability 
to amplify a single target of DNA molecules using PCR. The mRNA is converted to 
cDNA, which is then tagged to identify the various samples. The mRNA binds to the 
Figure 4.7 – Morphological HE 
Characterisation of Samples 
Generated for use in SOLEXA.  
hESC were differentiated to HE and RNA 
samples were collected at day 0, 3, 10 and 17. 
The RNA was further purified and analysed 
using SOLEXA. This panel shows the 
morphological changes that occur throughout 
differentiation. At day 0, the ES colonies are 
well defined with uniform cell structure. At 
day 3 primitive endoderm like cells begin to 
form; this is followed by the formation of 
large hexagonal shaped cells at day 10. Day 17 
HE show similar morphology of that observed 
in adult hepatocytes.   
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chip and is amplified and sequenced to identify each transcript expressed within the 




Figure 4.8 – HE Characterisation of Samples Generated for use in SOELXA.  
The figure depicts HE generated from hESCs cultured in CM. hESC-derived HE (Day 17) was stained for a hepatocyte marker, 
albumin (ALB). Immunostaining was recorded using a Leica DMIRB inverted microscope; all images were captured at a x40 
magnification. The graph shows 91% HE formation, four fields of view were counted, 500 cells in each view, and an additional 
20 fields of view of phase contrast images were measured (n=3, 3 different wells). IgG was used as a negative control. 
 
The pattern observed in HNF4 α expression of all the variants mimic what was noted 
in western blotting. The levels of HNF4 α increase to a peak level at day 10 (~20 
RPKM, reads per Kilo base of exon per million mapped reads) followed by a 
significant decrease at day 17 (Figure 4.9). Despite the decrease of HNF4 α 
transcription at day 17 (~9 RPKM), the reduction in transcript levels does not 
account for the barely detectable levels of HNF4 α seen in the western blots. This 
data suggests that HNF4 α is not only regulated at a transcriptional level but also 
post-transcriptionally. There is a modest difference in the expression values of the 
various variants throughout the differentiation process, each averaging 10-20 RPKM 
(reads per Kilo base of exon per million mapped reads) (Figure 4.9). The lack of 
differential expression between the variants and the low expression of variant 3 
within the day 17 HE may correlate to their subsequent arrest at the fetal stage. 
Unfortunately, in accordance with previous data, the levels of HNF4 α were lower 
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when compared to fetal (~ 49.3 RPKM) and adult hepatocytes (~68.8 RPKM), ~ 40.3 
RPKM and ~ 59.8 RPKM lower; respectively (average values were used). Once 
again, no significant difference in variant expression was noticed between fetal and 
adult samples (Figure 4.9). Contrary to the pattern observed in murine hepatocytes, 
no switch seems to occur within fetal and adult hepatocytes in the human. This result 
could be due to variations in the signalling pathways between different species. 
There is no published data regarding the variants expression pattern within the 
human liver, as such, this data may provide the first real insight into the mechanisms 
behind HNF4 α signalling pathway in the developing human liver.  
 
Figure 4.9 – Investigation of the Expression Profiles between the Various HNF4 α Variants 
using SOLEXA.  
The diagram shows the expression of the HNF4 α splice variants at different time points throughout differentiation and within 
fetal and adult liver. As seen at a translational level, HNF4 α levels peak at the primitive/foregut endoderm stage and decrease 
as the cells mature to hepatocytes. However, at day 17 the HNF4 α level in all variants are significantly lower than observed in 
both fetal and adult hepatocytes. The differences in expression between the splice variants is approximately 20 RPMK higher in 
variants 4, 5 and 6 when compared to variants 1, 2 and 3 in the adult hepatocytes. A similar pattern is observed in the fetal liver, 




In conclusion, the transcriptional patterning of HNF4 α matches that observed on a 
protein level, whereby expression levels are only comparable to fetal hepatocytes. No 
significant difference in expression could be detected between the HNF4 α variants 
in both the fetal and adult hepatocyte samples and only a slight change in expression 
of variant three was noted at day 17. The ‘switch’ between transcripts does not seem 
to occur in humans as demonstrated in mice, indicative of splice variant redundancy 
within the HNF4 α signalling cascade. Understanding the transcriptional networking 
of HNF4 α in hepatocytes may provide insight to its mode of regulation and 
subsequent function. This data suggests that HNF4 α is regulated on a translational 
level rather than modifying gene expression. 
 
4.2.4 INVESTIGATING POSSIBLE METHODS OF HNF4 α REGULATION IN HE 
Section 4.1.4 discusses the importance of phosphorylation on HNF4 α function and 
regulation. In order to manipulate HNF4 α within our system, it was important to 
initially understand the mechanisms behind its regulation and possible modes of 
function. The literature has regarded SUMOylation as a novel post translational 
modification altering proteins involved in a large number of cellular processes, 
hence, SUMOylation may play a role in HE differentiation, and more specifically in 
HNF4 α regulation or function. 
 
SUMOylation is a type of post translational modification that alters the function of 
hundreds of proteins involved in processes such as; gene transcription, degradation, 
cell cycle regulation and cellular localisation. Three homologues exist in mammals, 
SUMO -1, -2 and -3. SUMO -2 and -3 share 95% homology with each other, but 
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only share 50% identity with SUMO-1 (Johnson, 2004). SUMO has been found to 
bind to the lysine residue on the following consensus sequence; ψKxE (where ψ 
corresponds to a large hydrophobic amino acid, K is a lysine residue, x is any amino 
acid and E is a glutamic acid residue) on the target protein (Rodriguez et al., 2001). 
SUMO -2 and -3 have the ability to form poly SUMO chains, covalently binding to 
themselves via the lysine residue at the N terminus consensus motif ψKxE. SUMO-1 
lacks this consensus site and as a consequence is unable to form poly chains (Kroetz, 
2005) and acts as a poly SUMO chain terminator (Ulrich, 2009). The SUMO 
pathway is analogous to the ubiquitin pathway in many aspects (Desterro et al., 
1997). Both pathways rely on an E1 (activating enzyme), an E2 (conjugating 
enzyme) (Tatham et al., 2003, Desterro et al., 1999) and an E3 (the ligase), in 
addition to being reversible (Ulrich, 2009, Muller et al., 2001). However, there is no 
defined role for SUMO modification; the resulting effect is dependant on the protein 
modified. (Hannoun et al., 2010, Johnson, 2004, Kroetz, 2005, Muller et al., 2001)  
 
In order to ascertain the role of SUMOylation within our system; hESCs were 
differentiated using standardised protocols (Hay et al., 2008) and analysed using 
antibodies to the SUMO, Ubc9 and SENP proteins involved in the SUMO pathway 
and once again, β-Actin was used as a loading control (Figure 4.10). This was carried 
out to validate our approach in two different media; CM (Figure 4.10 A) and MT 
(Figure 4.10 B).  
 
The results from medium formulations demonstrate that hESCs in the self-renewal 
state have high levels of SUMO modified proteins in CM, which decrease as cells 
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begin to differentiate into primitive streak (Day 1 and 2), SUMO 2 modified proteins 
showed a similar pattern. The decrease is followed by an increase of SUMO 
modified proteins as the cells commit to definitive endoderm (Day 3-5), prior to 
HNF4 α expression.  
 
Figure 4.10 – Investigating SUMO Patterning in HE derived from hESCs Cultured in CM and 
MT.  
Cell extracts were collected at various time points throughout the differentiation protocol and probed with SUMO1, SENP 1 
and 7, HNF4 α, albumin and C Met antibodies using standard western blotting. Panel A displays HE derived from hESCs 
cultured in CM and panel B from hESCs cultured in MT. As previously observed, there is a decrease in SUMO modified 
proteins as cells adopt a more hepatic fate. This is in conjunction with the increase in the SUMO protease and mature factors 
such as albumin and C Met. A decrease in levels of HNF4 α is also observed. Similar patterns are observed in both medias. Β- 
Actin was used as a loading control. 
 
However, the initial SUMOylation pattern differs in MT cultured hESCs. The self-
renewal state displays low levels of SUMO 1 modified proteins followed by a 
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subsequent increase through days 1 to 5, hepatic commitment, a similar pattern was 
noted in SUMO 2 modified proteins. The difference in SUMOylation patterns in 
hESCs could be attributed to the surrounding environment (Frost et al., 2011).  
 
There is a substantial decrease in the level of SUMOylation subsequent to hepatic 
specification, the cells undergo maturation (days 7-17) where a dramatic decrease in 
SUMO modified proteins is illustrated, consistent in both media conditions. As the 
levels of SUMO modified proteins decrease, the levels of native SUMO increase 
(Figure 4.10). The increased expression of the SUMO deconjugating enzyme SENP 
7 further supported this observation.  Taken together, this data confirms the removal 
of SUMO from target proteins is achieved via SENPs activity.  Peak levels of HNF4 
α coincide with decreased levels of SUMOylation within the cell (Figure 4.10). In 
conjunction, increased levels of albumin and C-Met, indicative of hepatic maturation, 
corresponded to the decrease in HNF4 α, a pattern noted throughout development. In 
conclusion, SUMOylation seems to play a key role throughout hepatic development. 
Due to coinciding time points SUMOylation may also be involved in regulating 
HNF4 α. 
 
Transcriptional analysis using SOLEXA was employed to understand expression 
levels of SUMO pathway regulators during HE differentiation (Figure 4.11). The 
target genes include; SUMO 1 and 2, small ubiquitin like modifiers; SAE 1 and 2, 
the activating enzymes (E1); Ubc 9, the conjugating enzyme (E2); PIAS 1, the 
SUMO ligase (E3) and three SUMO deconjugating enzymes; SENP 1, 6 and 7. 
Coinciding with the data generated from western blotting, a decrease in the 
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expression of SUMO 1/2 and SAE1/2 as well as a steady expression of Ubc9 was 
observed. However, unlike the protein patterning, a peak in the deconjugating 
enzymes, SENP 1, 6 and 7 was noted at day 3. This was followed by a decrease at 
day 10 and an increase at day 17, which was detected at the protein level. This could 
suggest that SUMO protease expression is regulated at a translational level, whereby 
another signal is required to activate protein translation post gene expression. In 
accordance with the previous data, SUMO gene expression is more comparable to 
fetal than adult hepatocytes (Figure 4.11). 
 
Figure 4.11 – Transcriptional Analysis of the SUMO Pathway.  
In conjunction with analysing pathways at a translational level, SOLEXA was carried out to observe changes in gene expression 
at specific time points. The above graphs depict gene expression changes from day 0, 3, 10 and 17 hESC derived HE as well as 
fetal and adult human hepatocytes. The figure shows gene expression for the various components involved in the SUMO 
pathway. These include SUMO 1 and 2, the SUMO activating enzymes SAE1 and 2, the conjugating enzyme Ubc9, the E3 
ligase PIAS I and deconjugating enzymes SENP 1, 6 and 7 (Hannoun et al., 2010, Johnson, 2004, Kroetz, 2005, Melchior et al., 
2003).  Once again, the gene expression patterns define day 17 HE as more fetal like than adult. 
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In conclusion, SUMOylation may play a role in hepatic endoderm differentiation 
from hESCs. The peak levels of SUMOylation at the stage of hepatic specification 
followed by peak levels of HNF4 α suggests a possible regulatory role of 
SUMOylation on HNF4 α activity.  
 
The next chapter focuses on establishing connections between these two factors and 
illustrating their potential roles in HE differentiation, function and viability.    
 
4.3 DISCUSSION 
Despite the various sources of HE, they all suffer from disadvantages ranging from 
varied function to limited viability, which is defined by death and de-differentiation 
of the hepatocytes. In order to overcome these issues, efforts were we focused our 
efforts on understanding the biology of HNF4 α, a key transcription factor in 
hepatocyte biology (Odom et al., 2004). HNF4 α transcriptional activity and stability 
could therefore be manipulated in an attempt to fine-tune the functional and 
physiological nature of our differentiation model.  
 
HNF4 α is a critical transcription factor required for normal development of the liver 
and pancreas. HNF4 α has been shown to regulate pancreatic β- cell proliferation, 
maturation of mucin producing goblet cells and crypt formations throughout 
development (Gupta et al., 2007). Initial studies demonstrated the loss of HNF4 α 
within a de-differentiated hepatoma cell line, whereby constitutive HNF4 α 
expression rescued albumin, fibrinogen and HNF1 protein expression, important 
factors produced in hepatocytes (Kuo et al., 1992). In addition, studies have shown 
 169
that HNF4 α expression occurs at 4.5 days during embryogenesis in mice, and 
subsequent disruption of the gene leads to death by E10.5 with significant issues 
noted during gastrulation. Increased cell death was indicated in the HNF4 α null 
embryos, which resulted in embryo lethality (Chen et al., 1994). HNF4 α has also 
been implicated in tumourogenesis, where the loss of HNF4 α expression is 
indicative of tumour progression (Lazarevich et al., 2010). HNF4 α is a liver 
enriched transcription factor with a large number of target genes ranging from lipid 
metabolism to drug detoxification. The main HNF4 α targets within the visceral 
endoderm include transferrin; a key regulator of iron within the body, 
apolipoproteins; required for lipid metabolism and Cyp 3a; involved in 
detoxification. Other direct targets include transthyretin; thyroxin carrier vital for 
maintaining homeostasis and pregnane X receptor; essential receptor for recognition 
of foreign toxic substances resulting in the activation of genes required for 
detoxification (Watt et al., 2003). Overall, HNF4 α expression is required for the 
efficient execution of developmental processes in addition to maintenance of 
metabolic functions in the adult liver. 
 
SUMOylation patterns of hESCs cultured in CM and MT were also substantially 
different, whereby hESCs maintained in MT had reduced levels of SUMO modified 
proteins when compared to CM, figure 4.10. This data indicates the importance of 
standardising the hESC culture environment to generate a reliable and accurate 
model for further investigation. However, in both cases high levels of SUMO 
modified proteins were observed between days 3 and 5. This suggests the 
significance of SUMOylation throughout definitive endoderm formation. Further 
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investigation of the individual SUMOylated proteins is required to fully understand 
the impact of the PTM within the differentiation process. It is important to note that 
HNF4 α levels are required to decrease to induce maturation, however, a critical 
threshold value seems to be key in regulating optimal levels of maturation in addition 
to maintaining sufficient hepatic viability. 
 
The levels of HNF4 α gradually decrease to a point of limited detection at day 17 on 
both transcriptional and translational levels (Figure 4.4 and 4.9), which may suggest 
an important role in HE viability. However, the decrease in HNF4 α transcription 
does not account for the significant loss of the protein at day 17. The decrease in 
HNF4 α is also observed in primary hepatocytes cultured in vitro for longer than 3 
days (Tilles et al., 2002, Wege et al., 2003). This data suggests that HNF4 α is being 
regulated on both a transcriptional and translational level. Due to the changes in gene 
and protein expression, it can be assumed that translational control seems to be the 
more integrated form of regulation in this case.  
 
HNF4 α has 6 known variants, each with unique time and spatial expression patterns 
during development and in the developed body, however, there is no published data 
regarding expression patterns between the fetal and adult liver in humans. As such, 
the expression patterns of the variants within our differentiation system and in fetal 
and adult hepatocytes were investigated. This was initially carried out using reverse 
transcription PCR; however, as this method was qualitative and not quantitative we 
employed SOLEXA (Figure 4.9), a highly sophisticated method of quantifying 
absolute numbers of gene expression. RNA was collected from various days 
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throughout the differentiation and the samples were processed using SOLEXA. The 
results depict no significant difference in expression between the HNF4 α variants in 
the samples or in the fetal and adult hepatocyte controls (Figure 4.9). In addition, the 
levels of HNF4 α expression were significantly lower in day 17 HE when compared 
to both fetal and adult hepatocytes. This is indicative of the fetal nature of the HE, 
whereby enhanced HNF4 α expression could result in improved function and 
viability, comparable to adult hepatocytes. Previously published data has shown a 
substantial difference in expression of the variants between the fetal and adult liver 
within the mouse. However, no differences in splice variant expression were 
observed between the fetal and adult hepatocytes. In turn, this data provides the first 
transcriptional comparison of HNF4 α splice variant expression within human 
development. The lack of a ‘switch’ is indicative of functional redundancy within the 
HNF4 α signalling pathway, whereby individual transcripts compensate for the 
activity of another. Redundancy is an inevitable consequence of evolution and in 
certain instances, variants are known to be redundant in developmental pathways; 
however, their function begins to differ depending on various metabolic processes 
(Pickett et al., 1995). For example, all six HNF4 α splice variants are expressed 
throughout human development due to the vital function of the transcription factor in 
gastrulation and visceral endoderm generation. However, post-development the 
expression of the variants is maintained but the individual transcripts regulate 
different cellular processes.  
 
Several investigations have identified the various methods of regulating HNF4 α 
function (Section 4.14). An example includes phosphorylation, which directly alters 
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the transcriptional activity of HNF4 α by enhancing co- activator (Sladek et al., 
1999) and DNA binding (Sun et al., 2007). Preliminary data has suggested a possible 
role of SUMOylation in our differentiation system, with a more specific prospect of 
directly modifying HNF4 α. As described earlier (Section 4.2.4), protein samples 
from various time points were collected and western blotted using antibodies from 
proteins involved in the SUMO modification pathway. Results conclude a definite 
pattern of SUMOylation within our differentiation model. hESCs maintained in CM 
displayed high levels of SUMO modified proteins, which begun to decrease as the 
cells differentiated towards the primitive streak. Subsequently, the levels of 
SUMOylation increased as the cells initiated hepatic specification. This pattern 
differs in hESCs cultured in MT, whereby the self-renewal state of the cells 
maintained low levels of SUMOylation followed by an increase throughout hepatic 
commitment. Differences in HNF4 α expression were also noted. These 
discrepancies could be a result of epigenetic changes within the cells due to 
differences in the culture environment. Further analysis of each media is required to 
fully understand their subsequent effects on hESC epigenetics. On the other hand, as 
the cells began to mature a similar pattern was observed in both media. As the cells 
adopted a more hepatic phenotype the level of SUMO modification decreased in 
conjunction with the decrease of HNF4 α to barely detectable levels at day 17 
(Figure 4.10). This data is further supported when analysed at a transcriptional level 
using SOLEXA (Figure 4.11). In conclusion, SUMOylation may play a direct role in 
modifying HNF4 α function or regulating its stability. Subsequently, SUMOylation 
of HNF4 α may coordinate a mechanism essential for maintaining HE viability.  
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Moreover, significant differences between the transcriptional and translational levels 
of the SUMO deconjugating enzyme, SENP 7 were noted throughout hepatic 
differentiation. Gene expression of SENP 7 increased as the hESCs began to 
differentiate, followed by a decrease in expression at day 10, initiation of hepatic 
maturation, with a subsequent increase as the hepatocytes mature (Figure 4.11). In 
contrast, SENP 7 protein was only detected at day 11 in MT and 13 in CM with a 
gradual increase as the cells developed a more hepatic phenotype (Figure 4.10). The 
differences between transcription and translation can be attributed to post mRNA 
processing targeted degradation, whereby the day 3 SENP transcripts are not 
translated due to a number of inhibitor mechanisms. These include RNAi mediated 
mRNA degradation (Sonenberg et al., 2009), repressor proteins binding the 5’ 
capped sequence and the 3’ UTR on mRNA preventing ribosomal binding 
(Sonenberg et al., 2009), interfering with the 5’ cap recognition and reducing mRNA 
stability by cleavage of the 3’ UTR resulting in de-adenylation and subsequent 
degradation (Decker et al., 1994). Gene expression was re-initiated at day 10 
resulting in translation detected by SOLEXA with a gradual increase in both 
transcriptional and translational expression levels as the hepatocytes mature. This 
observation coincided with the decrease in SUMO modified proteins indicative of 
active de-SUMOylation of target proteins throughout hepatic differentiation. 
 
In conclusion, creating a physiological environment for hESC differentiation will 
allow us to unravel signalling pathways involved in hepatic differentiation. HNF4 α 
was identified as a potentially strong candidate to enhance HE viability required to 
support long-term hepatocyte culture. Previous investigations have defined a number 
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of regulatory mechanisms that affect HNF4 α stability and function. These findings 
suggest a potential role for SUMOylation in HNF4 α regulation. The next chapter 
focuses on defining the role of HNF4 α SUMOylation within our differentiation 
model. Furthermore, a mechanism may be elucidated, which in turn could be utilised 
to enhance HE stability and survival in culture. Subsequently, this tool could be 
translated for use in other hepatic cell types such including adult hepatocytes; each 
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Chapter 4 reviewed the importance of HNF4 α within our differentiation system. As 
a result, the potential modes of regulation were investigated and it was concluded 
that a possible relationship between SUMOylation and HNF4 α exists. This chapter 
focuses on elucidating the exact relationship between the post-translational modifier, 
SUMO, the vital hepatic transcription factor, HNF4 α, which may in turn prove to be 
a useful method of stabilizing HE viability for long-term culture, in vitro. 
 
SUMOylation is a post-translational modification (PTM) and has been known to 
modify a large number of proteins involved in cellular processes such as 
transcription, degradation, cellular localization, cell cycle regulation and 
differentiation. The SUMO modification pathway is dynamic whereby protein 
SUMOylation is a reversible process. However, the effect of SUMOylation is 
dependant on the target protein. The SUMOylation pathway relies predominately 
upon two enzymes; the SUMO activating enzyme complex, SAE1/2 and the 
conjugation enzyme, Ubc9, whereby SUMO is bound via an isopeptide bond on the 
lysine residue in the ψKxE consensus sequence. In vivo, specific substrates require 
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re-localization to the nucleus before SUMO conjugation (Rodriguez et al., 2001). 
Studies have shown, using specific substrates, that the E3 ligase, essential in 
ubiquitination, is not necessary for the formation of the isopeptide bond between 
SUMO and the target protein (Desterro et al., 1999). However, this is not the case in 
all situations and is dependant on the target protein.  
 
5.1.1 THE ROLES OF SUMO MODIFICATION THROUGHOUT DEVELOPMENT 
SUMOylation is an essential pathway required throughout development, and its 
disruption results in embryo lethality (Nacerddine et al., 2005) (Nowak et al., 2006). 
Mouse embryos deficient in Ubc9 die at the post-implantation stage. The embryos 
display significant chromosomal condensation and segregation defects, which lead to 
the inhibition of transcription vital for normal development (Nacerddine et al., 2005).  
In addition, blastocysts lacking Ubc9 were viable in culture for 2 days but were not 
able to expand due to apoptosis within the inner cell mass. The Ubc9 mutant cells 
demonstrated nuclear dysmorphy and nucleoli disruption inhibiting cell cycle 
progression (Nacerddine et al., 2005). As a result, other models need to be developed 
to elucidate the mechanisms behind the SUMO pathway throughout development, 
such as conditional knock downs. Due to the nature of the thesis, I will specifically 
focus on the roles of SUMOylation in hESCs and in endodermal differentiation. 
 
5.1.1.1 HUMAN EMBRYONIC STEM CELLS 
As mentioned in previous chapters, Oct4 is an essential transcription factor required 
for hESC self-renewal and pluripotency. Wei and colleagues have shown that Oct4 is 
SUMO modified and results in increased protein stability, DNA binding and 
enhanced transcriptional activity (Wei et al., 2007). The SUMO modification site is 
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located on lysine 118 within a SUMO consensus sequence near the N terminal DNA 
binding domain (Wei et al., 2007). Sex determining region Y box 2 (SOX 2) is 
another transcription factor required for undifferentiated hESC self-renewal and has 
been shown to be involved with SUMO, however further investigation is required 
(Van Hoof et al., 2009). SUMOylation may also indirectly affect the expression of 
Nanog, another vital pluripotency transcription factor. Sirtuin 1 (SIRT1) is an NAD 
dependant deacetylase involved in regulating p53 activity, a tumour suppressor 
protein vital for guarding the integrity of the genome (Han et al., 2008). Under stress, 
SIRT1 prevents nuclear localization of p53 induced by the production of reactive 
oxygen species (Han et al., 2008). This in turn, triggers apoptosis and alleviates 
inhibition of Nanog expression (Han et al., 2008). SUMOylation has been shown to 
enhance p53 transcriptional activity (Rodriguez et al., 1999), and may therefore may 
play a role in regulating Nanog expression.  
 
5.1.1.2 ENDODERM 
The endoderm layer is formed during embryogenesis and is the precursor of liver, 
pancreas, stomach, colon, urinary bladder, the lining of the urethra, the epithelial 
parts of trachea, pharynx, thyroid, parathyroid, lungs and intestines (Tam et al., 
2003). SUMO modification is an important factor in hepatic biology as it regulates 
C/EBP α, a crucial factor in hepatic differentiation (Sato et al., 2006, Pedersen et al., 
2001). SUMOylation of C/EBP α prevents its association with BRG1, a core subunit 
in the SW1/SNF chromatin-remodelling unit, which leads to the inhibition of 
albumin expression (Sato et al., 2006). In conjunction to this, a decrease in levels of 
SUMOylation as rat hepatocytes mature has also been observed (Sato et al., 2006), 
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suggesting an inhibitory effect of SUMOylation in hepatocyte terminal 
differentiation. This data is in line with the observations presented in chapters 3 and 
4.  
 
Another area of SUMO modification is its role in regulating mitochondria. The 
mitochondria are an essential component of hepatocytes, the main high-energy cell 
type in the liver, and are required for efficient liver function, due to its role as the 
central energy source. Mitochondrial levels within the cell are dynamic and 
continuously undergo fusion and fission (Twig et al., 2008, Frazier et al., 2006). An 
increase in SUMO-1 expression results in an increase in mitochondrial fragmentation 
implemented by the stabilization of the GTPase dynamin-related protein 1 (DRP1) 
(Harder et al., 2004). Additional investigations regarding the above pathway have 
revealed the importance of SENP 5, a SUMO deconjugating enzyme, in maintaining 
normal mitochondrial morphology and levels of reactive oxidative species within the 
cell, which is executed partly by SUMO deconjugation of DRP1 (Zunino et al., 
2007).  
 
5.1.2 THE ROLES OF SUMO MODIFICATION WITHIN THE CELL 
Over the last decade, a number of investigations have been carried out to establish 
the possible roles of SUMOylation within the cell in response to various external 
stimuli. SUMO has been shown to modify protein activity by regulating other PTMs 
such as ubiquitination and phosphorylation. For instance, the SUMOylation of IκBα, 
a vital element in the inflammatory response, inhibits its ubiquitination thus 
preventing its subsequent degradation, hindering NF-κB activation and nuclear 
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translocation (Desterro et al., 1998). Inactive NF-κB is maintained within the 
cytoplasm of unstimulated cells by IκB inhibitor proteins (Desterro et al., 1999). 
Once induced, IκB is targeted for ubiquitination and subsequent degradation via the 
26S proteasome releasing NF-κB, allowing its translocation into the nucleus and the 
activation of specific genes required for the inflammation response (Hay et al., 
1999). SUMOylation of IκBα prevents is degradation and retains NF-κB in an 
inactive state (Desterro et al., 1998). Interestingly, phosphorylation provides another 
level of regulation, whereby phosphorylation of IκBα is required for its 
ubiquitination whilst it inhibits SUMOylation (Desterro et al., 1999). Therefore, the 
phosphorylation state of IκBα determines its subsequent fate. 
 
SUMOylation has also been implicated in regulating the activity of ‘the guardian of 
the genome’, the tumour suppressor protein p53 (Rodriguez et al., 1999). In healthy 
cells, p53 is continuously ubiquitinated and degraded (Lu et al., 1993). However, 
upon stress induction, levels of p53 increase within the cells resulting in the 
expression of specific genes vital for cell cycle arrest and apoptosis (Waldman et al., 
1995). Rodriguez and colleagues have demonstrated the SUMOylated nature of p53 
in response to UV exposure. In addition, SUMOylation enhances the transcriptional 
activity of p53, an essential characteristic for protecting the integrity of the genome 
(Rodriguez et al., 1999).  
 
In response to heat shock, erythroleukemia cells induce transcription of heat shock 
factor 1 (HSF1). After its translation, HSF1 is phosphorylated prior to its 
SUMOylation, which enhances its DNA binding (Hong et al., 2001).  SUMO can 
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also regulate protein activity by modulating its interactions with other 
macromolecules or proteins. Various models have been proposed such as the 
addition of SUMO by altering protein configuration, creating a new interaction motif 
affecting its function (Johnson, 2004). An interesting example of interaction motifs is 
arsenic induced RNF4 mediated degradation of promyelocytic leukaemia (PML) 
bodies. In the presence of arsenic, PML is polySUMOylated, and following the 
recruitment of RNF4, an E3 Ub ligase, PML is ubiquitinated and degraded (Tatham 
et al., 2008). 
 
In conclusion, SUMO modification alters protein function in a variety of ways, and 
for this reason, this chapter focuses on the relationship between HNF4 α and SUMO.  
 
5.2 RESULTS 
The first stage of defining the relationship between SUMO and HNF4 α was to 
investigate whether HNF4 α can be SUMO modified in vitro. This was followed by 
mapping the SUMOylation site on HNF4 α and determining whether mono or poly-
SUMOylation played an important role in HNF4 α biology. In vitro work was carried 
out as a proof of principle, which in turn was reinforced with in vivo data.  
 
5.2.1 IN VITRO SUMO MODIFICATION OF HNF4 α 
The HNF4 α protein sequence was initially analysed using the software program, 
Abgent SUMOplotTM, for possible SUMO consensus motifs; ψKxE. Two possible 
SUMO motifs were located on the protein; one site was present in the amino 
terminus of HNF4 α (MKKE, residues 126-129) whilst the other site was located at 
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the carboxyl terminus (AKID, residues 364-367). Both sites are conserved between 
all six known human HNF4 α variants and within mice and rat variants. In order to 
assess whether these motifs were utilized for SUMO modification, an established in 
vitro SUMOylation assay was performed as previously described (Tatham et al., 
2008). 
 
Primorigen Inc. kindly provided us with recombinant human wild type (WT) HNF4 
α, which was industrially produced in SF-9 insect cells due to difficulties with its 
expression and purification.  WT HNF4 α was incubated with the SUMO 
conjugation machinery; including SUMO-1, E1-SAE1/2 and E2- Ubc9 for 3 hours at 
37°C (Section 2.7.1). The reaction was terminated at 70°C (for 10 minutes) in Nu-
Page (Invitrogen, UK) LDS Sample Buffer. This assay was initially carried out using 
SUMO-1 as a proof of principle. The samples were then run of Nu-Page SDS PAGE 
protein gels (Invitrogen, UK) and analysed using western blotting. These 
experiments were controlled by the inclusion of a SUMO specific protease control, 
SENP 1, (denoted +) which cleaved SUMO modified protein, Figure 5.1. Ran GAP, 












Figure 5.1 – SUMO Modification of HNF4 α, in vitro.  
An in vitro SUMOylation assay was carried out containing the wild type form of HNF4 α in conjugation with the SUMO 
conjugation machinery (E1-SAE1/2 and E2-Ubc9) (Tatham et al., 2008).  A control reaction which contained the SUMO 
deconjugating enzyme SENP1 was employed. SUMO 1 conjugation resulted in a ~10 kDa shift in protein weight, whilst SUMO 
deconjugation was measured by the disappearance of the band in the presence of SENP1. Ran GAP, a known SUMO substrate 




Figure 5.1 displays the western blots obtained from the in vitro SUMO assay. HNF4 
α was successfully SUMO modified as depicted by the upward shift in the HNF4 α 
band (65 kDa). This shift disappeared in the presence of the deconjugating enzyme 
confirming SUMO modification and reaction reversibility, Figure 5.1. The blot was 
then stripped and re-probed with a SUMO-1 antibody to ensure the overlap between 
the upper HNF4 α band and the SUMO positive band, Figure 5.1. Once again, the 
SUMO bands disappeared in the presence of SENP 1. A similar pattern was noted in 
the Ran GAP in vitro assay confirming optimal reaction efficiency. 
 
5.2.2 MAPPING SUMO MODIFICATION OF HNF4 α IN VITRO 
5.2.2.1 EXPRESSING THE N AND C TERMINUS HNF4 α DELETION MUTANTS 
HNF4 α possesses two potential SUMOylation sites within its structure. Deletion 
mutant analysis was performed to map the exact binding site. An amino (N) terminal 
and a carboxyl (C) terminal deletion of HNF4 α were expressed. Residues 1-139 
were deleted from the N terminal mutant of HNF4 α (ΔNT HNF4 α) which resulted 
in the loss of the DNA binding domain, Figure 5.4. The C terminal mutant (ΔCT 
HNF4 α) lacked residues 350-460 which resulted in the loss of the repression 
domain, Figure 5.4. C and N terminal deletions of the HNF4 α were generated by 
amplifying the respective fragment using primer specific PCR (Section 2.1.4 for 
primer details). A two cycle PCR program was used where initially the specific 
sequence was generated to be the predominant template in the reaction (50°C for 7 






Figure 5.2 – Sequencing of HNF4 α Deletion Mutants for SUMO Mapping, in vitro.  
These diagrams confirm the correct sequences for the deletion mutants present in the pET15b expression plasmid, providing His 
tags at the C terminus of the proteins. Sequencing was carried out by MWG Eurofins (Germany). A defines WT HNF4 α. B. 




products were then run on an agarose gel to ensure successful amplification, and that 
the products were well amplified and ran at the expected size (~1000 bp). The DNA 
sequences were then gel purified and sent for sequencing, MWG Eurofins 
(Germany), to ensure the DNA sequence for each mutant was accurate and that no 
point mutations had occurred during the process, Figure 5.2. 
 
Once the sequences of the mutants were confirmed, Figure 5.2, the fragments were 
cloned into the pET15b Vector (Novagen), using specific Bam HI and Nde I 
restriction sites. Digestion analysis was carried out to confirm the presence of the 
correct insert, indicated by the size of the digested bands, Figure 5.3.  All mutants 
contained a His tag to aid in the purification of the HNF4 α deletion mutants.  
 
Figure 5.3 – Generation of HNF4 α Deletion Mutants for SUMO Mapping, in vitro.  
The displayed gels show the bands corresponding to the specific deletion mutants, each at the expected base number, after 
digestion with BamHI and NdeI restriction enzymes, and uncut vectors were used as negative controls. The pET 15b expression 
plasmid was also digested and purified as the backbone vector for protein expression.  
 
The constructs were then transformed into BL21 E-coli (Stratagene) using chemical 




Figure 5.4 – Protein Expression of HNF4 α Deletion Mutants.  
HNF4α WT and the various deletion mutants were generated in order to identify the region of SUMO modification in HNF4α. 
HNF4 α contains a functional domain structure which includes; the activation domains (AD-1 and AD-2), the DNA binding 
domain (DNA BD), the ligand binding domain (LBD) and the repression domain (RD) (Sladek et al., 1990)The mutants were 
induced in BL 21 cells and run on SDS gels to check for correct expression. A. The gels depict four different clones of BL 21 
cells that contain the required plasmid with the Δ CT HNF4 α insert. Each clone was induced using IPTG, the cell pellets were 
lysed, run on an SDS PAGE gel and stained with Commassie Blue, in addition to a non induced control. The presence of a 
unique band at 39 kDa in the induced lane suggests the efficient expression of the Δ CT HNF4 α protein. This is band is not 
present in the non induced control. B. The same result occurs with the expression of the Δ NT HNF4 α protein, with a unique 





transformation and amplification was investigated. The BL21 cells were then 
cultured and induced with 0.5mM IPTG (Invitrogen) to stimulate protein expression, 
and non-induced BL21 clones were used as negative controls. The cells were spun 
down and were lysed in SUMO lysis buffer. The samples of the four clones for each 
mutant were then run on an SDS PAGE gel and analysed for protein expression 
using Coomassie staining, indicated by a band present only in the group of cells that 
were induced, Figure 5.4.   
 
As observed in Figure 5.4, all four clones expressed the mutant protein, which was 
not present in non-induced cell controls. ΔCT HNF4 α was successfully expressed at 
39 kDa, Figure 5.4 A, with high efficiency in clones 1 and 4. ΔNT HNF4 α was also 
optimally expressed at 30 kDa, Figure 5.4 B, with highest efficiency in clone 4. As a 
result, clone 4 for both the ΔCT and the ΔNT HNF4 α mutants were used for the 
remainder of the investigation. A large-scale induction was set up (400ml culture) to 
allow for sufficient protein production, Figure 5.5 A. The induced cells were pelleted 
and lysed using SUMO lysis buffer. Samples were collected, run on an SDS PAGE 
gels and Coomassie stained to ensure adequate protein expression, Figure 5.5 A. As 
noted in Figure 5.5 A, sufficient amounts of protein were produced for both mutants. 
The samples were then spun down using a high-speed centrifuge to separate the 
soluble and insoluble fractions, and stored at -80°C for later use. 
 
5.2.2.2 THE PURIFICATION AND CHARACTERIZATION OF THE N AND C TERMINUS HNF4 
α DELETION MUTANTS 
The second stage of expressing the ΔCT and the ΔNT HNF4 α mutants was to purify 
the individual proteins. Samples were collected from both the soluble and insoluble 
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fractions and were analysed using western blotting. The samples were probed with 
both His tag and HNF4 α specific antibodies in order to identify which fraction the 
protein was expressed in. It was found that both HNF4 α mutants were expressed in 
the soluble fraction. As such, the soluble fraction obtained from the induced bacterial 
cells for each mutant was purified using nickel agarose beads that specifically pull 
down His tagged proteins. The soluble fractions were then incubated with the nickel-




Figure 5.5 – The Large Scale Production and Purification of the HNF4 α Deletion Mutants.  
A. Unique bands present in the induced lanes at 40 kDa and 35 kDa suggest the expression of the Δ CT HNF4 α, Δ NT HNF4 α 
and the PM HNF4 α proteins, respectively, during large scale protein production. B. The cell pellets were lysed and purified 
using nickel beads that specifically pull down His tagged proteins. The resulting eluates were run on SDS gels and probed with 
HNF4 α and His Tag specific antibodies.  Specific bands at the correct molecular weights were observed for the Δ CT HNF4 α, 
Δ NT HNF4 α and the PM HNF4 α proteins. This confirms the successful expression of the required HNF4 α deletion mutants. 
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binding of the His tagged proteins. The columns were washed thoroughly to remove 
all non specific binding and improve protein purity. The His tagged HNF4 α protein 
mutants were then eluted and collected in 50 µl aliquots over 20 eppendorfs.  A 
Bradford assay was used to identify the samples that contained the majority of the 
eluted protein. The positive samples were then pooled and dialysis was carried out to 
further purify the proteins. The proteins were run on an SDS PAGE gel and analysed 
for the HNF4 α proteins using western blotting, Figure 5.5 B. 
 
The bands displayed in Figure 5.5 B are positive for the His tag and HNF4 α at the 
expected sizes, 39 kDa for the C terminal deletion and 30 kDa for the N terminal 
deletion. This confirms the successful expression and purification of high quality 
ΔCT and ΔNT HNF4 α proteins, each containing a His tag. The HNF4 α mutants 
were aliquoted and stored at -80°C for later use. 
 
5.2.2.3 IN VITRO SUMO MODIFICATION OF THE N AND C TERMINUS HNF4 α DELETION 
MUTANTS 
The C and N terminal HNF4 α deletion mutants were expressed, purified and 
characterized successfully. An in vitro SUMO assay was carried out on each mutant 
to map out the specific SUMOylation site, as previously mentioned in section 5.2.1. 
Ran GAP, SENP 1 and WT HNF4 α were used as additional controls for the 
reaction. The reactions were arrested after 3 hours and the samples were run on SDS 
PAGE gels and the results were analysed using western blotting. 
 
Figure 5.6 shows efficient SUMO modification noted by the shift in WT HNF4 α (65 
kDa) and Ran GAP proteins (37 kDa) (upper bands) which disappear in the presence  
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Figure 5.6 - Mapping SUMO Modification of HNF4α, in vitro.  
An in vitro SUMO assay was carried out to confirm the SUMOylation site within the HNF4 α protein. The use of the deletion 
constructs and point mutant (Lysine 365 to Arginine 365 and Aspartic acid 367 to Alanine 367) demonstrates that the C 
terminus in HNF4α is absolutely required for SUMOylation in vitro, specifically at lysine 365. A control reaction which 
contained the SUMO deconjugating enzyme SENP1 was employed denoted by +/-. SUMO conjugation resulted in a ~10 KDa 
shift in protein weight, marked with an *, whilst SUMO deconjugation was measured by the disappearance of the band in the 
presence of SENP1.  
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of the deconjugating enzyme SENP 1. A similar pattern in the band shift was 
observed in the ΔNT HNF4 α mutant protein (40 kDa, a 10 kDa shift upwards), 
Figure 5.6. The upper bands in all three cases were also positive for SUMO-1. 
However, no observable shift was noted in the ΔCT HNF4 α mutant protein (40 
kDa), Figure 5.6, and is thus not SUMO modified. This confirms the SUMO 
modification site is located in the C terminus of HNF4 α.  
 
In order to confirm the absolute requirement for the carboxyl terminal consensus site 
in the SUMO modification process, conservative point mutagenesis (PM) of the 
SUMO consensus motif Ψ-K-x-D/E between residues 364-367 at the carboxyl 
terminus was performed.  The lysine residue at position 365 was mutated to an 
arginine residue and the aspartic acid residue 367 was mutated to an alanine residue 
using single site directed mutagenesis. Two base pair mutations were generated to 
fully obliterate the ability for the site to be SUMO modified. This was implemented 
using the Quick Change II Site Directed Mutagenesis Kit (Stratagene). The mutated 
sequence was verified, Figure 5.2, and cloned into the pET 15b vector, which was 
then transformed into XL-1 Blue supercompetent cells using heat shock. Positive 
clones were identified using blue-white selection followed by small-scale protein 
expression and verification, Figure 5.4. The protein was then expressed on a large 
scale, Figure 5.5, purified, Figure 5.5, and employed in the in vitro SUMO assay, 
Figure 5.6, as previously described. SUMO modification (30 kDa) on the HNF4α 
PM was not detected, indicating that HNF4α SUMOylation proceeds through the 
SUMO consensus site at the carboxyl terminus on lysine residue 365, in vitro.  
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5.2.3 INVESTIGATING SENP PROTEIN SPECIFICITY IN SUMO-1 DECONJUGATION 
There are seven known isoforms for the SUMO specific isopeptidases; including 
SENP 1, 6 and 7 (Melchior et al., 2003). SENPs contain a Ulp domain, located at the 
C terminus and are responsible for cleaving the isopeptide bond between SUMO and 
the target protein (Mukhopadhyay et al., 2007). Each individual SENP has a unique 
N terminal sequence that alters its cellular localization. This suggests that the SENPs 
have a distinct set of substrates under their regulation (Mukhopadhyay et al., 2007). 
 
 Next, the deconjuation specificity of SENP 1, 6 and 7 in cleaving the isopeptide 
bond between SUMO-1 and WT HNF4 α was investigated.  
 
Figure 5.7 – Determining SUMO-1 Deconjugating Enzyme Specificity.  
There are several known SUMO specific deconjugating enzymes known as SENPs (Mukhopadhyay et al., 2007, Hannoun et al., 
2010). To establish if these SENPs have differing specificities, in vitro SUMOylation assays were carried out using SUMO 1 
and subsequent deconjugation with SENPs 1, 6 and 7 were performed. The results show that SENP1 was the most efficient 
deconjugating enzyme to cleave the isopeptide bond between SUMO 1 and the target protein, HNF4 α. The use of SENP 1 
resulted in the highest level of free SUMO (10 kDa band) when compared to SENP 6 and 7. 
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Professor Hay, (The University of Dundee), kindly provided the recombinant SENP 
proteins. An in vitro SUMO assay was carried out using WT HNF4 α as the target 
protein and deconjugation assays were performed using three different SENPs and 
the samples were analysed using western blotting. Figure 5.7 depicts the varied 
specificity between each SUMO specific protease. The reactions that contain the 
SENPs are denoted by a + sign. SENP 1 had the greatest level of specificity when 
deconjugating HNF4 α, with no conjugated HNF4 α remaining. SENP 6 and 7 
possessed limited deconjugating capabilities, distinguished by the residual 
conjugated forms of HNF4 α. SENP 1 was also able to recycle the deconjugated 
SUMO-1 protein back into the reaction, noted by a positive band for SUMO-1 at 10 
kDa. The SUMO-1 proteins deconjugated by SENP 6 and 7 were either still bound to 
the SENP protein itself or to another component in the reaction, and therefore, no 
free SUMO-1 was noted in the reactions. Overall, SENP1 is the most efficient 
isopeptidase for deconjugating SUMO-1 from HNF4 α. (Kaikkonen et al., 2009, 
Lima et al., 2008, Dou et al., 2011) 
 
5.2.4 INVESTIGATING SUMO MODIFICATION OF HNF4 α IN VIVO 
HNF4 α is SUMO modified in vitro at its C terminus specifically on lysine residue 
365. Consequently, the SUMOylation state of HNF4 α within our differentiation 
system was examined. hESCs were differentiated using our standardized protocol 
and protein samples were collected at various time points. The protein extracts were 
subsequently used for immuno-precipitation to specifically pull down the 
endogenous HNF4 α protein. This was achieved by cross-linking the HNF4 α 
antibody to protein A beads (Sigma Aldrich, UK), incubating the extracts with the 
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cross-linked beads and eluting the bound proteins. The eluate was then analysed by 
western blotting. 
 
5.2.4.1 CROSS LINKING THE ANTIBODIES 
The HNF4 α antibody was cross-linked to protein A sepharose beads using dimethyl 
pimelimidate and ethanolamine. Cross linked and non-cross linked antibodies and 
beads were incubated with Nu PAGE LDS sample buffer at 70°C for 10 minutes to  
 
Figure 5.8 – Production of Sepharose Beads Cross Linked with the HNF4 α Antibody.  
A. The disappearance of the 55 kDa band in the cross linked lane suggests the successful cross linking of the HNF4 α and IgG 
antibodies to the Protein A sepharose beads. B. The beads crossed linked to the HNF4 α antibody were used in a test pull down 
experiment using cell extract from the hepatocarcinoma cells line, C3A's.  As observed in the blots, a band at 55 kDa is positive 
for the HNF4 α antibody, which is not present when using non-cross linked beads. The band intensifies as the amount of beads 
used in the pull down increases to 10ul. This data confirms the specificity and efficiency of the HNF4 α cross-linked protein A 
sepharose beads.  
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break all non-covalent bonds and linearise the proteins. The samples were run on 
SDS PAGE gels and Coomassie stained. This technique provides evidence for cross-
linking efficiency. As observed in Figure 5.8 A, no bands were present in the cross 
linked samples suggesting that the antibody has been covalently attached to the 
sepharose beads. The non-cross linked samples had a band present at approximately 
60 kDa, indicating the presence of the HNF4 α antibody, Figure 5.8 A.  A goat IgG 
antibody was also cross-linked and examined, representing a negative control for the 
immunoprecipitation (IP). 
 
The Coomassie stained gel shows the successful cross-linking of the HNF4 α and 
IgG antibody to the protein A sepharose beads. The next step was to carry out a test 
IP to investigate the efficiency of the cross-linked beads. C3A cells, a sub clone of 
the hepatoblastoma HepG2 cell line, were lysed in SUMO lysis buffer and were 
incubated with the HNF4 α and IgG cross-linked sepharose beads. The beads were 
washed thoroughly and the bound proteins were eluted. The eluates were then run on 
an SDS PAGE gels and analysed using western blotting.  
 
Figure 5.8 B substantiates the ability of the cross-linked sepharose beads to 
specifically pull down the HNF4 α protein from cell lysate. A no antibody control 
was used to account for background staining and non-specific binding. The volume 
of sample loaded was doubled to demonstrate the linear increase of the HNF4 α 
protein detected, which was found to be a 1.5 fold increase (carried out by 
densitometry analysis). In conclusion, the HNF4 α and IgG antibodies were cross 
 196
linked effectively to protein A sepharose and were capable of specifically 
precipitating HNF4 α from cell extracts.  
 
5.2.4.2 IMMUNOPRECIPITATION OF HNF4 α  
Immunoprecipitation was employed to identify the SUMOylation state of the HNF4 




Figure 5.9 - SUMO Modification of HNF4 α, In Vivo.   
hESCs were differentiated to hepatic endoderm and samples were prepared at the days indicated (Hay et al., 2008). HNF4 α was 
pulled down using HNF4 α and an IgG control antibody covalently cross linked to Protein G sepharose beads. Following 
incubation and extensive washing; the beads were eluted, separated by SDS PAGE and Western blotted and probed for SUMO 
2. An increase in HNF4 α protein modification by SUMO-2 was observed as differentiation progressed. The negative control 
IgG demonstrated that the assay was operating specifically. The increase in levels of SUMO 2 modification on HNF4 α is timed 
with the decrease in the levels of HNF4 α throughout hepatocyte differentiation. As such, SUMO modification of HNF4 α may 
affect its subsequent stability. 
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Protein extracts were collected at various time points throughout differentiation and 
were individually incubated with the antibody cross-linked beads. This resulted in 
the specific purification of the HNF4 α protein from these extracts, an IgG antibody 
was used as a negative pull down control. The immunoprecipitated complexes were 
separated using SDS PAGE electrophoresis, western blotted and probed for SUMO 1 
and 2. Differentiating between SUMO 1 and 2 modification may provide insight into 
the mode of regulation and possible mechanism of function.  
 
HNF4 α was indeed modified by SUMO 2 within the differentiating cells, Figure 5.9. 
No detectable levels of SUMO 1 modification were observed on the HNF4 α protein. 
The results were specific to HNF4 α as no bands were present in the IgG pull down 
control as expected, Figure 5.9. Interestingly, despite the gradual decrease of HNF4 α 
throughout differentiation, Figure 5.9, an increase in levels of SUMO 2 in the 
immunoprecipitation experiments was noted. This suggests that SUMO 2 may be 
involved in regulating HNF4 α protein stability in vivo. Interestingly, multiple HNF4 
α bands defining poly-SUMOylation were not noted, this could be due to degradation 
of the poly-SUMOylated chain during the IP process. In conclusion, HNF4 α is 
SUMO-2 modified in vivo, most likely poly-SUMOylated, which in turn may play a 
role in regulating protein stability. 
 
5.2.5 ELUCIDATING THE EFFECT OF SUMO MODIFICATION ON HNF4 α 
5.2.5.1 THE INVOLVEMENT OF RNF4 IN HE DIFFERENTIATION 
Recent developments in the field have suggested that RNF4 and poly-SUMOylation 
play a role in regulating protein stability. Tatham and colleagues have proved that 
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poly-SUMOylation of the promyelocytic leukaemia (PML) protein in the presence of 
arsenic resulted in its subsequent ubiquitination and degradation via RNF4 (Tatham 
et al., 2008). It should be noted that PML is only poly-SUMOylated in the presence 
of arsenic. RNF4 is an E3 ubiquitin ligase with specialized regions known as SUMO 
interaction motifs (SIMs) (Sun et al., 2007). RNF4 is vital throughout development 
as deletion mutants result in embryonic lethality and demonstrate increased levels of 
DNA methylation (Hu et al., 2010).  RNF4 contains a conserved RING domain 
responsible for its ligase properties and four SIM domains required for poly-
SUMOylation recognition (Sun et al., 2007). SIM motifs consist of a hydrophobic 
core attached to a stretch of acidic or phosphorylated residues aligned as a β strand 
providing a complementary SUMO binding region (Ulrich, 2008). Mutation of the 
SIM regions progressively hindered poly-SUMO chain binding (Tatham et al., 2008). 
It was also found that RNF4 could not distinguish between SUMO 1 and SUMO 2 
chains. A mutant SUMO 1 protein capable of forming SUMO chains was generated 
and used for poly-SUMOylation, which in turn was recognized by RNF4. Hence, 
RNF4 is solely capable of detecting and interacting with poly-SUMO chains with no 
preference to the isoform present (Tatham et al., 2008). However, SUMO 1 is unable 
to form chains in its native environment (Johnson, 2004). 
 
In response to this body of work, the role of the RNF4 within our differentiation 
system was investigated. RNF4 expression was detected in vitro from days 5 to 17 
throughout differentiation, Figure 5.10. RNF4 protein expression increased gradually 
throughout differentiation, which coincided with the decrease in HNF4 α expression 
and the increase in levels of SUMO-2 modified HNF4 α. This observation is 
compatible with the idea that poly-SUMOylation and RNF4 regulate HNF4 α 
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stability. RNF4 expression was detected in adult hepatocytes, which could suggest 
the involvement of RNF4 in maintaining the terminally differentiated state of mature 




Figure 5.10 –RNF4 Patterning Within Hepatic Differentiation.   
A-hESCs were differentiated to hepatic endoderm and protein samples were prepared at the days indicated (Hay et al., 2008). 
The samples were then run on an SDS PAGE gel and analysed for RNF4 using western blotting. A gradual increase in RNF4 
expression is noted from day 5 onwards, peaking at day 17 in conjunction with peak levels of SUMO modified HNF α obtained 
from IP experiments. This coincides with the decrease in levels of endogenous HNF4 α. This data supports the role of RNF4 
and SUMO-2 in regulating HNF4 α stability. B- Sections were DAB stained for RNF4 to analyse the spatial patterning within 
the adult liver. The sections were positive for RNF4 as indicated by brown staining. The images were taken at x40 
magnification.  However, due to discrepancies between various sections no conclusions could be drawn. 
 
In conjunction with the above experiments; adult liver sections were also DAB 
stained using enzymatic antigen retrieval to observe the spatial patterning of RNF4 
within the adult liver, Figure 5.10 B. The sections stained positive for RNF4, 
indicated by the brown stained regions, Figure 5.10 B, which confirmed the western 
blot data noted in Figure 5.10 A.  
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5.2.5.2 POLY-SUMOYLATION OF HNF4 α IN VITRO 
The next stage in the investigation was to assess the ability of HNF4 α to be poly-
SUMOylated in vitro. The in vitro SUMO assay was employed using SUMO-2 in 
replacement of SUMO-1. SENP 1 was once again used as a control to ensure 
efficient SUMOylation. Ran GAP was also SUMOylated and used as a positive 
control to measure the efficiency of the reaction. Once the reactions were stopped, 
the proteins were run on an SDS PAGE gel and western blotted.  Figure 5.11 
confirms the ability of HNF4 α to be poly-SUMOylated. Multiple bands were present 
in both the HNF4 α and Ran GAP reactions indicating the various lengths of the 
SUMO chains attached. The bands disappeared in the presence of the deconjugating 
enzyme SENP 1, Figure 5.11. These blots were stripped and probed for SUMO 2, 
and a similar pattern was observed, data not shown.  
 
 
Figure 5.11 – Poly-SUMOylation of HNF4 α, In Vitro. 
HNF4 α was poly-SUMOylated using an in vitro SUMO assay and replacing SUMO 1 with SUMO 2. The reactions were run 
on SDS PAGE gels and western blotted for HNF4 α. Ran GAP and SENP 1 were used as control for the reaction. Both HNF4 α 





5.2.5.3 INVESTIGATING SENP PROTEIN SPECIFICITY IN SUMO-2 DECONJUGATION 
An in vitro SUMO assay was performed followed by deconjugation assays using 
SENP 1, 6 and 7 in order to measure the efficiency of each isopeptidase to cleave 
































Figure 5.12 – Determining SUMO-2 Deconjugating Enzyme Specificity.  
A. There are several known SUMO specific deconjugating enzymes known as SENPs (Mukhopadhyay et al., 2007, Hannoun et 
al., 2010). To establish if these SENPs have varied specificities, in vitro SUMOylation assays were carried out using SUMO 2 
and subsequent deconjugation with SENPs 1, 6 and 7 were performed. The results show that SENP1 was the most efficient 
deconjugating enzyme to cleave the isopeptide bonds between SUMO 2 chains and the target protein, in this case HNF4 α. The 
use of SENP 1 resulted in the highest level of free SUMO (10 kDa band) when compared to SENP 6 and 7, whilst 
deconjugating all poly-SUMOylated HNF4 α. B. The graph displays the decrease in the levels of SUMO modified HNF4 α 
once the deconjugating enzymes were added. Densitometry analysis displays a 10 fold decrease in SUMOylated HNF4 α in the 





The results were depicted in western blots, Figure 5.12. Once again, SENP 1 was 
able to fully deconjugate poly-SUMOylated HNF4 α whilst SENP 6 and 7 had 
limited cleaving capabilities. The HNF4 α blot was stripped and re-probed with 
SUMO 2, similar patterns were noted. Overall, SENP-1 has greatest specificity when 
cleaving mono and poly SUMOylated forms of HNF4 α, Figure 5.7 and 5.12 
respectively. However, this may not be an accurate representation of what occurs in 
vivo, as the in vitro environment may promote and favour SENP 1 activity. It should 
be noted that the SENP 7 reaction contained free SUMO proteins in the absence of 
the deconjugating enzyme. This may be attributed to less than optimal SUMOylation 
of HNF4 α in the initial reaction (below 100% efficiency), which occurs when 
SUMOylating certain substrates (Johnson, 2004). 
 
Densitometry analysis was carried out using Image J software on the lanes before 
and after deconjugation, Figure 5.12 B, and indicates that SENP1 is the most 
effective isopeptidase for deconjugating SUMO 1 and SUMO 2 modified proteins. 
As observed, the levels of poly-SUMOylated HNF4 α decreased by more than 10 
fold in the presence of SENP 1 when compared to the 2.5 and 1.5 fold decrease when 
utilizing SENP 6 and 7, Figure 5.12 B. In conclusion, SENP 1 is capable of 








5.2.6 POLY-SUMOYLATION TARGETS HNF4 α FOR INCREASED RNF4 MEDIATED 
UBIQUITINATION, IN VITRO 
We hypothesized that poly-SUMOylation of HNF4 α results in its ubiquitination via 
RNF4. In order to test our hypothesis, we set up an in vitro ubiquitination assay in 
the presence and absence of RNF4. Unmodified HNF4 α was compared to HNF4 α 
that had been SUMO-1 and SUMO-2 modified, Figure 5.13 A. The western blots 
confirmed sufficient mono and poly SUMOylation of HNF4 α before use in the 
ubiquitination assay. The substrates were then incubated with excess ubiquitin in 
addition to the E1 and E2 enzymes, with and without RNF4. Four hours post 
incubation; the reactions were immunoprecipitated to specifically isolate the HNF4 α 
protein. The elutes were subsequently run on SDS PAGE gels and probed for 
ubiquitin using western blotting. 
 
Ubiquitination was solely detected in reactions containing RNF4, confirming the 
requirement of the E3 ligase for the covalent attachment of ubiquitin, Figure 5.13 B. 
Furthermore, our in vitro assay demonstrated that poly-SUMOylation of HNF4 α 
resulted in a three-fold increase in ubiquitination when compared to mono 
SUMOylated HNF4 α and a six-fold increase in comparison to native HNF4 α, 
Figure 5.13 C. To ensure specific isolation of HNF4 α, the blots were probed with 
RNF4, a non-covalent interaction with the target protein, Figure 5.13 B. 
 
No bands were detected, therefore, HNF4 α was specifically pulled down with the 







Figure 5.13 - Poly SUMOylation Marks HNF4a for RNF4 Mediated Ubiquitination, In Vitro.  
A. In order to study the stability of SUMOylated HNF4a in vitro we employed an RNF4 Ubiqutination assay. WT HNF4α was 
mono and poly SUMOylated using SUMO-1 and SUMO-2 but absent from the control lane. B. SUMOylated HNF4α protein 
was incubated with ubiquitination machinery (E1 and E2) in the presence and absence of RNF4 (E3). Following assay 
completion, HNF4α was immunoprecipitated and ubiquitin conjugation analysed using western blotting. Ubiquitination only 
occurred in the presence of RNF4 and was increased when HNF4α was poly SUMOylated. No bands were positive for RNF4 
suggesting specific isolation of HNF4 α. C.  Densitometry Analysis was performed using Image J software, and the level of 
ubiquitination increased by 6 fold over the control when HNF4 α is poly SUMOylated when compared to 4 fold when HNF4 α 
is mono SUMOylated.  
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addition, ubiquitin positive bands for HNF4 α at approximately 40-45kDa were 
observed and were suggested to be HNF4 α degradation products. The degraded 
forms of HNF4 α were also present in previous in vitro SUMOylation assays and 
were positive for SUMO modification.  
 
This data suggests that poly-SUMOylation of HNF4 α leads to preferential 
ubiquitination by RNF4, in vitro. Densitometry quantification was performed using 
the Gel Analyzer plug-in from ImageJ software. The bands were selected and equal 
pixels numbers were applied. A histogram was plotted using the band intensity and 
the area under the peak was measured accordingly. In conclusion, the above 
experiment has provided evidence supporting the role of SUMO modification in 
regulating HNF4 α stability, in vitro.  
 
RNF4 to date is the only known ubiquitin ligase in humans that specifically 
recognises poly-SUMO chains via its SIM domains. The RNF4 protein is conserved 
throughout various species such as; Saccharomyces cerevisiae Slx5–Slx8 and 
Dictyostelium discoideum MIP1, whereby Slx5-8 deletion mutants result in genomic 
instability and a build up of SUMOylated proteins (Prudden et al, 2007). A similar 
phenotype is also noted in humans (Hun et al, 2010). Further investigation is required 
to isolate other possible ubiquitin E3 ligases containing SIM domains, which may 
have a function comparable to RNF4. Evidence from a number of investigations and 
the data presented in this chapter suggests that poly-SUMOylation may have a direct 
role in regulating protein degradation within cells, in conjugation with other cellular 
functions.  
 206
5.2.7 POLY-SUMOYLATION TARGETS HNF4 α FOR UBIQUITIN MEDIATED 
DEGRADATION, IN VIVO 
Section 5.2.5.1 confirms RNF4 expression in our mature hepatocyte like cells, Figure 
5.10 A. As such, our in vivo system contains the correct machinery required for 
HNF4 α modification and degradation. To gain further insight behind this process 
within our system, we incubated day 17 hepatic endoderm in the presence and 
absence of MG132, a defined proteasome 26S inhibitor. The cell extracts were 
collected and analyzed for HNF4 α and the SUMO proteins using western blotting.  
 
HNF4 α was stabilized in the presence of MG132, indicating that ubiquitin 
dependant proteolysis is responsible for regulating levels of HNF4 α within our cells, 
Figure 5.14 A. Furthermore, a doublet band at ~75 kDa signifies the preservation of 
modified forms of HNF4 α in the absence of the 26S proteasome activity, Figure 
5.14 A. We also observed a build up of SUMO-2 modified proteins in blots probed 
with the SUMO-2 antibody, which is compatible with our previous results, Figure 
5.14 B. In addition to this, a doublet band was noted at ~75 kDa, also present in the 
HNF4 α blot, Figure 5.14 B. The doublet band present in Figure 5.14 A, not present 
in Figure 5.9, may be a result of successful preservation of poly-SUMOylation 
throughout the protein isolation and detection process. The IP process may have 
resulted in the cleavage of the poly-SUMO chain, which was avoided in this 
experiment as the cell extracts were immediately run on SDS page gels and probed 
for HNF4 α using western blotting. We then examined the stability of SUMO 1 
modified proteins in the presence and absence of MG132. In contrast to SUMO 2 
conjugated proteins, we observed a decrease in SUMO 1 modified proteins in 
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response to MG132 treatment, Figure 5.14 B. Correlating with our in vitro data; the 
above investigation reinforces the ubiquitin dependant regulation of HNF4 α stability 
within our differentiation system. The likely mechanism is as follows; an 
environmental cue induces poly-SUMOylation of HNF4 α resulting in the RNF4 
mediated ubiquitination and subsequent degradation via the 26S proteasome. As 
such, SUMO modification plays a vital role in regulating HNF4 α stability in vivo. 
 
Figure 5.14 - Poly SUMOylation Marks HNF4α for Degradation, In Vivo.  
A. In order to assess if Ubiquitin mediated proteolysis played a central role in the stability of HNF4α, we inhibited the 26S 
proteasome using MG132. The Day 17 hepatic endodermal cells were incubated with and without MG132 and whole cell 
extracts were collected, separated, Western blotted and probed for HNF4α, duplicates were run for each condition. HNF4α 
levels were stabilized in the presence of MG132, demonstrating the importance of ubiquitination and the 26S proteasome in the 
regulation of HNF4α stability. These data suggest that RNF4 mediated ubiquitination of poly-SUMOylated HNF4 α regulates 
protein stability in vivo. B. In accordance to this data, we observe a build up of SUMO 2 modified proteins in the presence of 
MG132, suggesting its involvement in protein degradation. The opposite is shown in SUMO 1 where there is a decrease in the 
level of SUMO 1 modified proteins in the presence of MG132. Overall, this data suggests that SUMO 2 may play a more global 
role in regulating protein degradation, which may be linked to its ability to form poly-SUMO chains. The asterisks denote bands 
present at 55kDa and 75kDa, similar to that observed in A, suggestive of poly-SUMOylated HNF4α. 
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5.3 DISCUSSION 
In an effort to refine our differentiation system, we focused on HNF4 α, a 
transcription factor responsible for regulating hepatic function and viability, 
controlling the active expression of ~40% of genes within the liver (Odom et al., 
2004). We were interested in a particular post translational modification of HNF4 α, 
SUMOylation, and its subsequent effect within our cells. HNF4 α regulates the 
formation of the visceral endoderm throughout development and is vital for 
gastrulation to occur (Chen et al., 1994, Watt et al., 2003). In the adult liver, HNF4 α 
maintains the expression of an array of genes required for efficient liver metabolism 
such as detoxification and tissue homeostasis (Watt et al., 2003).  In addition, 
mutations in HNF4 α have been directly associated with pancreatic and liver diseases 
such as maturity onset diabetes of the young (MODY) (Ellard et al., 2006) and 
cancer (Lazarevich et al., 2004). Therefore, HNF4 α is an ideal candidate for refining 
our differentiation system. 
 
HNF4 α has been demonstrated to be phosphorylated by protein kinase C on a 
conserved serine residue, which hinders DNA binding and reduces transcriptional 
activation in addition to enhancing its degradation (Sun et al., 2007). In conjunction, 
protein kinase A (Viollet et al., 1997), p38 kinase (Guo et al., 2006) and AMP 
activated protein kinase (Hong et al., 2003) have been demonstrated to phosphorylate 
the serine residue resulting in similar consequences. Acetylation, on the other hand, 
enhances DNA binding activity and co-activator interactions (Soutoglou et al., 2000). 
Hence, PTM’s play a significant role in regulating HNF4 α function and stability. 
Initially, we found that HNF4 α was SUMO modified, in vitro, Figure 5.1. We found 
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2 potential SUMOylation sites; one located in the amino terminus and one found at 
carboxyl terminus of the protein. Through deletion and point mutation analysis we 
determined that the critical region for HNF4α modification was the consensus site 
found at the carboxyl terminus, Figure 5.2 - 5.6. Whilst HNF4α SUMOylation took 
place in vitro, immune precipitation experiments confirmed that HNF4α was SUMO 
modified in vivo, Figure 5.9. Moreover, and in contrast, to the correlation of HNF4 α 
and general SUMOylation pattern we observed an increase in protein SUMOylation, 
which resulted in decreased HNF4α stability, Figure 5.9. HNF4 α was found to by 
modified by SUMO-2 in vivo. SUMO-2, unlike SUMO-1, contains a consensus 
SUMO modification motif and is thus capable of forming SUMO chains (Johnson, 
2004). SUMO-1 however, can be used as a chain terminator (Kroetz, 2005).  Poly-
SUMO chains were formed on HNF4 α in vitro, substantiating the in vivo data, 
Figure 5.11. 
 
Literature reviews lead us to investigate the role of RNF4 throughout this process. 
RNF4 is a ubiquitin E3 ligase that contains specific SIM motifs responsible for 
recognizing poly-SUMO chains. Our results demonstrated that RNF4 expression 
increased as the levels of HNF4 α decreased during hepatic differentiation, Figure 
5.10. As HNF4 α was capable of being poly-SUMOylated in vitro, Figure 5.11, we 
carried out a ubiquitination assay in the presence and absence of RNF4. 
Ubiquitination only occurred in the presence of RNF4, confirming its requirement in 
this process, Figure 5.13. Interestingly, we found that poly-SUMOylation of HNF4 α 
resulted in a 6-fold increase in its RNF4 mediated ubiquitination when compared to 
native HNF4 α and a 3-fold increase in comparison to mono-SUMOylated HNF4 α, 
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Figure 5.13.  In order to gain further understanding of our differentiation system, 
were employed the use of a proteasome inhibitor, MG132. The results demonstrated 
that HNF4 α was stabilized in the presence of MG132, with a doublet band present at 
~75 kDa, suggesting poly-SUMOylation, Figure 5.14 A. This was re-established by 
the increase in the levels of SUMO 2 modified proteins in samples containing 
MG132, with a doublet band noted at ~75 kDa, Figure 5.14 B. This suggests that 
SUMO-2 may in fact play a larger role in protein regulation mediated by proteasome 
26S degradation.  In contrast, SUMO 1 modified proteins decreased in the presence 
of MG132, Figure 5.14 B. These investigations support our hypothesis, Figure 5.15.  
 
HNF4 α expression decreases throughout hepatic differentiation, which is timed with 
the increase in the level of SUMO-2 modification of the protein during which RNF4 
expression peaks, Figure 5.10 A. We have also shown that HNF4 α can be modified 
in vitro by both SUMO-1 as monomers and SUMO-2 as chains, Figure 5.1 and 5.11. 
This data in conjunction with the literature suggests that the poly-SUMOylation of 
HNF4 α results in its ubiquitination and subsequent degradation mediated by RNF4. 
RNF4 is able to recognize poly-SUMOylation via its SIM domains, the close 
proximity between RNF4 and HNF4 α causes it to be ubiquitinated via the RING 
domain. Poly ubiquitin chains attached to HNF4 α results in its degradation via the 
26S proteasome. Figure 5.15 displays the schematic of the above hypothesis. The 
poly-SUMOylation of HNF4 α may be caused in response to changes in cellular 







Figure 5.15 – RNF4 Mediated Degradation of poly-SUMOylated HNF4 α 
This schematic represents the proposed hypothesis whereby the poly-SUMOylation of HNF4 α leads to ubiquitination and its 
consequential degradation mediated by RNF4. A- Poly-SUMOylated HNF4 α is recognized by RNF4 and binds via the SIM 
domains. B- RNF4 is an E3 ligase and binding to poly-SUMOylated HNF4 α causes its ubiquitination. C- Ubiquitinated HNF4 
α results in its degradation via the 26S proteasome.  
 
 
Studies have established similar mechanisms of regulating protein stability via poly-
SUMOylation. Tatham and colleagues have demonstrated that upon arsenic 
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induction, promyelocytic leukaemia (PML) protein is poly-SUMOylated, which 
results RNF4 mediated ubiquitination followed by its subsequent degradation via the 
26S proteasome (Tatham et al., 2008). Subsequent investigations demonstrated that 
arsenic trioxide also induced the RNF4 mediated degradation of the oncogenic fusion 
PML protein, PML and the retinoic acid receptor, responsible for causing acute 
promyelocytic leukaemia (Lallemand-Breitenbach et al., 2008). These studies 
provided insight into a mechanism that is translatable into a possible long-term 
treatment for leukaemia. Another example of RNF4 mediated protein degradation 
was demonstrated by Van Hagen and colleagues.  Hypoxia-inducible factor 2 α 
(HIF-2 α), vital for regulating cell survival during hypoxia, is a direct target of 
SUMOylation, which results in reduced transcriptional activity of the transcription 
factor. Furthermore, inhibition of the 26S proteasome in conjugation with generating 
RNF4 knock outs indicated that poly-SUMOylation of HIF-2 α induced RNF4 
mediated ubiquitination and its subsequent degradation. (van Hagen et al., 2010) 
 
Poly-SUMOylation has also been implicated in regulating global cellular 
degradation, noted in Figure 5.14; whereby SUMO 2 modified proteins accumulate 
on proteasomal inhibition. Uzunova and colleagues has also observed a similar 
SUMOylation pattern in both human cells and yeast (Saccharomyces cerevisiae) 
when the proteasome has been inhibited. Additionally, when RING finger proteins 
where knocked down in the ubc4 and 5 yeast cell lines, levels of poly-SUMOylated 
proteins increased (Uzunova et al., 2007). Taken together, the results are indicative 
of a coordinated role between SUMOylation and ubiquitination in mediating the 
degradation processes within eukaryotic cells.   
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HNF4 α is SUMOylated at lysine residue 365, which is located in the activation 
domain-2 (AD-2). The AD-2 region alters its conformational state to regulate the 
activity of the ligand-binding domain, which adopts two different conformations 
depending on AD-2.  As such, we have shown that the SUMOylation of HNF4 α at 
the AD-2 domain plays an important role in HNF4α stability and transcriptional 
activation during hESC stem cell differentiation. Furthermore, HNF4 α is highly 
dependant on co-activator interactions to enhance DNA binding and transcriptional 
activation (Watt et al., 2003, Hadzopoulou-Cladaras et al., 1997, Sladek et al., 1990). 
SUMOylation of HNF4 α may alter its ability to bind co-activators and DNA 
affecting its transcriptional capabilities.  During hepatocyte differentiation HNF4 α 
was progressively modified with SUMO-2 which peaked at day 17 which, coincided 
with mature HNF4 α transcriptional activity, confirmed by increased serum protein 
production of direct HNF4 α gene targets (Figure 4.5), and reduced protein stability.  
However, post day 17 the HNF4α was not detected and the hepatocytes enter a 
program of de-differentiation. 
 
In conclusion, HNF4 α is a crucial transcription factor required for hepatocyte 
function and viability. Within our differentiation system, levels of HNF4 α decrease 
initially which may activate the expression of hepatic genes responsible for inducing 
maturation. The decrease in HNF4 α is observed throughout development, however, 
the levels of HNF4 α are stabilized in the adult liver due to its involvement in 
regulating hepatic function (Cereghini, 1996, Costa et al., 2003, Lemaigre et al., 
2004). As a result, the reduced viability within our differentiation system may be 
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attributed to decreased levels of HNF4 α, which in turn has been indicated to be 
regulated by poly-SUMOylation resulting in RNF4 mediated ubiquitination followed 
by its degradation. This mechanism has been observed in other proteins such as HIF-
2 α (van Hagen et al., 2010) and PML (Tatham et al., 2008). Therefore, maintaining 
the balance between HNF4α stability and mature transcriptional activity is a key 
regulatory process in differentiation and maintenance of cell phenotype. The next 
chapter will focus on the roles of HNF4 α SUMOylation in hepatic endoderm 
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HNF4 α is an important factor required throughout hepatic endoderm differentiation 
and poly-SUMOylation seems to play a role in the process. The focus of chapter 6 
was to alter the expression levels of HNF4 α and observe its subsequent impact on 
hepatic function in living systems. 
 
6.1.1 TECHNIQUES EMPLOYED FOR PATHWAY MANIPULATION 
The two most effective methods for manipulating pathways and studying their 
respective consequences are pathway inhibition or stimulation using specific 
chemical substrates and genetic modification of the pathway using over expression 
and knock down systems. We carried out a thorough investigation of the field and 
concluded that HNF4 α had no known substrates that specifically inhibit or promote 
its expression and functional activity. Due to the limited knowledge and investigation 
of the SUMO pathway, we were unable to identify proteins or chemical molecules 
that explicitly targets SUMOylation. As a result, we employed the use of techniques 




6.1.2 GENETIC ENGINEERING 
There are a number of successful molecular genetic approaches that result in the 
inhibition or stimulation of target genes. Gene targeting via homologous 
recombination is a popular approach as it specifically alters the native gene within 
the DNA without affecting other sequences. This technique can introduce genetic 
mutations, insert reporter genes, alter the promoter sequence or delete a gene. 
Plasmid vectors are another way of altering gene expression by introducing the 
modified DNA sequence in a host plasmid before transforming it into the target cells. 
This method results in transient modifications and is usually utilized in bacterial 
cells. However, both these techniques rely on external methods to introduce the 
recombinant DNA into the cells. These include electroporation; creating miniscule 
pores in the cell membrane to allow the DNA to enter the cell, microinjection; this 
method is used to introduce new genetic material without biological vectors and most 
recently a new method referred to as bioballistics was developed. Bioballistics 
involves the use of metal slivers coated with the genetic material in interest, which is 
then ‘shot through’ the cells using a shotgun. The metal sliver passes through the cell 
leaving the genetic material behind. (Hartwell et al., 2010) This technique was 
adapted from the initial protocol using gold nano particles for plant cell 
transformation (Klein et al., 1987, Finer et al., 1990). 
 
Viruses are particles that can be utilized as useful backbone carriers capable of 
incorporating large amounts of recombinant DNA. Due to the infectious nature of 
viruses, they are easily able to enter the target cell. The lentivirus contains a vesicular 
stomatitis virus G glycoprotein responsible for interacting with the phospholipid 
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component on the cell membrane initiating viral entry by membrane fusion (Burns et 
al., 1993). Viral entry is not dependant on specific protein receptors, therefore 
permitting entry into a range of host cells (Burns et al., 1993).  The virus is 
frequently disabled to prevent it from hijacking the host’s machinery and replicating 
uncontrollably. Lenti-viruses, a class of retro viruses, have an added advantage; they 
contain long terminal repeats (LTRs) that prevent gene silencing. These provide ideal 
tools for genetic manipulation. (Hartwell et al., 2010) 
 
Gene expression can be altered either by inhibiting expression or be over-expressing 
it. The modifications will result in a change in the normal cellular process, which can 
then be analysed using a variety of methods. Over expression is achieved when the 
gene of interest is cloned into a vector containing a strong constitutively active 
promoter such as CMV. The vector containing the gene of interest (GOI) in 
subsequently transformed into the target cell. Due to the nature of the promoter, the 
mRNA is continuously transcribed which results in an up regulation of the target 
protein. (Hartwell et al., 2010) 
 
Inhibiting gene expression can be accomplished using gene targeting however, 
successful recombination occurs at very low efficiencies with a high rate of false 
positive results. Gene knock downs can also be achieved by utilizing an ingenious 
strategy harnessing the abilities of RNA interference (RNAi). RNAi is a process 
initiated by short double stranded RNA molecules (siRNA or miRNA) that are then 
recognized by the RNA induced silencing complex (RISC). The complex then 
locates other mRNA strands that contain the siRNA sequence resulting in its 
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cleavage, implemented by Dicer, and subsequent gene silencing. (Hartwell et al., 




Figure 6.1 – Gene Over Expression and Knock Down 
A. The target gene is cloned into a vector containing a strong constitutively active promoter driving the expression of the gene 
of interest resulting in increased production of the required protein. B. Gene knock down is a result of the expression of specific 
shRNA sequences inducing the degradation of the complimentary mRNA sequence. This inhibits all translational of the target 
mRNA strand reducing protein levels within the cell. 
 
6.1.3 CHALLENGES ASSOCIATED WITH GENETIC MODIFICATION AND HESCS 
Genetically modifying hESCs provides a useful tool to study and manipulate a 
variety of processes. The ability to express or knock down certain genes within 
hESCs will result in the ability to regulate processes such as directed differentiation, 
study developmental pathways and alter immunogenicity required for therapeutic 
applications. Numerous investigations were carried out comparing the various 
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genetic modification strategies and isolating the most effective techniques. However, 
the previously employed strategies suffer from low efficiency of success, limited 
control of gene expression, random mutations and gene silencing. (Strulovici et al., 
2007) 
 
Initial methods required to introduce the new genetic material into the hESCs 
involved chemical transfection or electroporation. Unfortunately, both methods result 
in low yields due to limited cell viability. These are defined as non-viral forms of 
modification and their effects are transient, as the introduced gene is not integrated 
into the target genome. Viral vectors contain glycoproteins present on the surface of 
their capsid structure, which are able to interact with the surface receptors on the 
target cells resulting in membrane fusion and viral entry (Burns et al., 1993). The 
gene or sequence of interest is randomly integrated into the host genome, frequently 
in multiple locations. Unfortunately, the integrated transgenes are then susceptible to 
gene silencing and random mutations due to the robust property of hESCs. 
Lentiviruses, a form of retroviruses, are able to over come this issue as they contain 
long terminal repeats immune to silencing. Long terminal repeats (LTRs) are 700-
1000 nucleotides long and are responsible for inducing and regulating the expression 
of viral genes vital for integration, replication and packaging (Laimins et al., 1984). 
Thus, LTRs contain features that inhibit subsequent gene silencing and transposition 
(Zhang et al., 2010). The 5’ LTR acts as an RNA polymerase II promoter whilst the 
3’ LTR causes transcriptional termination, in addition to providing ‘sticky ends’ 
which are integrated into the host genome with the aid of the integrase protein 
(Takebe et al., 1988). The viral vectors replication gene is usually disabled to prevent 
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host machinery hijacking and uncontrolled replication. This in turn, allows the safe 
implementation of lentiviral vectors as tools in genetically manipulating hESCs. 
(Strulovici et al., 2007) 
 
6.1.4 THE STRATEGY DEVELOPED TO INVESTIGATE THE EFFECT OF 
SUMOYLATION AND HNF4 α IN LIVING SYSTEMS 
Lentiviral vectors are the most effective tools for introducing transgene 
modifications within hESCs. As a result, we employed the use of the lentiviral 
vectors, pLVX and pLenti4 to alter the expression of genes involved in the SUMO 
pathway in conjunction with HNF4 α. The most efficient method of elucidating the 
effects of SUMO in living systems was to identify changes associated with the over 
expression and inhibition of the pathway. hESCs were transiently transduced with 
lentivirus constructs for over expressing SUMO-1 and Ubc9 (E2) (S1OE), SUMO-2 
and Ubc9 (S2OE), and Ubc9 was knocked down (U9KD) to reduced SUMOylation. 
To examine the effect of HNF4 α in our system we created two subsets of cells, one 
over expressing HNF4 α (H4OE) and the second deficient in HNF4 α expression 
(H4KD). Gene over expression was implemented by the use of the pLVX vector, 
whilst pLenti4 was required for siRNA mediated gene silencing. The results 
discussed in chapter 5 indicate a role of poly-SUMOylation in regulating HNF4 α 
stability. Thus SUMO-2 over expression constructs should result in the reduction of 
HNF4 α levels, whilst Ubc9 knock down cells should stabilize HNF4 α levels. No 
changes in HNF4 α levels should be noted in SUMO-1 over expression cells. In 
addition, increased hepatic viability is expected in cells over expressing HNF4 α and 
premature de-differentiation in HNF4 α knock down cells. In order to express 
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SUMO1/2 and Ubc9 as separate proteins, the 2A sequence was cloned in between 
the two genes flanked by specific restriction sites. The 2A sequence is a short peptide 
sequence capable of self-cleavage on translation, resulting in the division of proteins 
on either end of the peptide (Trichas et al., 2008).  
 
The C3A hepatoma cell line, an important research tool, was initially used to 
optimize the transfection conditions and investigate the viral integration and 
expression efficiency. The procedure was then implemented in day 11 differentiating 
hESCs to investigate the roles of SUMOylation and HNF4 α within our hepatic 
differentiation system. The technique can then be utilized in primary human 
hepatocytes, which are regarded as the gold standard control.  
 
6.2 RESULTS 
6.2.1 THE CONSTRUCTION OF THE OVER EXPRESSION AND KNOCK DOWN 
LENTIVIRAL VECTORS 
6.2.1.1 THE PLVX OVER EXPRESSION VECTORS 
The pLVX lentivector (Clontech, USA) is an HIV-1 based vector with a modified 
form of the human cytomegalovirus immediate early promoter (P-tight) to allow 
strong constitutive expression of the transgene, Figure 6.2 A. In also contains the 
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), which 
enhances RNA processing and induces transport of the transgene RNA into the 
nucleus, Figure 6.2 A. This in turn, improves viral titers, the concentration of 
resulting active packaged virus, and gene expression. pLVX expresses the ampicillin 
resistance gene allowing for selection in bacteria and the puromycin resistance gene 
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required for target cell selection, Figure 6.2 A. The presence of ψ sequence induces 
effective viral packaging carried out in 293T host cells. This vector does not contain 
its own packaging and replication genes to ensure personal safety when handling the 
virus in the lab. Additional vectors containing the Pol, Rev, Gag and VSV 
glycoprotein lentiviral genes are co-transfected with the pLVX vector containing the 
transgene in 293T cells to promote replication, nuclear translation, core protein 
expression and viral packaging, respectively. The Gag and Pol genes were expressed 
under the CMV promoter in the pLP1 plasmid vector also containing the human β-
globin intron, which enhances the expression of the gag/pol genes in mammalian 
cells. The Rev mRNA transcript is generated from the pLP2 plasmid vector under the 
control of the RSV promoter. The VSV G gene responsible for expressing the 
glycoprotein required for viral entry is contained within the pLP/VSVG vector in 
addition to the β-globin intron both under the CMV promoter. The VSV G protein 
present on the lentivirus permits infection into a number of cell types, including non-
dividing cells, thus promoting efficiency of transfection in hESCs and their derivates. 
 
The first step required for creating the lentivectors was to analyze their respective 
multiple cloning sites and identify unique restriction sites for the insertion of the 
modified DNA sequence. The SUMO 1 and SUMO 2 DNA sequences were flanked 
BamHI and NotI restriction sites. A 2A sequence was inserted between the SUMO 
and Ubc9 genes, flanked by a NotI and a MluI restriction site, to separate the proteins 
post-translationally. The 2A sequence is a short peptide capable of self cleavage once 
the DNA sequence has been translated. A MluI and an EcoRI site flanked the Ubc9  
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Figure 6.2 – Over Expression Vector Construction 
A. The pLVX lentivector is a useful tool for over expressing a transgene. It contains a CMV promoter driving constitutive 
expression of the inserted gene in conjunction with ampicillin and puromycin resistance genes required for accurate selection. 
The presence of the ψ sequence signals promotes effective packaging thus providing the necessary machinery to infect a 
number of various cell types. B.  The bands depict the accurate expression of the various inserts amplified from their respective 
image clones. The PCR products were run on an agarose gel and the insert size was verified (base pairs, bp). C. A diagnostic 
digest was carried out to validate the presence of the correct inserts within the PCR 2.1 vector prior to sequences. As noted, all 
the inserts were present at the correct size, as depicted by the lower bands. The digested PCR 2.1 vector can be identified as the 
8000bp band.  
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sequence. Specific primers for each gene were designed and included the unique 
restriction sites required for vector construction in conjugation with distinctive 
protein tags. SUMO-1 and -2 were tagged using the HA sequence and Ubc9 was 
Myc tagged.  
 
The target genes were amplified from specific image clones using PCR, Figure 6.2 
B. The plasmid DNA for the image clones was isolated from bacteria containing the 
vector using a midi prep kit (QIAGEN, UK). The concentration and quality of the 
plasmid vector containing the image clone was measured using the Nanodrop. The 
PCR products were then used in a blunt end ligation reaction (TOPO TA Cloning 
Kit, Invitrogen) whilst a sample was extracted and run on an agarose gel to assess 
gene amplification. Ligating the recombinant DNA into the PCR2.1 vector allows for 
easily manipulation of our transgene and provides a host carrier to carry out analysis 
before the sequence is cloned into the pLVX vector. The ligated plasmids were 
transformed into DH5α E-coli cells, which were plated out on agar plates containing 
ampicillin and incubated overnight. Antibiotic selection ensures the propagation of 
the host vector as it contains the resistance gene necessary for survival and suggests 
the successful ligation or recombination of the plasmid vector containing the insert. 
Clones were selected and cultured to amplify the vector DNA, which was then 
isolated using a mini prep kit (QIAGEN, UK). This process was repeated for each 
gene; SUMO1, SUMO2, 2A and Ubc9.   
 
The PCR 2.1 vectors for each transgene were then digested with BamHI and NotI to 
confirm the SUMO-1 and -2 inserts and MluI and EcoRI to verify the Ubc9  
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Figure 6.3 – Over Expression Transgene Sequencing 
The individual transgene sequences cloned into the PCR 2.1 plasmid vector were sequenced to confirm the amplification 
accuracy and ensure no mutations had been generated throughout the cloning process. The graphs verify the correct transgene 
sequences, whereby A.  confirms the correct SUMO 1 insert tagged with HA, B. defines the SUMO 2 and HA tagged insert, C. 
and D. validates the 2A and Ubc9 sequence, respectively and E. displays the correct HNF4 α sequence. 
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sequence, respectively, Figure 6.2 C. The digests were run on an agarose gel to 
validate the presence of the inserts, substantiated by their size (bp), Figure 6.2 C. The 
correct inserts were verified as noted by the lower bands. The band present at ~ 8000 
bp, Figure 6.2 C, defined the digested PCR 2.1 vector, which no longer contained the 
respective insert. The clones containing the correct insert were then cultured at a 
larger scale and maxi prepped to isolate the plasmid DNA, which was subsequently 
sequenced (MWG Eurofins, Germany), Figure 6.3. On sequence verification, the 
plasmids were digested with the previously mentioned restriction enzymes in 
conjunction with pLVX vector digestion using BamHI and EcoRI. The inserts were 
then carefully isolated using the gel extraction and purification technique. After 
weeks of optimization, a four way ligation was employed and the respective ratios 
used were as follows; 100ng pLVX: 450ng Ubc9: 250ng SUMO1/2: 50ng 2A. The 
ligation was incubated at 16°C overnight.  
 
The two ligation reactions were transformed into DH5 α cells, plated out, selected for 
ampicillin resistance, clones were selected and propagated. The SUMO-1 and -2 
pLVX vectors were digested to confirm the presence of the correct insert, Figure 6.4 
A. To determine the presence of the full insert, the vector was digested with BamHI 
and EcoRI. Once the correct sized insert, ~2000 bp, was noted the vectors were 
purified using a maxi prep kit and sent for sequencing to verify the transgene 
sequences, Figure 6.4 B-D. The digested pLVX vector is recognized as the band 
present at ~ 7000 bp. The insert sequences were confirmed, Figure 6.4 B - D, 
completing the process of constructing the SUMO-1 (B) and SUMO-2 (C) over  
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Figure 6.4 – pLVX Over Expression Lentiviral Vector Construction 
A. The ligated pLVX vectors containing the transgenes were transformed and propagated in bacterial cells and subsequently 
purified using a QIAGEN Midi prep kit. The resulting plasmid DNA was digested with BamHI and EcoRI to determine the 
presence of the full transgene insert. The HNF4 α insert was detected via EcoRI digest. As observed, the bands at the expected 
sizes were noted and the pLVX vectors were sent for sequencing. B. C. and D.  verify the correct transgene sequences within 
the pLVX lentiviral vector. 
 229
expression lentiviral vectors. Please note that SUMO-1 and SUMO-2 over expression 
vectors refer to the full SUMO-2A-Ubc9 insert present in the pLVX vector.  
 
The same techniques were applied for the creation of the HNF4 α over expression 
lentiviral vector. The full-length sequence of HNF4 α variant three was flanked with 
EcoRI restriction sites using PCR, Figure 6.2 B. The fragment was cloned into the 
PCR2.1 plasmid vector and a diagnostic digestion was carried out to confirm the 
presence of the insert, Figure 6.2 C. Once the insert was observed, the vector was 
sent for transgene sequencing, Figure 6.3 E. On sequence verification, the insert was 
EcoRI digested and ligated into the pLVX vector. After the resistant clones were 
selected and digested to detect the insert (~1500 bp), Figure 6.4 A, the sequence was 
validated once again to confirm the correct orientation and sequence of the insert. 
Figure 6.4 D confirms the correct in frame HNF4 α sequence required for gene over 
expression in our differentiating hESCs. 
 
6.2.1.2 THE PLENTI4 KNOCK DOWN VECTORS 
Short hairpin RNA (shRNA) sequences were designed to silence the Ubc9 and HNF4 
α genes in hESC derived hepatic endoderm. This technique employs the strategy 
whereby Ubc9 and HNF4 α mRNA strands are recognized and cleaved in response to 
the shRNA sequence expression initiated by the pLenti4 lentiviral vector (Invitrogen, 
UK). The BLOCK-iT™ Inducible H1 Lentiviral RNAi System was applied to 
generate the Ubc9 and HNF4 α knock down vectors. The knock down system utilizes 
an entry vector whereby the ligated shRNA sequence recombines into the pLenti4 
destination vector, which is subsequently transformed and propagated in Stabl3 E-
coli cells, Figure 6.5 A. The entry vector provides and easy and efficient method for 
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cloning the shRNA sequence into an RNAi specific cassette required for effective 
shRNA expression resulting in gene knock down. This form of RNAi dependant 
gene silencing exploits the structure of the shRNA. Once the sequence is expressed, 
the RNA molecule transforms into a stem-looped structure as the complementary 
regions at either end anneal. Dicer detects and cleaves these RNA structures forming 
an siRNA (small interfering RNA) duplex.  
 
Figure 6.5 – Knock-Down Vector Construction 
A. The pENTR™/H1/TO and the pLenti4/BLOCK-iT™-DEST lentivectors are a useful tool for knocking down a specific gene. 
It contains a human H1 promoter driving expression of shRNA sequence in conjunction with kanamycin (entry vector), 
ampicillin and zeocin (destination vector) resistance genes required for accurate selection. The presence of the 5’ and the ψ 
sequence in the destination vector promotes effective packaging thus providing the necessary machinery to infect a number of 
various cell types. Fail-safe mechanisms are also in place to improve the bio-safety of the vector. The entry vector containing 
the ligated shRNA sequence recombines with pLenti4 to generate the complete knock down vector B.  The upper bands depict 
the accurate annealing of the shRNA oligonucleotides ~100 base pairs, suggesting the formation of double stranded DNA 
complexes (DS arrow) required for successful ligation into the entry vector.   
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The destination vector, pLenti4/BLOCK-iT™-DEST (pLenti4), contains the Rous 
sarcoma virus (RSV) enhancer/promoter required for viral mRNA expression in 
conjunction with the HIV-1 5’ LTR necessary for reverse transcription of the viral 
mRNA, Figure 6.2 A. The ψ sequence and the 5’LTR permit efficient viral 
packaging, however 5’ donor sites and 3’ acceptor sites ensures the removal of the ψ 
sequence and the HIV-1 Rev dependant reverse response element (RRE), involved in 
unspliced viral mRNA nuclear export, preventing the Rev dependant expression of 
the shRNA sequence in the target cell Figure 6.5 A. The ΔU3/HIV-1 truncated 3’ 
LTR provides another fail-safe to guarantee the bio-safety of the lentivector, which 
promotes viral packaging but results in the inactivation of the 5’LTR Figure 6.5 A. 
The ampicillin resistance gene contributes to selection in E-coli cells whilst the 
Zeocin resistance (Sh ble) gene allows stable selection in mammalian cell lines. The 
above elements in addition to the RNAi cassette, containing the human H1 RNA 
polymerase III based promoter required for shRNA expression, results in the 
efficient and stable production of RNAi complexes essential for gene silencing. 
 
The Ubc9 and HNF4 α shRNA sequences were designed using the Invitrogen 
BLOCK-iT™ RNAi Designer. The shRNA complexes consisted of a top strand 
oligonucleotide complementary to a bottom strand oligonucleotide with 5’ and 3’ 
overhangs required for ligation into the entry vector (pENTR™/H1/TO). The shRNA 
oligonucleotides were annealed as described in the BLOCK-iT™ Invitrogen manual. 
The reactions were subsequently run on an agarose gel to verify the annealing 
efficiency, Figure 6.5 B, confirmed by the detection of double stranded DNA 
sequences (DS arrow). Annealing reactions require an efficiency of 50% or greater 
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for successful ligation to occur. The annealed reactions were combined with the entry 
vector and the T4 DNA ligase under optimal ligating conditions. The ligation was 
incubated at room temperature for two hours to ensure improved colony yields. The 
entry vectors containing the ligated shRNA sequence were then transformed into One 
Shot® TOP10 competent E-coli permitting vector propagation and kanamycin 
dependant selection. Resistant colonies, signifying the presence of the entry vector 
containing the shRNA insert, were picked and cultured. The vector DNA was then 
isolated using a midi prep kit (QIAGEN, UK). The transformants were then 
sequenced to verify the double stranded shRNA oligonucleotides. On sequence 
confirmation, one clone was selected propagated and the vector DNA was isolated 
using a maxi prep kit (QIAGEN, UK) to improve DNA retrieval and purity.  
 
Figure 6.6 – Knock-Down Lentiviral Vector Sequencing 
The sequencing graphs confirm the accurate annealing and recombination of the Ubc9 (A) and HNF4 α (B) shRNA sequences 




The LR recombination reaction, occurring between the attL and attR sites, was set up 
using the entry vector positive for the correct shRNA sequence and the pLenti4 
destination vector and left for 16 hours to promote higher colony yields. Proteinase K 
was used to arrest the reaction, which was then transformed and ampicillin selected 
in Stabl3™ competent E-coli. Resistant clones were chosen and propagated, 
followed by vector DNA isolation using a maxi prep kit (QIAGEN, UK). The 
resulting vector DNA was sent for sequencing using the H1 forward and V5 reverse 
primers to verify the insert. Figure 6.6 confirms the correct shRNA sequences of the 
Ubc9 and HNF4 α genes within the pLenti4 destination vector. The knock down 
vectors are ready for generating Ubc9 and HNF4 α knock down cells. 
 
6.2.2 GENERATING INFECTIOUS OVER EXPRESSION AND KNOCK DOWN 
LENTIVIRAL VECTORS 
6.2.2.1 VIRAL PACKAGING 
The next stage of pathway modification required the packaging of the three over 
expression vectors; SUMO1/Ubc9, SUMO 2/Ubc9 and HNF4 α in conjunction with 
the knock down vectors; Ubc9 and HNF4 α. A self ligated pLVX vector was used as 
a negative control for the over expression vectors and a scrambled shRNA sequence 
was used as a knock down negative control. This ensures that any observable 
changes are a result of the over expression or knock down and not due to the 
lentiviral transfection process. Seven lentiviral vectors were used for this 
investigation. To simplify the nomenclature of each lentiviral vectors the following 
acronyms were used; S1OE, S2OE and H4OE refer to the SUMO1, SUMO2 and 
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HNF4 α over expression vectors. U9KD and H4KD define the Ubc9 and HNF4 α 
knock down vectors. CT is used to identify the respective control lentiviral vectors.  
 
The lentiviral vectors (LVs) were initially incubated with the ViraPower™ 
packaging mix in Opti-MEM® media, which promotes the formation of the DNA-
lipofectamine® 2000 complexes. The packaging mix contains the pLP1, pLP2, 
pLP/VSVG plasmids in optimal concentrations to induce high efficiency viral 
packaging promoting mammalian cell infection. Lipofectamine ® 2000 was diluted 
in Opti-MEM® in a separate sterile 5ml tube. The LVs and the packaging mix were 
combined with lipofectamine®2000 and were incubated for 20 minutes at room 
temperature. This provides ample time for the DNA-lipofectamine®2000 complexes 
to form. This form of transfection utilizes the cationic lipid based properties of 
lipofectamine®2000 to alter the cellular plasma membrane and allow nucleic acid 
transfer into the cell. The DNA-lipid complexes are then combined with resuspended 
293FT cells and incubated overnight at 37°C. The human 293FT cell line is a 
derivative of the human embryonic kidney 293 cell lines where the SV40 large T 
antigen is constitutively expressed. 293FT cells are ideal for efficient lentiviral 
production as they can be easily transfected, they retain robust viability in culture 
and the SV40 antigen ensures high levels of viral protein expression vital for capsule 
formation. The media is replenished 24 hours post transfection and the supernatants 
are harvested 48-72 hours later, however no significant differences in viral yields 
were noted between these two time points. The supernatants were purified using 




6.2.2.2 LENTIVIRAL VECTOR TITERS 
Titrating lentiviral stocks provides a measure of the virus particle concentration 
present in the supernatant, which assesses the efficiency of target cell transfection. In 
addition, the viral titer can also be used to regulate the number of integrated copies of 
the vector in the host genome as well as the generation of reproducible results.  The 
viral titer for the seven LVs was calculated by transfecting 293FT cells with 10-fold 
serial dilutions of the viral stock, 1ml starting volume, in the presence of Polybrene® 
(6µg/ml) (hexadimethrine bromide), a transduction enhancer. The 293FT cells were 
then selected for 12-14 days using the appropriate antibiotic, puromycin for the over 
expression vectors and Zeocin® for knock down LVs. The remaining surviving 




Figure 6.7 – Over Expression and Knock Down Lentiviral Stock Titers 
Viral titers provide an effective method to measure transfection efficiency, regulate the number of integrated copies of the 
vector within the host genome and generate reproducible results.  Viral titers were calculated by transfecting 293FT cells with 
the respective viral supernatant and were then selected for 12-14 days. The remaining colonies were stained with crystal violet 
and counted. The final titers for S1, S2 and H4 over expression stocks were calculated to be 1.9, 2.8 and 2.2 (x 104) TU/ml, 
respectively. The U9 and H4 knock down vectors were measured to be 8.5 and 1.3 (x 105) TU/ml, respectively, with the control 
vectors titers found to be 1.8(x 104) TU/ml.  
 
Expected viral titers range from 5 x 105 to 2 x 107 transducing units per ml (TU/ml).  
The over expression vector viral titers for S1, S2 and H4 were calculated to be 1.9, 
2.8 and 2.2 (x 104) TU/ml, respectively, Figure 6.8. The U9 and H4 knock down 
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vectors resulted in higher titers measured to be 8.5 and 1.3 (x 105) TU/ml, 
respectively, with the control vectors titers found to be 1.8(x 104) TU/ml, Figure 6.7. 
Despite the lower than expected levels of the LV titers, the viral stocks are sufficient 
for effective transfection as an increased volume will be added per reaction to 
compensate for the reduced concentration.  
 
6.2.2.3 ANTIBIOTIC KILL CURVES 
Antibiotic kill curve experiments were carried out simultaneously with the viral 
packaging process. Kill curves are generated to assess the optimum antibiotic 
concentration used for target cell selection.  
 
 
Figure 6.8 – Antibiotic Kill Curves 
C3A cells (A) and hESCs (B) were incubated with varied concentrations of blastocydin, puromycin and Zeocin®. A kill curve 
was generated to assess the optimum concentration of antibiotic selection, which is defined by the death of 50-70% of the cells. 
The optimum antibiotic concentrations for C3A cells were calculated to be 20µg/ml, 1.5µg/ml and resistant, respectively. 
hESCs proved to be more sensitive due to their fragile nature in response to stressed environments. The optimum concentrations 
were found to be .5 µg/ml, 0.2 µg/ml and 0.75 µg/ml, respectively.  
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Optimum antibiotic concentrations vary widely between different cell lines and 
culture conditions; as such they should be assessed before each set of transfection 
experiments. Optimum antibiotic concentrations are defined when 50%-70% of the 
confluent cells lift and die. Positive selection ensures that the surviving cells 
efficiently express the lentiviral vector containing the sequence of interest in addition 
to the antibiotic resistance gene. 
 
hESCs and C3A cell lines were incubated with various concentrations of the 
blastocydin, puromycin and Zeocin® antibiotics, ranges applied were generated 
using data from previous investigations. Figure 6.8 A displays the kill curves 
required for C3A cell selection. The optimum antibiotic concentrations blastocydin 
and puromycin were found to be 20µg/ml and 1.5µg/ml, respectively. Interestingly, 
the C3A’s seemed to be resistant to Zeocin® with only 10% cell death at a 
concentration of 1mg/ml, suggesting the inefficiency of this form of selection. 
hESCs, on the other hand, were found to be more sensitive to antibiotic selection 
than C3A’s. Figure 6.8 B displays the kill curves for the mentioned antibiotics, 
whereby the optimum concentrations of blastocydin, puromycin and Zeocin® noted 
were 1.5 µg/ml, 0.2 µg/ml and 0.75 µg/ml, respectively. The increased sensitivity of 
hESCs can be expected, as the cells are more fragile with reduced cell viability in 
stress-induced conditions when compared to the more robust nature of the cancer 




6.2.3 VERIFICATION OF LENTIVIRAL GENE KNOCK DOWN AND OVER EXPRESSION  
Prior to the large-scale pathway manipulation in primary human hepatocytes, the 
C3A cell line and hepatic derivates of hESCs, we set up a preliminary transfection to 
confirm the vectors ability to knock down and over express the required genes. C3A 
cells were the ideal cell line of choice due to their robust method of culture, high 
transfection efficiency and rapid cellular replication. 1ml of each viral vector stock 
was incubated with C3A cells at 20-30% confluency for approximately 24 hours, 
achieving a multiplicity of infection (MOI) of approximately 5. It should be noted 
that C3A cells were examined and confirmed to express the SUMO pathway 
machinery including SUMO 1 (10 kDa), SUMO 2 (10 kDa), Ubc9 (18 kDa) and 
SENP 7 (110 kDa), using western blotting, Figure 6.9. β-actin was used as a protein 
loading control.  
 
Figure 6.9 – Identification of SUMO Machinery within C3A Cells 
The western blots confirm the expression of the required SUMO machinery analysed from C3A cell extracts. Specifically, 
SUMO1/2, Ubc9 and SENP 7 were sufficiently expressed within the cells. β-actin was used as a loading control.  
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The C3A cells were cultured for  another 48 hours, after which their protein extracts 
were collected and analysed for gene knock down and over expression using western 
blotting, Figure 6.10. 
 
Figure 6.10 A displays the knock down effects of the HNF4 α and Ubc9 LVs. All 
changes in expression were calculated using densitometry analysis on Image J. The 
HNF4 α LV resulted in 100% successful knock down in the C3A cells, whilst Ubc9 
depicted gene knock down by a lesser extent, 50% decrease (arrows). Densitometry 
analysis displays greater than 5 fold decrease in the expression of HNF4 α and less 
than two fold decrease in Ubc9 within the knock down cells.   With respect to the 
over expression vectors, Figure 6.11; SUMO1, SUMO2, Ubc9 and HNF4 α 
demonstrated a significant increase in protein expression; 1.2, 1.7, 1.4 and 2.2 fold 
increase between the cells transformed with the over expression LVs compared to the 
empty vector control, Figure 6.11. Knock down cells display a reduction in 






Figure 6.10 – Verification of Lentiviral Gene Knock Down and Over Expression, Western 
Blotting 
A. The western blots show 100% HNF4 α knock down whilst Ubc9 displayed 50% gene silencing, ideal for cell survival and 
significant enough to detect a notable change within the cell (arrows).  B. The over expression vectors were able to significantly 
enhance protein expression of the SUMO1/2, Ubc9 and HNF4 α genes, demonstrated by the darker bands (arrows). Overall, this 
data has confirmed the ability of the LVs to effectively transform, knock down and over expression the genes of interest. The 
manipulation of the gene expression pattern should create an observable difference within each living system.  
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Despite the reduced efficiency of Ubc9 knock down, the resulting advantage is 
improved cell survival as previous investigations stated in chapter 5 suggest the 
requirement of Ubc9 expression for healthy cell growth. β actin was used as a 
loading control. This data confirms the ability of the LVs to efficiently transfect 
mammalian cells lines resulting in a high level of gene knock down and protein 
expression. The genetic modification of these pathways should create a significant 






























Figure 6.11 – Verification of Lentiviral Gene Knock Down and Over Expression, Graphical 
Representation 
The graph displays the densitometry analysis of the change in expression of the respective transgenes. Knock downs refer to a 
fold decrease whilst over expressions define a fold increase. As noted, HNF4 α knock down was the most efficient, followed by 
a less than 2 fold decrease in Ubc9 expression. SUMO 1/2, Ubc9 and HNF4 α averaged a 1.5 increase in expression when 
compared to the controls. 
 
6.2.4 INVESTIGATING THE EFFECT OF SUMO AND HNF4 α PATHWAY 
MANIPULATION IN VITRO 
Genetically modifying the expression patterns of the SUMO and HNF4 α pathway in 
differentiating hESCs may result in an identifiable phenotypic change relevant to 
hepatic differentiation, viability and function. The transient modification experiments 
were carried out, whereby the differentiating hESCs were separated into three 
 242
groups; over expression, knockdowns and control groups. The differentiating hESCs 
were infected with virus at an MOI of one. hESCs were differentiated into HE using 
the standard differentiation protocol and were subsequently transfected with viral 
supernatant at day 11, hepatic specification and maturation stage. Day 11 was 
selected to be an effective time point for pathway manipulation, as this stage defines 
the beginning of hepatic maturation. As such, altering the signalling pathways at this 
stage should affect the end stage hepatic phenotype; morphologically, 
transcriptionally or functionally. The resulting HE were cultured for a further 3 days 
(Day 20) to monitor the effects on hepatic de-differentiation and viability. Protein 
and RNA extracts were collected at day 13, 15, 17 and 20, in addition to functional 
analysis of the hepatocytes on days 17 and 20.  
 
Effective transfection and the subsequent effects were characterized using a range of 
accepted techniques. Vector integration into the host genome was verified by 
amplification of the sample mRNA through PCR using primers that exclusively 
recognize the foreign sequences of the lentiviral vector. The viral supernatant was 
removed 24 hours after infection, and the cells were washed several times to remove 
all non-integrated viral particles. This ensured that viral sequence detected through 
PCR was in fact an integrated vector within the host genome. The PCR utilized 
primers specific to the 5’ and 3’ long terminal repeats within the lentiviral vectors 
and as such only detect integrated viral particles within the host genome. Western 
blotting confirmed the down stream translational effects of gene knockdown and 
over expression, with respect to the target proteins and other hepatic markers 
defining maturity, function and viability.  
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6.2.4.1 Assessing Viral Integration into the Host Genome 
PCR validated the successful integration of all viral vectors into both day 17 and 20 
hESC derived HE, denoted by bands present at 100bp for the knockdown lentiviral 
vectors (A) and 1200 bp for the over expression lentiviral vectors (B), Figure 6.12. 
However, slightly reduced pLVX copies were integrated into the host genome as 
indicated by the faint 1200 bp band at day 17, Figure 6.12 B. The bands present at 50 
base pairs in both the knockdown and over expression groups depict primer dimers.  
 
Figure 6.12 – Assessing Lentiviral Vector Integration into the hESC Derived HE Genome 
A. Bands present at 100bp (arrow) suggests successful integration of the knockdown vectors into the host genome. B. The 1200 
bp bands denote the presence of the over expression vectors in the host genome, observed in all four lentiviral vectors (arrow). 
Bands at 50 bp are due to primer dimers (arrow). A negative no template control was used to remove false positives. This data 
confirms the successful integration of all seven LVs into the host genome, signifying efficient transfection. 
 
The effective transfection and integration of the lentiviral vectors into the hESC 
derived HE genome indicates optimal MOI and infection conditions, despite the sub-




6.2.4.2 Investigating the Translational Effects of Altering Gene Expression 
In spite of the successful HNF4 α LVs integration into the host genome, there were 
no significant differences in HNF4 α expression between the knockdown and over 
expression samples when compared to the control, Figure 6.13 A. This suggests the 
unreliable nature of LV transfection, as only a collection of samples were 
successfully infected. The differences between the transcriptional and translational 
results could also be attributed to subsequent gene silencing in the hESC derived HE. 
Consequently, the expression levels of the mature markers, Albumin and Cyp 3A4, 
and de-differentiation markers, E-cadherin and vimentin remained constant, Figure 
6.13 A. A similar pattern was noted in the SUMOylation over expression and knock 
down cells where no observable difference could be noted between the samples, 
Figure 6.13 B. As such, no defined conclusions could be drawn from this 
investigation and further refinement of the transfection technique is required.  
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Figure 6.13– Investigating Protein Expression Post-Transfection 
A. The blots displayed refer to the sample of cells targeted for HNF4 α over expression and knockdown. No noticeable changes 
were observed in the levels of HNF4 α expression, with no subsequent changes in maturity and viability marker expression. E-
cadherin expression peaked at day 17, suggesting a stable state of HE. Contrary, to previous results, the levels of HNF4 α and 
albumin only decreased slightly as the cells matured and began de-differentiating. B. HE transfected with SUMO over 
expression and knockdown vectors displayed the expected expression pattern, as noted in previous experiments. The levels of 
SUMO modified proteins decrease as differentiation proceeds, followed by the decrease in HNF4 α and albumin expression. 
SUMO 1 and 2 was successfully over expressed in day 20 samples; however, no further change in other factors was noted. 
Therefore, no firm conclusions can be drawn from this investigation. 
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6.2.4.3 The Effect of HNF4 α Knock Down and Over Expression in Apoptosis 
Caspase 3 is a member of the cysteine- aspartic acid protease family and is 
responsible for interacting with caspase 8 and 9 resulting in apoptosis (Alnemri et al., 
1996). Caspase 3 is activated when triggered by extrinsic death ligands or intrinsic 
mechanisms, for example mitochondrial stimulation (Salvesen, 2002).  Therefore, 
caspase 3 is a good indicator of apoptosis. Caspase 3 activity was measured in a 
manner similar to Cyp 3A4. A caspase 3 substrate conjugated to luciferin was 
incubated with C3A cells transformed with lentiviral vector. C3A cells transfected 
with pLVX were used as a base line control.  
 
Apoptosis was measured in day 20 hESC derived HE transfected with knock down 
the HNF4 α LV. Caspase 3, an acknowledged method for identifying apoptosis, 
activity was measured in the knock out cells and in the vector control. The reduction 
in HNF4 α expression resulted in a 1.5 fold increase in caspase 3 activity (2.3 million 
RLU/mg of protein/ hr +/- 0.18, p=0.003), Figure 6.14.  The up regulation of caspase 
3 in HNF4 α knockdown HE may suggest a role of HNF4 α in sustaining hepatic 








Figure 6.14 – The Effect of HNF4 α Knock Down in HE Apoptosis 
Caspase 3 activity was used to measure the rate of apoptosis within hESC derived HE transfected with the HNF4 α knock 
down vector and the pLVX vector, used as the control. Caspase 3 levels were found to be 1.5 fold higher in HNF4 α knock 
down HE when compared to the control (2.3 million RLU/mg of protein/ hr +/- 0.18, p=0.003). This data suggests that 




In addition, caspase 3 activity was measured in C3A cells over expressing HNF4 α. 
Caspase 3 activity was significantly reduced in cells containing the HNF4 α over 
expression vector when compared to the pLVX infected cells (p=0.0006), Figure 
6.15. Caspase 3 levels in C3As over expressing HNF4 α were 2.5 fold lower than the 
control cells; respective values were calculated to be 0.34 (+/- 0.02) and 0.85 (+/- 
0.08) RLU (million/mg of protein/hr), signifying the possible role of HNF4 α in 


















Figure 6.15 – The Effect of HNF4 α Over Expression in C3A Cell Apoptosis 
Caspase 3 activity was used to measure the rate of apoptosis within C3A cells transfected with the HNF4 α over expression 
vector and the pLVX vector, used as the control. Caspase 3 levels were found to be 2.5 fold lower in cells over expressing 
HNF4 α when compared to control cells (p=0.0006). The caspase 3 values for C3As expressing HNF4 α and pLVX were 0.34 
(+/- 0.02) and 0.85 (+/- 0.08) RLU (million/ mg of protein/ hr), respectively. 
 
Overall, the caspase 3 data in these two cell types suggest that HNF4 α may in fact 
play a direct role in maintaining hepatic viability, whereby HNF4 α knock down cells 
displayed an increase in apoptotic events and cells with HNF4 α over expression 
demonstrated a reduced number of cells entering apoptosis within the population. 
However, further investigation with a more refined system is required before 
conclusive data could be drawn. 
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6.3 DISCUSSION 
Real time investigation of important pathways in living systems provides significant 
insight into the mechanisms in action and their subsequent effects. Therefore, the use 
of lentiviral vectors to over express and knockdown specific genes is an ideal 
technique utilized for effective pathway manipulation. hESC differentiation into 
hepatic endoderm has been shown to be efficient however; the hepatocytes are not 
viable for long term culture. This observation is also noted in freshly isolated 
primary hepatocytes cultured in vitro. Previous investigations in conjunction with 
literature reviews suggest a possible role for HNF4 α in maintaining hepatic stability 
in culture. Our data has also shown that SUMOylation plays a role in maintaining 
HNF4 α stability in both vitro and vivo. As such, gene expression of HNF4 α and 
SUMO pathway components were optimized in the hepatoma C3A cell line and 
subsequently altered in hESC derived HE. The technique can eventually be used in 
primary human hepatocytes, the gold standard model in research. 
 
The lentiviral vectors were packaged, titered and a trial transfection was set up in 
C3A cells to investigate transfection and expression efficiency. All vectors were 
successfully able to infect, integrate and significantly express the required sequences, 
as observed in Figure 6.10.  Therefore, the transfection procedure was effectively 
optimized in the C3A cell line. The next stage of the experiment was to investigate 
the effect of HNF4 α and SUMO modification in hESC derived HE. The combined 
results highlight the disadvantages associated with lenti viral transfection within 
hESCs. Lentiviral vectors were demonstrated to integrate into the differentiating 
hESC genome; however, no subsequent protein expression differences were noted. 
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Therefore, no defined conclusions could be drawn. Caspase 3 activity was associated 
with changes in HNF4 α expression, indicating that HNF4 α may play a direct role in 
maintain hepatic viability. However, reproducing the data in a more refined model is 
required before drawing definitive conclusions. Therefore, optimization in C3A cell 
lines was not sufficient in generating reproducible results in differentiating hESCs. 
Thus, further investigation is required to generate suitable transfection conditions for 
successful manipulation of expression pathways within hESCs. 
 
There are a number of factors that have been attributed to affecting the 
transformation efficiency of lentivirus. The optimal multiplicity of infection (MOI) 
seems to be different between various cell lines and types, in addition to the 
confluency of the cells at the point on transfection. High levels of viral infection and 
integration have been demonstrated when transfecting cells at 20-30% confluency. 
Unfortunately, due to our differentiation model, this was not possible as passaging 
hepatic endoderm during differentiation would result in significant cell death and 
loss of the hepatic phenotype within minimal replating efficiency. Studies have 
shown that introducing the hepatitis B virus (HBV) enhancers and the post-
transcriptional regulatory element into a lentiviral vector significantly improves 
hepatocyte transfection efficiency (Seppen et al., 2002). In addition, Selden and 
colleagues have demonstrated that the use of growth factors, specifically hepatocyte 
growth factor (HGF) and epidermal growth factor (EGF), resulted in the 
improvement of the expression level of the transgene and increased levels of 
expression per cell, signifying a greater number of integrated viral copies (Selden et 
al., 2007). Viral handling has also been found to affect transfection ability. Long-
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term storage of viral supernatants at -80°C in addition to repetitive freezing and 
thawing results in a significant reduction in transfection efficiency. Overall, 
improvement of transient transfection in differentiating hESCs may require 
increasing the MOI, using freshly generated viral supernatant and creating a more 
stable environment for viral infection and integration, i.e.: addition of supplementary 
growth factors. Altering the time of viral transfection throughout the differentiation 
process may also play a significant role in affecting the efficiency of altering 
endogenous gene expression. For example, inducing HNF4 α knock down at day 6 
may prove to be more successful, as HNF4 α expression can be reduced before peak 
levels are reached within the cells. The phenotype, in turn, may be more defined.  
 
Nevertheless, another method could be implemented to overcome these issues, the 
generation of stable cell lines. Generating stable cell lines expressing the required 
transcripts involves the initial transfection of the cells using the lentiviral vectors as 
previously described, followed by specific antibiotic selection. This ensures that 
every surviving cell contains the integrated form of the LV in addition to the stable 
and constitutive expression of the gene or sequence of interest as well as the 
resistance gene required for survival. The stable cell lines generated could be 
inducible, resulting in the ability to initiate or suppress gene expression at any point 
in time. The mechanism relies on the continuous expression of the Tet repressor in 
the host cell, which binds as a homo-dimer to the promoter region of the lentivector, 
previously integrated into the genome, inhibiting its expression. The addition of 
tetracycline results in the high affinity binding to the Tet repressor initiating a 
conformational change. Consequently, the Tet repressor is no longer able to bind to 
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the TetO2 sequence on the viral promoter, inducing the expression of the required 
transcript. (Yao et al., 1998) The creation of a more stable inducible gene 
manipulation system will result in an ideal tool for manipulating the differentiation 
process altering the end production. This technique is translatable to other living 
system such as primary human hepatocytes, which in turn could be stabilized for 
long-term survival in culture, a property necessary for the use in therapeutic and 
research applications. 
 
Generating an indefinite supply of functional hepatocytes provides an indispensible 
tool essential for industrial and clinical uses such as drug discovery and disease 
modelling. The provision of clinically relevant cell types will in turn contribute to 
our understanding of developmental mechanisms resulting in use of these cells for 
cellular therapy (Alison et al., 2007, Asahina et al., 2006). Functional hepatocytes are 
a scarce resource, with the majority of sources suffering from limited viability in 
long-term culture.  
 
A large number of factors have been attributed to efficiently differentiating and 
maintaining hepatocytes in culture (Agarwal et al., 2008, Hannoun et al., 2010, Wege 
et al., 2003); however, this thesis isolated HNF4 α as a vital factor in regulating 
hepatic viability. Interestingly, studies have shown that the levels of HNF4 α are 
significantly reduced in human and rodent hepatocellular carcinomas, which results 
in the increase in cellular proliferation and dedifferentiation, in addition to tumour 
metastasis (Lazarevich et al., 2010). Therefore, HNF4 α is not only required for 
healthy development and adult liver function, but is also a vital factor in disease such 
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as renal (Lucas et al., 2005) and liver cancers (Lazarevich et al., 2004) and pancreatic 
disorders such as MODY1 (Ellard S FAU - Colclough et al., ).  
 
HNF4 α stability was directly associated with poly-SUMOylation, which may have 
resulted in RNF4 mediated ubiquitination and subsequent degradation via the 26S 
proteasome. An in depth analysis of the SUMOylation and HNF4 α was attempted 
within differentiating hESCs. However, due to limitations within the transfection 
system no defined conclusions could be drawn. Thus, optimization of the transfection 
technique within hESCs is required to accurately investigate the mechanisms behind 
HNF4 α and SUMOylation within living systems. This in turn, may provide 
significant insight required to generate an infinite supply of hESC-derived 






















The research presented in this thesis has laid the foundations for detailed studies 
involved in the development of an in vitro system for the derivation of hepatocytes, 
whereby the role of HNF4 α was investigated within hESC differentiation into 
hepatic endoderm. 
 
Human embryonic stem cells (hESCs) are a useful tool for investigating human 
development and cancer. hESCs are able to self renew indefinitely whilst retaining 
pluripotentency, (Thomson et al., 1998), as a result they can differentiate into cell 
types from all three germ layers. hESCs are isolated from the inner cell mass 
(Thomson et al., 1998), which is responsible for forming the embryo post 
fertilization.  For this reason, in conjunction with their ability to be directly 
differentiated, hESCs provide good models for studying development. hESCs could 
provide an indefinite supply of somatic cell types for use in drug discovery, disease 
modelling, extra-corporeal device construction and eventually cell based therapies 
(Anna et al., 2005, Cai et al., 2006, Henrik, 2005).  
 
Since the derivation of hESCs from blastocysts in 1998 (Thomson et al., 1998), a 
large amount of resources have been employed to elucidate the ideal culture 
conditions for maintaining hESCs in an undifferentiated state whilst retaining 
pluripotency. Culture techniques range from the use of mouse embryonic fibroblasts 
(Cai et al., 2006); to provide matrix support and the required nutrients for growth, to 
 255
feeder free cultures grown on vitronectin (Braam et al., 2008) or Matrigel™ (Amit et 
al., 2003) to xeno-free culture systems (Barbara S Mallon et al., 2006). However, 
most culture conditions suffer from xeno-contamination, lack of definition, limited 
reproducibility and scalability. Therefore, defining the optimal environmental 
conditions may allow a better understanding of hESC biology. In an effort to 
overcome these issues we investigated the potential of a serum free commercial 
available media, mTeSR® (MT, Stem Cell Technologies, UK), as a replacement for 
conditioned media (CM), the current gold standard for hESC culture (Hannoun et al., 
2010). Our results indicate that MT is a good substitute for culturing hESCs as the 
cells maintained all embryonic stem cell characteristics. In addition, we observed an 
improvement in HE generation and function. Therefore, MT standardizes the culture 
of hESCs providing a suitable platform for efficiently generating functional 
hepatocytes. Unfortunately, due to limitations associated with batch to batch 
variation and the requirement for reproducible results, CM was utilized for the 
remaining investigations.  
 
Functional hepatocytes are a scarce resource with limited viability in long-term 
culture (Kim et al., 2007). hESC derived HE may in turn alleviate the requirement 
for the utilization of primary hepatocytes in a number of clinical and research 
applications (Agarwal et al., 2008, Baharvand et al., 2008). Prior to replacing PHH, it 
is essential that hESC derived HE exhibit the required hepatic characteristics 
comparable to freshly isolated PHH. In depth transcriptional analysis of 
differentiating hESCs using SOLEXA, which verified a gene expression pattern 
analogous to the hepatic gene expression observed in the developing liver, (Zaret, 
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2000, Zaret, 2001, Cereghini, 1996, Costa et al., 2003). Functional and 
transcriptional analysis reinforces the employment of hESC derived HE for a variety 
of applications. However, further research is vital for refining the differentiation 
model, resulting in improved hepatocyte function and viability. Hepatic endoderm 
viability is the most significant limitation with use in all sources of HE. Primary 
human hepatocytes and hESC derived HE suffer from de-differentiation and death 
when maintained in long-term culture (Kim et al., 2007). This observation coincides 
with a decrease in levels of HNF4 α, indicative of a possible role in regulating HE 
stability. Knock down of HNF4 α during development results in embryo lethality 
(Chen et al., 1994) and metabolic disorders within the adult liver. Studies have also 
shown that over-expression of HNF4 α can drive transdifferentiation from 
hematopoietic cells into hepatocytes (Khurana et al., 2010) and that bone marrow 
cells relocate to the liver in response to injury and differentiate into hepatocytes 
defined by the up regulation of HNF4 α (Terai et al., 2003).  The combination of the 
data indicates the importance of HNF4 α in liver development, differentiation and 
maintenance (Duncan, 2003, Zhao et al., 2005) (Nagaoka et al., 2010). 
 
In an attempt to improve our differentiation model we studied HNF4 α, a key 
transcription factor required for maintaining HE function and viability. HNF4 α is a 
constitutively active highly conserved orphan receptor (Wisely et al., 2002), which 
has been demonstrated to be an essential transcription factor required for healthy 
liver development and adult liver metabolism (Chen et al., 1994, Lemaigre et al., 
2004).  As such, we investigated the expression pattern of HNF4 α within our 
differentiation system. We observed a gradual decrease in HNF4 α expression as 
 257
hepatic differentiation proceeded. In the developing liver, levels of HNF4 α decrease 
in order to stimulate the expression of mature factors; however, post natal, HNF4 α 
expression is stabilized to preserve normal liver function (Cereghini, 1996, Duncan, 
2003, Lemaigre et al., 2004, Runge et al., 1998).  
 
Post translational modifications play important roles in various cellular processes. 
HNF4 α function is regulated by phosphorylation and Acetylation. However, another 
important PTM known to alter the function of a variety of proteins is SUMOylation.  
SUMOylation is an important regulator in a number of cellular processes such as 
transcription, cell cycle regulation, degradation and differentiation (Johnson, 2004, 
Kroetz, 2005). To date, the mechanism behind the regulation of HNF4 α stability and 
function via SUMOylation remains unknown. Therefore, we investigated the 
relationship between SUMO and HNF4 α within our differentiation model. 
 
HNF4 α was SUMO modified in vitro on lysine residue 365, conserved between all 
six variants, whereby the decrease in HNF4 α expression throughout differentiation 
coincided with an increase in the levels of SUMO 2 modification, indicative of poly 
SUMOylation. Interestingly, Tatham and colleagues established that the poly-
SUMOylation of the promyelocytic leukaemia protein (PML) resulted in its 
ubiquitination, mediated by RNF4, before its degradation via the 26S proteasome 
(Tatham et al., 2008). In our in vitro model, RNF4 was expressed as the levels of 
HNF4 α decreased following poly-SUMOylation. This process could be inhibited 
using a proteasome 26S inhibitor, MG132.  
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In an attempt to dissect the biological mechanism, we employed the lentivirus 
technology. The LVs were packaged and used to transfect C3A cells, a hepatoma cell 
line. Once the technology was optimized, the LV constructs were used to infect 
hESCs at different time points during cellular differentiation.  Despite the effective 
vectors, no defined conclusions could be drawn. Therefore, further refinement of the 
technology is required before elucidating the mechanisms within differentiating 
hESCs.   
 
One method to overcome this issue is the creation of stable cell lines, which could 
also be inducible. This technique involves antibiotic selection, whereby the 
remaining surviving cells express the integrated lentiviral vector containing the 
specific transgene, in addition to the resistance gene, as it is required for survival.  
Continuous selection ensures that each cell within the population expresses the LV. 
Transgene expression can also be regulated by the Tet repressor creating inducible 
stable cell lines. Inducible systems function by inhibiting the expression of the 
specific transgene by binding the Tet repressor, which is constitutively expressed, 
onto the lentivirus promoter/enhancer region. The addition of tetracycline results in 
the binding and conformational change of the Tet repressor, thus promoting the 
expression of the required transgene.  This mechanism in turn can be used to regulate 
the expression or repression of the gene of interest. Therefore, employing the above 
technique would be the next step in this investigation. The resulting hESC population 
will express the required transgene and therefore defined conclusions could be drawn 
upon manipulation of gene expression. In addition, due to the inducible nature of the 
system, optimal time points for induction may be developed, further refining the 
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differentiation system. Optimising hESC viral transfection and successfully 
manipulating gene expression patterns will, in turn, provide an effective platform that 
may be translated into various cellular models and differentiation systems, vital in 
research and clinical applications.  
 
Hepatocyte differentiation is a complex process requiring regulation at multiple 
levels. This thesis highlights the importance of SUMOylation in creating a stable 
model for human liver biology. The next stage of this project is to generate inducible 
stable cells lines which will allow function dissection of the relationship between 
SUMOylation and HNF4 α within differentiating hESCs.  This mechanism in turn 
may provide insight into techniques that can be used to refine the differentiation 
model thus providing an indefinite supply of functional viable hepatic endoderm 
from both hESCs and induced pluripotent stem cells (iPSCs). iPSCs are generated 
from terminally differentiated somatic cells, whereby pluripotency factors such as 
Oct4 and Nanog are over expressed, resulting in the reversion of the phenotype into 
an  embryonic stem cell like state (Takahashi et al., 2007). Utilization of iPSCs 
alleviates the controversy associated with hESCs as they by-pass the requirement of 
the embryo (Chakraborty et al., 2010). In addition, potential use of iPSCs in therapy 
reduces the complications attributed to immuno-rejection (Chakraborty et al., 2010). 
Therefore, iPSCs provide a good platform for modelling hepatic differentiation 
resulting in potential use in a variety of clinical and research applications. The 
resulting HE will initially be utilized for disease modelling and drug discovery. 
Further advances in the technology will afford the opportunity for use in extra 
corporeal devices with the inevitable employment in cellular therapy once the system 
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is completely refined. Advancements in each of these fields have been documented; 
some examples have been described below.  
 
A significant number of differentiation protocols have been successfully developed, 
resulting in the generation of functional hepatocytes.  However, most of the 
techniques suffer from limitations, specifically complications preventing their use in 
cell-based therapies. These include xeno-contamination, lack of definition and an 
impure differentiated population.  However, a novel strategy has been established 
that has efficiently derived hepatocytes directly from mouse fibroblasts using defined 
factors, bypassing the requirement of embryonic stem cells and iPSCs (Huang et al., 
2011). Mouse tail-tip fibroblasts were transduced using lentiviral vectors expressing 
Gata4, HNF1 α and Fox3a and inactivated p19Arf (Huang et al., 2011). The resulting 
hepatocytes displayed the correct morphology in conjugation with hepatic specific 
gene expression and metabolic functions (Huang et al., 2011). The investigation 
contributed a novel strategy for generating functional hepatocytes directly from 
terminally differentiated cells, ideal for sourcing an indefinite supply of HE. This 
technique may be translated into various model systems, human, advancing the 
utilization of hepatocytes in clinical and therapeutic applications.   
 
Reproducible and scalable models are vital for applications such as drug discovery as 
it may alleviate the high costs associated with animal tests and clinical trials. An 
accurate developmental model generated from hESCs derived HE will aid in treating 
liver disease, which is translatable into other model systems (Sokal, 2011). iPSCs 
have also been utilized for disease modelling, whereby iPSCs are formed from 
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patients suffering from various liver disorders (Rashid et al., 2010). Once 
differentiated, the hepatocytes display phenotypic characteristics of each disease, 
such as misfolded α1-antitrypsin in the endoplasmic reticulum demonstrated in 
patients suffering from α1-antitrypsin deficiency and reduced LDL receptor mediated 
cholesterol uptake from patients suffering from familial hypercholesterolemia 
(Rashid et al., 2010). In addition, generating HE from induced pluripotent stem cells 
(iPSCs) depicting individual polymorphic variations within metabolic genes will 
enhance our understanding of drug metabolism and will improve drug development 
and toxicology analysis within pharmaceutical companies (Rashid et al., 2010). 
 
Another potential use of iPSC and hESC generated HE is in extra corporeal devices. 
Extra corporeal devices, the bioartificial liver, have been developed as a support 
mechanism in acute liver failure cases relieving stress from the damaged liver (Wang 
et al., 2010). The requirement for a constant supply of functional hepatocytes is vital 
for such a treatment. Furthermore, provision of functional hepatic endoderm may 
result in the identification of novel biomarkers and potential drug targets, which will 
provide significant advancements in both the research and clinical fields (Sokal, 
2011). 
 
Formation of iPSCs from individual patients with subsequent differentiation into HE 
and hESC derived HE, will provide a good tool for cell based therapies. However, 
the employment of iPSC generated HE reduces implications associated with 
immuno-rejection and should result in improved cellular engraftment. Liu and 
colleagues have demonstrated a proof of principle for the use of differentiated HE in 
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cell therapy. The results demonstrated successful integration of iPSC lines, generated 
from each germ layer, within the cirrhotic liver of mice, resulting in tissue 
repopulation and efficient hepatic function, indicated by the presence of human 
serum proteins within the mouse blood (Liu et al., 2011). The investigation confirms 
the possibility of the technique as a possible treatment for liver disease in the future 
in addition to demonstrating that iPSCs generated from every origin can successfully 
be differentiated into hepatocytes, despite varying methylation patterns defining their 
epigenetic memory (Liu et al., 2011).  
 
Refining hESCs and iPSCs hepatic endoderm differentiation is vital for its 
subsequent use in industry, clinic and therapy. This thesis has provided novel 
evidence of the expression and regulation mechanism of HNF4 α, an essential 
hepatic transcription factor, within human hepatocyte differentiation. Further 
investigation into the mechanism and the subsequent effects of HNF4 α regulation in 
hepatic differentiation may provide insight for the improvement of the differentiation 
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Supplementary Figure 1 – HNF4 α Splice Variants Primer Binding Sites 
The diagram denotes the annealing positions of the specific HNF4 α splice variant 
primers in RT-PCR. A – HNF4 α Variant 1, B – HNF4 α Variant 2, C – HNF4 α 
Variant 3, D – HNF4 α Variant 4, E – HNF4 α Variant 5 and F – HNF4 α Variant 6. 
 
 
 
 
